| 1 |
Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fucà G, Rametta A, Zattarin E, Leporati R, Presti D, Cantarelli B, Depretto C, Vingiani A, Manoukian S, Scaperrotta G, Bianchi GV, Capri G, Pruneri G, de Braud F, Vernieri C. Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. Clin Breast Cancer 2023;23:e151-62. [PMID: 36599769 DOI: 10.1016/j.clbc.2022.12.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Murazawa C, Hashimoto N, Kuraishi K, Motoyama M, Hashimoto SI, Ikeuchi M, Norimura S, Matsunaga T, Teramoto K, Haba R, Abe N, Yajima T, Kontani K. Status and prognostic value of immunological biomarkers of breast cancer. Oncol Lett 2023;25:164. [PMID: 36960188 DOI: 10.3892/ol.2023.13750] [Reference Citation Analysis]
|
| 3 |
Chartier S, Brochard C, Martinat C, Coussy F, Feron JG, Kirova Y, Cottu P, Marchiò C, Vincent-Salomon A. TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas. Histopathology 2023;82:664-71. [PMID: 36527253 DOI: 10.1111/his.14852] [Reference Citation Analysis]
|
| 4 |
Rodríguez Pérez A, Felip Font E, Chicas-Sett R, Montero-Luis Á, de Paz Arias L, González-Del-Alba A, López-Campos F, López López C, Hernando Requejo O, Conde-Moreno AJ, Arranz Arija JÁ, de Castro Carpeño J. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer. Clin Transl Oncol 2023;25:882-96. [PMID: 36525231 DOI: 10.1007/s12094-022-03011-6] [Reference Citation Analysis]
|
| 5 |
Zhang X, Zhuge J, Liu J, Xia Z, Wang H, Gao Q, Jiang H, Qu Y, Fan L, Ma J, Tan C, Luo W, Luo Y. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1153423] [Reference Citation Analysis]
|
| 6 |
Chew Minmin S, Bacotti A, Chen Y, Anders C, Sambade M, Deal AM, Trembath D, McKee MJ, Brogi E, Seidman AD. Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases. Breast Cancer Res Treat 2023. [PMID: 36930347 DOI: 10.1007/s10549-023-06908-0] [Reference Citation Analysis]
|
| 7 |
Tan Q, Chi Y, Su M, Zhou J, Zhou D, Zheng F, Man X, Sun S, Huang J, Li H. Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer. Front Genet 2023;14. [DOI: 10.3389/fgene.2023.1125970] [Reference Citation Analysis]
|
| 8 |
Kim J, Kim J, Cho EY, Park YH, Ahn JS, Kim K, Im Y. Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1146934] [Reference Citation Analysis]
|
| 9 |
Yang T, Li W, Huang T, Zhou J. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. JPM 2023;13:526. [DOI: 10.3390/jpm13030526] [Reference Citation Analysis]
|
| 10 |
Robert ME, Rüschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Justo M, Kodach LL, Srivastava A, Wang HL, Tang LH, Troncone G, Rojo F, Van Treeck BJ, Pratt J, Shnitsar I, Kumar G, Karasarides M, Anders RA. High Interobserver Variability among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction and Esophageal Adenocarcinoma. Mod Pathol 2023;:100154. [PMID: 36925069 DOI: 10.1016/j.modpat.2023.100154] [Reference Citation Analysis]
|
| 11 |
Nunes Filho P, Albuquerque C, Pilon Capella M, Debiasi M. Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review. Oncol Ther 2023. [PMID: 36917399 DOI: 10.1007/s40487-023-00224-9] [Reference Citation Analysis]
|
| 12 |
Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell 2023:S0092-8674(23)00099-5. [PMID: 36931265 DOI: 10.1016/j.cell.2023.01.040] [Reference Citation Analysis]
|
| 13 |
Virassamy B, Caramia F, Savas P, Sant S, Wang J, Christo SN, Byrne A, Clarke K, Brown E, Teo ZL, von Scheidt B, Freestone D, Gandolfo LC, Weber K, Teply-Szymanski J, Li R, Luen SJ, Denkert C, Loibl S, Lucas O, Swanton C, Speed TP, Darcy PK, Neeson PJ, Mackay LK, Loi S. Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell 2023;41:585-601.e8. [PMID: 36827978 DOI: 10.1016/j.ccell.2023.01.004] [Reference Citation Analysis]
|
| 14 |
Chao X, Zhang Y, Zheng C, Huang Q, Lu J, Pulver EM, Houthuijzen J, Hutten S, Luo R, He J, Sun P. Metastasis of breast cancer to bones alters the tumor immune microenvironment. Eur J Med Res 2023;28:119. [PMID: 36915210 DOI: 10.1186/s40001-023-01083-w] [Reference Citation Analysis]
|
| 15 |
Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, Wang W, Chen ZS, Han CH. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther 2023;8:113. [PMID: 36906600 DOI: 10.1038/s41392-023-01383-x] [Reference Citation Analysis]
|
| 16 |
Mekky RY, Ragab MF, Manie T, Attia AA, Youness RA. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer. Transl Oncol 2023;31:101653. [PMID: 36907052 DOI: 10.1016/j.tranon.2023.101653] [Reference Citation Analysis]
|
| 17 |
Downs-Canner S, Mittendorf EA. Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study. Ann Surg Oncol 2023. [PMID: 36897418 DOI: 10.1245/s10434-023-13267-z] [Reference Citation Analysis]
|
| 18 |
Dogra A, Kumar J. Biosynthesis of anticancer phytochemical compounds and their chemistry. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1136779] [Reference Citation Analysis]
|
| 19 |
L. Russell B, T. Malindisa S, A. Sooklal S, Ntwasa M. Current Advances in Immune Checkpoint Therapy. Immune Checkpoint Inhibitors - New Insights and Recent Progress 2023. [DOI: 10.5772/intechopen.107315] [Reference Citation Analysis]
|
| 20 |
Thacker G, Henry S, Nandi A, Debnath R, Singh S, Nayak A, Susnik B, Boone MM, Zhang Q, Kesmodel SB, Gumber S, Das GM, Kambayashi T, Dos Santos CO, Chakrabarti R. Immature natural killer cells promote progression of triple-negative breast cancer. Sci Transl Med 2023;15:eabl4414. [PMID: 36888695 DOI: 10.1126/scitranslmed.abl4414] [Reference Citation Analysis]
|
| 21 |
Li Q, Liu X, Yan C, Zhao B, Zhao Y, Yang L, Shi M, Yu H, Li X, Luo K. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy. Small 2023;:e2206211. [PMID: 36890780 DOI: 10.1002/smll.202206211] [Reference Citation Analysis]
|
| 22 |
Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membrez-Antonioli V, Zürrer-Härdi U, Caspar CB, Deuster S, Senn M, Winterhalder R, Rochlitz C. A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. Sci Rep 2023;13:3705. [PMID: 36879012 DOI: 10.1038/s41598-023-30950-z] [Reference Citation Analysis]
|
| 23 |
Berlin, 7. Dezember 2022 – Aktuelle Empfehlungen zum Lieferengpass von Nanopartikel-Albumin-gebundenem Paclitaxel (nab-Paclitaxel). Senologie - Zeitschrift für Mammadiagnostik und -therapie 2023;20:22-24. [DOI: 10.1055/a-1994-9296] [Reference Citation Analysis]
|
| 24 |
Villacampa G, Cresta Morgado P, Navarro V, Viaplana C, Dienstmann R. Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy. Cancer Treatment Reviews 2023. [DOI: 10.1016/j.ctrv.2023.102542] [Reference Citation Analysis]
|
| 25 |
Sandoval M, Wechsler AH, Alhajji Z, Viets-Upchurch J, Brock P, Lipe DN, Al-Breiki A, Yeung SJ. Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. Heliyon 2023;9:e13725. [PMID: 36851967 DOI: 10.1016/j.heliyon.2023.e13725] [Reference Citation Analysis]
|
| 26 |
Li K, Cao L, Li C, Wu J, Chen B, Zhang G, Li X, Wen L, Jia M, Wei G, Lin J, Li Y, Zhang Y, Mok H, Ren C, Wang Y, Qi X, Guo L, Che Y, Liao N. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations. Cancer Med 2023;12:5195-208. [PMID: 36404592 DOI: 10.1002/cam4.5314] [Reference Citation Analysis]
|
| 27 |
Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 2023;22:213-34. [PMID: 36509911 DOI: 10.1038/s41573-022-00615-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 28 |
Stickeler E, Fehm T. Immuntherapie beim triple-negativen Mammakarzinom – State of the Art. Gynäkologie 2023. [DOI: 10.1007/s00129-023-05064-2] [Reference Citation Analysis]
|
| 29 |
Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V. Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review. Cancer Treat Rev 2023;114:102511. [PMID: 36638600 DOI: 10.1016/j.ctrv.2023.102511] [Reference Citation Analysis]
|
| 30 |
Xie XQ, Yang Y, Wang Q, Liu HF, Fang XY, Li CL, Jiang YZ, Wang S, Zhao HY, Miao JY, Ding SS, Liu XD, Yao XH, Yang WT, Jiang J, Shao ZM, Jin G, Bian XW. Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell Res 2023;33:215-28. [PMID: 36627348 DOI: 10.1038/s41422-022-00766-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Rizvi N, Ademuyiwa FO, Cao ZA, Chen HX, Ferris RL, Goldberg SB, Hellmann MD, Mehra R, Rhee I, Park JC, Kluger H, Tawbi H, Sullivan RJ. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. J Immunother Cancer 2023;11. [PMID: 36918220 DOI: 10.1136/jitc-2022-005920] [Reference Citation Analysis]
|
| 32 |
Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open 2023;8:100884. [PMID: 36863095 DOI: 10.1016/j.esmoop.2023.100884] [Reference Citation Analysis]
|
| 33 |
Yang X, Tang W, He Y, An H, Wang J. A novel fatty-acid metabolism-based classification for triple negative breast cancer. Aging (Albany NY) 2023;15:1177-98. [PMID: 36880837 DOI: 10.18632/aging.204552] [Reference Citation Analysis]
|
| 34 |
Montoyo-Pujol YG, García-Escolano M, Ponce JJ, Delgado-García S, Martín TA, Ballester H, Castellón-Molla E, Martínez-Peinado P, Pascual-García S, Sempere-Ortells JM, Peiró G. Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures. Int J Mol Sci 2023;24. [PMID: 36901916 DOI: 10.3390/ijms24054478] [Reference Citation Analysis]
|
| 35 |
Zhou X, Li C, Chen T, Li W, Wang X, Yang Q. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy. Mol Cancer 2023;22:36. [PMID: 36810108 DOI: 10.1186/s12943-023-01746-6] [Reference Citation Analysis]
|
| 36 |
Deb S, Chakrabarti A, Fox SB. Prognostic and Predictive Biomarkers in Familial Breast Cancer. Cancers (Basel) 2023;15. [PMID: 36831687 DOI: 10.3390/cancers15041346] [Reference Citation Analysis]
|
| 37 |
Zhang X, Jiang Q, Su Y, Bu L, Sun Z, Wu X, Gao B, Wang L, Lin Y, Xie W, Guo J. AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy. Br J Cancer 2023. [PMID: 36807336 DOI: 10.1038/s41416-022-02127-4] [Reference Citation Analysis]
|
| 38 |
Yazaki S, Salgado R, Shimoi T, Yoshida M, Shiino S, Kaneda T, Kojima Y, Sumiyoshi-Okuma H, Nishikawa T, Sudo K, Noguchi E, Murata T, Takayama S, Suto A, Ohe Y, Yonemori K. Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer. Br J Cancer 2023;128:568-75. [PMID: 36522476 DOI: 10.1038/s41416-022-02072-2] [Reference Citation Analysis]
|
| 39 |
Lee J. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). J Clin Med 2023;12. [PMID: 36836059 DOI: 10.3390/jcm12041524] [Reference Citation Analysis]
|
| 40 |
Olguin JE, Mendoza-Rodriguez MG, Sanchez-Barrera CA, Terrazas LI. Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment? World J Gastrointest Oncol 2023; 15(2): 251-267 [DOI: 10.4251/wjgo.v15.i2.251] [Reference Citation Analysis]
|
| 41 |
Curvello R, Kast V, Ordóñez-morán P, Mata A, Loessner D. Biomaterial-based platforms for tumour tissue engineering. Nat Rev Mater 2023. [DOI: 10.1038/s41578-023-00535-3] [Reference Citation Analysis]
|
| 42 |
Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer 2023;9:7. [PMID: 36781869 DOI: 10.1038/s41523-023-00508-3] [Reference Citation Analysis]
|
| 43 |
Sun H, Zhang Y, Wang G, Yang W, Xu Y. mRNA-Based Therapeutics in Cancer Treatment. Pharmaceutics 2023;15. [PMID: 36839944 DOI: 10.3390/pharmaceutics15020622] [Reference Citation Analysis]
|
| 44 |
Lam BM, Verrill C. Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. Cancers (Basel) 2023;15. [PMID: 36831506 DOI: 10.3390/cancers15041164] [Reference Citation Analysis]
|
| 45 |
Du J, Wu K. PCDHA1 High Expression is Associated With Poor Prognosis and Correlated With Immune Cell Infiltration in Breast Cancer. Clin Breast Cancer 2023:S1526-8209(23)00031-9. [PMID: 36858841 DOI: 10.1016/j.clbc.2023.02.001] [Reference Citation Analysis]
|
| 46 |
Luo J, Zou H, Guo Y, Tong T, Chen Y, Xiao Y, Pan Y, Li P. The oncogenic roles and clinical implications of YAP/TAZ in breast cancer. Br J Cancer 2023. [PMID: 36759723 DOI: 10.1038/s41416-023-02182-5] [Reference Citation Analysis]
|
| 47 |
Rosado MM, Pioli C. Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. Cancers (Basel) 2023;15. [PMID: 36831435 DOI: 10.3390/cancers15041093] [Reference Citation Analysis]
|
| 48 |
Wang K, Zheng C, Xue L, Deng D, Zeng L, Li M, Deng X. A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: Progress in the past 17 years. Front Med (Lausanne) 2023;10:999312. [PMID: 36844225 DOI: 10.3389/fmed.2023.999312] [Reference Citation Analysis]
|
| 49 |
Wu Y, Xie H, Li Y, Bao X, Lu GL, Wen J, Gao Y, Li Y, Zhang Z. Nitric Oxide-Loaded Bioinspired Lipoprotein Normalizes Tumor Vessels To Improve Intratumor Delivery and Chemotherapy of Albumin-Bound Paclitaxel Nanoparticles. Nano Lett 2023;23:939-47. [PMID: 36701555 DOI: 10.1021/acs.nanolett.2c04312] [Reference Citation Analysis]
|
| 50 |
Chen P, Yang W, Nagaoka K, Huang GL, Miyazaki T, Hong T, Li S, Igarashi K, Takeda K, Kakimi K, Kataoka K, Cabral H. An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors. Adv Sci (Weinh) 2023;:e2205139. [PMID: 36739605 DOI: 10.1002/advs.202205139] [Reference Citation Analysis]
|
| 51 |
Kotsos D, Tziomalos K. Microsomal Prostaglandin E Synthase-1 and -2: Emerging Targets in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2023;24. [PMID: 36769370 DOI: 10.3390/ijms24033049] [Reference Citation Analysis]
|
| 52 |
Long Y, Chen R, Yu X, Tong Y, Peng X, Li F, Hu C, Sun J, Gong L. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner. Cancer Immunol Res 2023;11:241-60. [PMID: 36484740 DOI: 10.1158/2326-6066.CIR-22-0439] [Reference Citation Analysis]
|
| 53 |
Tahtacı G, Günel N, Sadioğlu A, Akyürek N, Boz O, Üner A. LAG-3 expression in tumor microenvironment of triple-negative breast cancer. Turk J Med Sci 2023;53:142-8. [PMID: 36945923 DOI: 10.55730/1300-0144.5567] [Reference Citation Analysis]
|
| 54 |
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility. JAMA Netw Open 2023;6:e230698. [PMID: 36826813 DOI: 10.1001/jamanetworkopen.2023.0698] [Reference Citation Analysis]
|
| 55 |
Dey A, Ghosh S, Jha S, Hazra S, Srivastava N, Chakraborty U, Roy AG. Recent advancement in breast cancer treatment using CAR T cell therapy-: A review. Advances in Cancer Biology - Metastasis 2023. [DOI: 10.1016/j.adcanc.2023.100090] [Reference Citation Analysis]
|
| 56 |
Marini W, Wilson BE, Reedijk M. Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. DNA Cell Biol 2023;42:73-81. [PMID: 36579947 DOI: 10.1089/dna.2022.0578] [Reference Citation Analysis]
|
| 57 |
Berlin, 7. Dezember 2022 – Aktuelle Empfehlungen zum Lieferengpass von Nanopartikel-Albumin-gebundenem Paclitaxel (nab-Paclitaxel). Geburtshilfe Frauenheilkd 2023;83:158-159. [DOI: 10.1055/a-1998-7964] [Reference Citation Analysis]
|
| 58 |
Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol Sin 2023;44:288-307. [PMID: 35927312 DOI: 10.1038/s41401-022-00953-z] [Reference Citation Analysis]
|
| 59 |
Morganti S, Tolaney SM. Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer. Hematol Oncol Clin North Am 2023;37:133-50. [PMID: 36435606 DOI: 10.1016/j.hoc.2022.08.014] [Reference Citation Analysis]
|
| 60 |
Dang YC, Kong QT, Wang Z, Sang H. Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study. Curr Probl Cancer 2023;47:100934. [PMID: 36580870 DOI: 10.1016/j.currproblcancer.2022.100934] [Reference Citation Analysis]
|
| 61 |
Yan T, Yu L, Shangguan D, Li W, Liu N, Chen Y, Fu Y, Tang J, Liao D. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. Int Immunopharmacol 2023;115:109638. [PMID: 36587500 DOI: 10.1016/j.intimp.2022.109638] [Reference Citation Analysis]
|
| 62 |
Mullally WJ, Greene J, Jordan EJ, Horgan AM, O'Connor M, Calvert PM. The prognostic value of the derived neutrophil-to-lymphocyte ratio (dNLR) in patients treated with immune checkpoint inhibitors. Ir J Med Sci 2023;192:83-7. [PMID: 35304710 DOI: 10.1007/s11845-022-02982-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 63 |
Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med 2023;23:1-16. [PMID: 35031885 DOI: 10.1007/s10238-021-00781-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 64 |
Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Okamura T, Kumaki N, Hozumi K, Iwamoto T, Honda C, Kurozumi S, Niikura N. Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment. Breast Cancer Res 2023;25:13. [PMID: 36721218 DOI: 10.1186/s13058-023-01606-7] [Reference Citation Analysis]
|
| 65 |
Dhara A, Majumder S, Pahari S, Kar D. Improved Targeting of Therapeutics by Nanocarrier-Based Delivery in Cancer Immunotherapy and Their Future Perspectives. BioNanoSci 2023. [DOI: 10.1007/s12668-023-01065-6] [Reference Citation Analysis]
|
| 66 |
Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, Romano E, Rothé F, Sotiriou C, Buisseret L. Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. J Clin Med 2023;12. [PMID: 36769602 DOI: 10.3390/jcm12030953] [Reference Citation Analysis]
|
| 67 |
Rizzo A, Mollica V, Tateo V, Tassinari E, Marchetti A, Rosellini M, De Luca R, Santoni M, Massari F. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunol Immunother 2023. [PMID: 36695827 DOI: 10.1007/s00262-023-03366-x] [Reference Citation Analysis]
|
| 68 |
Hu G, Wang S, Wang S, Ding Q, Huang L. LAG-3(+) tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients. Front Oncol 2022;12:986903. [PMID: 36761428 DOI: 10.3389/fonc.2022.986903] [Reference Citation Analysis]
|
| 69 |
Guo B, Qu Y, Sun Y, Zhao S, Yuan J, Zhang P, Zhong Z, Meng F. Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative "cold" triple-negative breast cancer. Bioact Mater 2023;25:61-72. [PMID: 36733927 DOI: 10.1016/j.bioactmat.2023.01.014] [Reference Citation Analysis]
|
| 70 |
Noske A, Steiger K, Ballke S, Kiechle M, Oettler D, Roth W, Weichert W. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens. J Clin Pathol 2023:jcp-2022-208637. [PMID: 36669878 DOI: 10.1136/jcp-2022-208637] [Reference Citation Analysis]
|
| 71 |
Petrosyan V, Dobrolecki LE, Thistlethwaite L, Lewis AN, Sallas C, Srinivasan RR, Lei JT, Kovacevic V, Obradovic P, Ellis MJ, Osborne CK, Rimawi MF, Pavlick A, Shafaee MN, Dowst H, Jain A, Saltzman AB, Malovannaya A, Marangoni E, Welm AL, Welm BE, Li S, Wulf GM, Sonzogni O, Huang C, Vasaikar S, Hilsenbeck SG, Zhang B, Milosavljevic A, Lewis MT. Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. iScience 2023;26:105799. [PMID: 36619972 DOI: 10.1016/j.isci.2022.105799] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 72 |
Valenza C, Rizzo G, Passalacqua MI, Boldrini L, Corti C, Trapani D, Curigliano G. Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. Ther Adv Med Oncol 2023;15:17588359221146129. [PMID: 36743524 DOI: 10.1177/17588359221146129] [Reference Citation Analysis]
|
| 73 |
Xu Q, Zhou Y, Zhang H, Li H, Qin H, Wang H. Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer. Healthcare (Basel) 2023;11. [PMID: 36766879 DOI: 10.3390/healthcare11030304] [Reference Citation Analysis]
|
| 74 |
Chervoneva I, Peck AR, Sun Y, Yi M, Udhane SS, Langenheim JF, Girondo MA, Jorns JM, Chaudhary LN, Kamaraju S, Bergom C, Flister MJ, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Palazzo JP, Bibbo M, Hyslop T, Nevalainen MT, Pestell RG, Fuchs SY, Mitchell EP, Rui H. High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. JCO Precis Oncol 2023;7:e2100498. [PMID: 36652667 DOI: 10.1200/PO.21.00498] [Reference Citation Analysis]
|
| 75 |
Hu Y, Li Y, Yao Z, Huang F, Cai H, Liu H, Zhang X, Zhang J. Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer. Cancers (Basel) 2023;15. [PMID: 36765522 DOI: 10.3390/cancers15030563] [Reference Citation Analysis]
|
| 76 |
Kreipe HH. Prädiktive Pathologie für die Immuntherapie. Gynäkologie 2023. [DOI: 10.1007/s00129-022-05034-0] [Reference Citation Analysis]
|
| 77 |
Tierno D, Grassi G, Zanconati F, Bortul M, Scaggiante B. An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer. Int J Mol Sci 2023;24. [PMID: 36675313 DOI: 10.3390/ijms24021799] [Reference Citation Analysis]
|
| 78 |
Tatarova Z, Blumberg DC, Bensen A, Mills GB, Jonas O. Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma. Cells 2023;12. [PMID: 36672243 DOI: 10.3390/cells12020308] [Reference Citation Analysis]
|
| 79 |
Liu J, Jiang X, Feng X, Lee MJ, Li Y, Mao J, Weichselbaum RR, Lin W. A Three-in-One Nanoscale Coordination Polymer for Potent Chemo-Immunotherapy. Small Methods 2023;:e2201437. [PMID: 36638256 DOI: 10.1002/smtd.202201437] [Reference Citation Analysis]
|
| 80 |
Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother 2023. [PMID: 36633661 DOI: 10.1007/s00262-022-03349-4] [Reference Citation Analysis]
|
| 81 |
Wu J, Chen Y, Chen L, Ji Z, Tian H, Zheng D, Yang Q, Liu Y, Cai J, Zheng J, Chen Y, Li Z. Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis. Front Oncol 2022;12:1002667. [PMID: 36713507 DOI: 10.3389/fonc.2022.1002667] [Reference Citation Analysis]
|
| 82 |
Choi H, Kim K. Theranostics for Triple-Negative Breast Cancer. Diagnostics (Basel) 2023;13. [PMID: 36673082 DOI: 10.3390/diagnostics13020272] [Reference Citation Analysis]
|
| 83 |
Tashireva LA, Kalinchuk AY, Gerashchenko TS, Menyailo M, Khozyainova A, Denisov EV, Perelmuter VM. Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer. Int J Mol Sci 2023;24:1433. [PMID: 36674951 DOI: 10.3390/ijms24021433] [Reference Citation Analysis]
|
| 84 |
Schreier A, Zappasodi R, Serganova I, Brown KA, Demaria S, Andreopoulou E. Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. Front Oncol 2022;12:1061789. [PMID: 36703796 DOI: 10.3389/fonc.2022.1061789] [Reference Citation Analysis]
|
| 85 |
Kar R, Dhar R, Mukherjee S, Nag S, Gorai S, Mukerjee N, Mukherjee D, Vatsa R, Chandrakanth Jadhav M, Ghosh A, Devi A, Krishnan A, Thorat ND. Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics. ACS Biomater Sci Eng 2023;9:577-94. [PMID: 36621949 DOI: 10.1021/acsbiomaterials.2c01329] [Reference Citation Analysis]
|
| 86 |
Fasching PA, Hein A, Kolberg HC, Häberle L, Uhrig S, Rübner M, Belleville E, Hack CC, Fehm TN, Janni W, Hartmann A, Erber R, Theuser AK, Brucker SY, Hartkopf AD, Untch M. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041). Eur J Cancer 2023;184:1-9. [PMID: 36871424 DOI: 10.1016/j.ejca.2023.01.001] [Reference Citation Analysis]
|
| 87 |
Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A, Nakamura H, Hosoda F, Shibata T, Motoi N, Nakayama T, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Ohe Y, Horinouchi H. Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma. Front Oncol 2022;12:966527. [PMID: 36698400 DOI: 10.3389/fonc.2022.966527] [Reference Citation Analysis]
|
| 88 |
Onkar SS, Carleton NM, Lucas PC, Bruno TC, Lee AV, Vignali DAA, Oesterreich S. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discov 2023;13:23-40. [PMID: 36620880 DOI: 10.1158/2159-8290.CD-22-0475] [Reference Citation Analysis]
|
| 89 |
Hosseini M, Seyedpour S, Khodaei B, Loghman AH, Seyedpour N, Yazdi MH, Rezaei N. Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review. Vaccines (Basel) 2023;11. [PMID: 36679991 DOI: 10.3390/vaccines11010146] [Reference Citation Analysis]
|
| 90 |
Deng H, Wang L, Wang N, Zhang K, Zhao Y, Qiu P, Qi X, Zhang D, Xu F, Liu J. Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. BMC Cancer 2023;23:29. [PMID: 36611131 DOI: 10.1186/s12885-023-10515-z] [Reference Citation Analysis]
|
| 91 |
Jacob SL, Huppert LA, Rugo HS. Role of Immunotherapy in Breast Cancer. JCO Oncol Pract 2023;:OP2200483. [PMID: 36608303 DOI: 10.1200/OP.22.00483] [Reference Citation Analysis]
|
| 92 |
Santa-Maria CA. Optimizing and Refining Immunotherapy in Breast Cancer. JCO Oncol Pract 2023;:OP2200722. [PMID: 36608302 DOI: 10.1200/OP.22.00722] [Reference Citation Analysis]
|
| 93 |
Zhou Y, Liang Z, Xia Y, Li S, Liang J, Hu Z, Tang C, Zhao Q, Gong Q, Ouyang Y. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer. Chem Biol Interact 2023;369:110260. [PMID: 36414028 DOI: 10.1016/j.cbi.2022.110260] [Reference Citation Analysis]
|
| 94 |
Knopf P, Stowbur D, Hoffmann SHL, Fransen MF, Schwenck J, Pichler BJ, Kneilling M. Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging Approach. Mol Imaging Biol 2023. [PMID: 36600172 DOI: 10.1007/s11307-022-01797-z] [Reference Citation Analysis]
|
| 95 |
Zheng L, Yang Q, Li C, Xu G, Yuan Q, Hou J, Wu G. Ubiquitin-Specific Peptidase 8 Modulates Cell Proliferation and Induces Cell Cycle Arrest and Apoptosis in Breast Cancer by Stabilizing Estrogen Receptor Alpha. J Oncol 2023;2023:8483325. [PMID: 36644233 DOI: 10.1155/2023/8483325] [Reference Citation Analysis]
|
| 96 |
Sun H, Li Y, Zhang Y, Zhao X, Dong X, Guo Y, Mo J, Che N, Ban X, Li F, Bai X, Li Y, Hao J, Zhang D. The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer. Front Immunol 2022;13:1042835. [PMID: 36685583 DOI: 10.3389/fimmu.2022.1042835] [Reference Citation Analysis]
|
| 97 |
Pusztai L, Kahn A, Golestani R, Haringopal M. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer.. [DOI: 10.21203/rs.3.rs-2326290/v1] [Reference Citation Analysis]
|
| 98 |
Li L, Zhang F, Liu Z, Fan Z. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. Cancers (Basel) 2023;15. [PMID: 36612317 DOI: 10.3390/cancers15010321] [Reference Citation Analysis]
|
| 99 |
Janrao C, Khopade S, Bavaskar A, Gomte SS, Agnihotri TG, Jain A. Recent advances of polymer based nanosystems in cancer management. J Biomater Sci Polym Ed 2023;:1-62. [PMID: 36542375 DOI: 10.1080/09205063.2022.2161780] [Reference Citation Analysis]
|
| 100 |
Morse W, Nawaz H, Choudhry AA. Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer. J Egypt Natl Canc Inst 2023;34:58. [PMID: 36588130 DOI: 10.1186/s43046-022-00159-8] [Reference Citation Analysis]
|
| 101 |
Dabbs DJ, Huang RS, Ross JS. Novel markers in breast pathology. Histopathology 2023;82:119-39. [PMID: 36468266 DOI: 10.1111/his.14770] [Reference Citation Analysis]
|
| 102 |
Li JJX, Tse GM. Marker assessments in ER-positive breast cancers: old markers, new applications? Histopathology 2023;82:218-31. [PMID: 35945680 DOI: 10.1111/his.14767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 103 |
Shimomura A, Yoshida M, Kubo T, Yamashita S, Noguchi E, Nagayama A, Hanamura T, Okazaki M, Mukohara T, Tsuruga A, Tanaka K, Kawamura Y, Higuchi T, Takahashi Y, Kurozumi S, Hayashida T, Ichikawa H, Ushijima T, Suto A. Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer. Breast Cancer Res Treat 2023;197:593-602. [PMID: 36494460 DOI: 10.1007/s10549-022-06822-x] [Reference Citation Analysis]
|
| 104 |
Layfield LJ, Zhang T, Esebua M. PD-L1 immunohistochemical testing: A review with reference to cytology specimens. Diagn Cytopathol 2023;51:51-8. [PMID: 36053989 DOI: 10.1002/dc.25043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 105 |
Peters U, Turner B, Alvarez D, Murray M, Sharma A, Mohan S, Patel S. Considerations for Embedding Inclusive Research Principles in the Design and Execution of Clinical Trials. Ther Innov Regul Sci 2023;57:186-95. [PMID: 36241965 DOI: 10.1007/s43441-022-00464-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 106 |
Zou H, Luo J, Guo Y, Tong T, Liu Y, Chen Y, Xiao Y, Ye L, Zhu C, Deng L, Wang B, Pan Y, Li P. Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast cancer. Cell Mol Life Sci 2023;80:41. [PMID: 36633714 DOI: 10.1007/s00018-023-04688-w] [Reference Citation Analysis]
|
| 107 |
Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, Sanders ME, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Wheless A, Rezk S, Garrett AL, Parker JS, Foy KK, Shen H, Park BH, Krop I, Anders C, Gastier-Foster J, Rimawi MF, Nanda R, Lin NU, Isaacs C, Marcom PK, Storniolo AM, Couch FJ, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu MC, Hilsenbeck SG, Norton L, Richardson AL, Symmans WF, Wolff AC, Davidson NE, Carey LA, Lee AV, Balko JM, Hoadley KA, Laird PW, Mardis ER, King TA, Perou CM; AURORA US Network. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer 2023;4:128-47. [PMID: 36585450 DOI: 10.1038/s43018-022-00491-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 108 |
Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
|
| 109 |
Möller K, Knöll M, Bady E, Schmerder MJ, Rico SD, Kluth M, Hube-Magg C, Blessin NC, Mandelkow T, Lennartz M, Menz A, Luebke AM, Höflmayer D, Fraune C, Bernreuther C, Lebok P, Uhlig R, Contreras H, Weidemann S, Gorbokon N, Jacobsen F, Clauditz TS, Steurer S, Burandt E, Minner S, Sauter G, Simon R, Marx AH, Krech T. PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples. Cancer Biomark 2023;36:177-91. [PMID: 36683495 DOI: 10.3233/CBM-220030] [Reference Citation Analysis]
|
| 110 |
Sanguedolce F, Zanelli M. Assessing PD-L1 Expression in Different Tumor Types. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_168-1] [Reference Citation Analysis]
|
| 111 |
Subham S, Jeppson JD, Worcester C, Schatmeyer B, Zhao J, Madan R, Lakis NS, Kimler BF, McGuirk JP, Chen RC, Stecklein SR, Akhavan D. EGFR as a potent CAR T target in triple negative breast cancer brain metastases. Breast Cancer Res Treat 2023;197:57-69. [PMID: 36318382 DOI: 10.1007/s10549-022-06783-1] [Reference Citation Analysis]
|
| 112 |
di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, Laganà M, Grisanti S, Cosentini D, Berruti A. Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report. Front Oncol 2023;13:1139372. [PMID: 36890829 DOI: 10.3389/fonc.2023.1139372] [Reference Citation Analysis]
|
| 113 |
Incorvaia L, Perez A, Brando C, Gristina V, La Mantia M, Castiglia M, Fanale D, Galvano A, Badalamenti G, Russo A, Bazan V. Liquid biopsy and immunotherapy: is all that glitter gold? Liquid Biopsy 2023. [DOI: 10.1016/b978-0-12-822703-9.00005-3] [Reference Citation Analysis]
|
| 114 |
Gupta T, Vinayak S, Telli M. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Res Treat 2023;197:51-6. [PMID: 36318381 DOI: 10.1007/s10549-022-06780-4] [Reference Citation Analysis]
|
| 115 |
Prakash A, Gates T, Zhao X, Wangmo D, Subramanian S. Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. Pharmacol Ther 2023;241:108332. [PMID: 36526013 DOI: 10.1016/j.pharmthera.2022.108332] [Reference Citation Analysis]
|
| 116 |
Zhang J, Jin H, Pan S, Han C, Sun Q, Han X. Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment. Front Immunol 2023;14:1073550. [PMID: 36814908 DOI: 10.3389/fimmu.2023.1073550] [Reference Citation Analysis]
|
| 117 |
Pan J, Huang T, Deng Z, Zou C. Roles and therapeutic implications of m6A modification in cancer immunotherapy. Front Immunol 2023;14:1132601. [PMID: 36960074 DOI: 10.3389/fimmu.2023.1132601] [Reference Citation Analysis]
|
| 118 |
Sun H, Xu J, Dai S, Ma Y, Sun T. Breast cancer brain metastasis: Current evidence and future directions. Cancer Med 2023;12:1007-24. [PMID: 35822637 DOI: 10.1002/cam4.5021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 119 |
Lin Y, Wilk U, Pöhmerer J, Hörterer E, Höhn M, Luo X, Mai H, Wagner E, Lächelt U. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. Small 2023;19:e2205318. [PMID: 36399647 DOI: 10.1002/smll.202205318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 120 |
Udayasiri RI, Luo T, Gorringe KL, Fox SB. Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast. Histopathology 2023;82:106-18. [PMID: 36482277 DOI: 10.1111/his.14804] [Reference Citation Analysis]
|
| 121 |
Cai SL, Liu JJ, Liu YX, Yu SH, Liu X, Lin XQ, Chen HD, Fang X, Ma T, Li YQ, Li Y, Li CY, Zhang S, Chen XG, Guo XJ, Zhang J. Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer. Front Oncol 2023;13:1119611. [PMID: 36874102 DOI: 10.3389/fonc.2023.1119611] [Reference Citation Analysis]
|
| 122 |
Futamura M, Ishihara K, Nagao Y, Ogiso A, Niwa Y, Nakada T, Kawaguchi Y, Ikawa A, Kumazawa I, Mori R, Kitazawa M, Hosono Y, Kuno M, Kawajiri M, Nakakami A, Takeuchi M, Morikawa A, Tokumaru Y, Katagiri Y, Asano Y, Mushika Y, Shimokawa T, Matsuhasih N. Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast Cancer 2023;30:293-301. [PMID: 36609911 DOI: 10.1007/s12282-022-01425-2] [Reference Citation Analysis]
|
| 123 |
Tsang JY, Tse GM. Update on triple-negative breast cancers - highlighting subtyping update and treatment implication. Histopathology 2023;82:17-35. [PMID: 36468263 DOI: 10.1111/his.14784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 124 |
Lengyel CG. Mechanisms of Resistance to Immunotherapies in Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_335-1] [Reference Citation Analysis]
|
| 125 |
Jiang M, Qin B, Li X, Liu Y, Guan G, You J. New advances in pharmaceutical strategies for sensitizing anti-PD-1 immunotherapy and clinical research. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2023;15:e1837. [PMID: 35929522 DOI: 10.1002/wnan.1837] [Reference Citation Analysis]
|
| 126 |
Koutu V, Gupta M, Das S, Rawat DK, Kharade V, Pasricha RK. Nanotechnology in Lung Cancer Therapeutics: A Narrative Review. Cureus 2023;15:e34245. [PMID: 36855484 DOI: 10.7759/cureus.34245] [Reference Citation Analysis]
|
| 127 |
Qian L, Liu YF, Lu SM, Yang JJ, Miao HJ, He X, Huang H, Zhang JG. Construction of a fatty acid metabolism-related gene signature for predicting prognosis and immune response in breast cancer. Front Genet 2023;14:1002157. [PMID: 36936412 DOI: 10.3389/fgene.2023.1002157] [Reference Citation Analysis]
|
| 128 |
Zhang W, Yan Y, Peng J, Thakur A, Bai N, Yang K, Xu Z. Decoding Roles of Exosomal lncRNAs in Tumor-Immune Regulation and Therapeutic Potential. Cancers (Basel) 2022;15. [PMID: 36612282 DOI: 10.3390/cancers15010286] [Reference Citation Analysis]
|
| 129 |
Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees EC, Santa-Maria CA, Connolly RM, Force J, Moreno-Aspitia A, Herndon JM, Carmody M, Davies SR, Larson S, Pfaff KL, Jones SM, Weirather JL, Giobbie-Hurder A, Rodig SJ, Liu Z, Hagemann IS, Sharon E, Gillanders WE. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer 2022;8:134. [PMID: 36585404 DOI: 10.1038/s41523-022-00500-3] [Reference Citation Analysis]
|
| 130 |
Hintelmann K, Petersen C, Borgmann K. Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. Cancers (Basel) 2022;15. [PMID: 36612206 DOI: 10.3390/cancers15010211] [Reference Citation Analysis]
|
| 131 |
Takada M, Yoshimura M, Kotake T, Kawaguchi K, Uozumi R, Kataoka M, Kato H, Yoshibayashi H, Suwa H, Tsuji W, Yamashiro H, Suzuki E, Torii M, Yamada Y, Kataoka T, Ishiguro H, Morita S, Toi M. Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. Sci Rep 2022;12:22397. [PMID: 36575361 DOI: 10.1038/s41598-022-27048-3] [Reference Citation Analysis]
|
| 132 |
Chen X, Feng L, Huang Y, Wu Y, Xie N. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. Cancers (Basel) 2022;15. [PMID: 36612100 DOI: 10.3390/cancers15010104] [Reference Citation Analysis]
|
| 133 |
Boguszewska-byczkiewicz K, Wow T, Szymańska B, Kosny M, Kolacinska-wow A. The molecular portrait of triple-negative breast cancer: the LAG3 gene single nucleotide polymorphism rs2365094 has no impact on the clinical picture.. [DOI: 10.21203/rs.3.rs-2389420/v1] [Reference Citation Analysis]
|
| 134 |
Porciello N, Franzese O, D'Ambrosio L, Palermo B, Nisticò P. T-cell repertoire diversity: friend or foe for protective antitumor response? J Exp Clin Cancer Res 2022;41:356. [PMID: 36550555 DOI: 10.1186/s13046-022-02566-0] [Reference Citation Analysis]
|
| 135 |
Mao M, Chen Y, Yang J, Cheng Y, Xu L, Ji F, Zhou J, Zhang X, Li Z, Chen C, Ju S, Zhang J, Wang L. Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer. J Immunother Cancer 2022;10. [PMID: 36543379 DOI: 10.1136/jitc-2022-005668] [Reference Citation Analysis]
|
| 136 |
Lv H, Zhu Y, Xue J, Jia X, Chen J. Targeted Drug Delivery System Based on Copper Sulfide for Synergistic Near-Infrared Photothermal Therapy/Photodynamic Therapy/Chemotherapy of Triple Negative Breast Cancer. Langmuir 2022;38:15766-75. [PMID: 36508193 DOI: 10.1021/acs.langmuir.2c02667] [Reference Citation Analysis]
|
| 137 |
Chen H, Pu S, Mei N, Liu X, He J, Zhang H. Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment. Cancer Biomark 2022;35:379-93. [PMID: 36373309 DOI: 10.3233/CBM-220073] [Reference Citation Analysis]
|
| 138 |
Guven DC, Ozbek DA, Sahin TK, Kavgaci G, Aksun MS, Erul E, Yildirim HC, Chalabiyev E, Cebroyilov C, Yildirim T, Dizdar O, Aksoy S, Yalcin S, Kilickap S, Erman M, Arici M. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors. Anticancer Drugs 2022. [PMID: 36729111 DOI: 10.1097/CAD.0000000000001463] [Reference Citation Analysis]
|
| 139 |
Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, Song C, Ou X, Wu S, Wu L, Xie Y, Tian W, Tang Y, Wong CW, Chen ZS, Xie X, Tang H. The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. Adv Sci (Weinh) 2023;10:e2203699. [PMID: 36529697 DOI: 10.1002/advs.202203699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 140 |
Wang Q, Zhang Z, Qiu D, Mao X, Zhou Z, Xia T, Wei J, Ding Q, Zhang X. LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation. Nanomaterials (Basel) 2022;12. [PMID: 36558330 DOI: 10.3390/nano12244478] [Reference Citation Analysis]
|
| 141 |
Wang G, Romero Y, Thevarajan I, Zolkiewska A. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer. Oncoimmunology 2023;12:2158006. [PMID: 36545255 DOI: 10.1080/2162402X.2022.2158006] [Reference Citation Analysis]
|
| 142 |
Dang Y, Liu H, Wang Z, Zhou Y, Chen J, Kong Q, Sang H. Cutaneous adverse events associated with PD-1 inhibitor-based therapy in patients with non-small-cell lung cancer. Future Oncology 2022. [DOI: 10.2217/fon-2022-0888] [Reference Citation Analysis]
|
| 143 |
Wang Q, Mao Z, Li W, Wang S, Wang L, Chen L, Yang Z, Fu X, Jiang P, Bai Y, Xu L, Zhang S, Hou Y, Jia X, Jiang L, Liu M, Zhang G, Jiang Y, Guo H. Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma. Front Immunol 2022;13:1042072. [PMID: 36591290 DOI: 10.3389/fimmu.2022.1042072] [Reference Citation Analysis]
|
| 144 |
Krawczyk N, Fehm T, Ruckhäberle E, Brus L, Ruf F, Banys-paluchowski M. Immunonkologie beim Mammakarzinom: neue Therapieoption für die triple-negative Patientin. Gynäkologie 2022. [DOI: 10.1007/s00129-022-05024-2] [Reference Citation Analysis]
|
| 145 |
Percivalle NM, Carofiglio M, Conte M, Rosso G, Bentivogli A, Mesiano G, Vighetto V, Cauda V. Artificial and Naturally Derived Phospholipidic Bilayers as Smart Coatings of Solid-State Nanoparticles: Current Works and Perspectives in Cancer Therapy. Int J Mol Sci 2022;23. [PMID: 36555455 DOI: 10.3390/ijms232415815] [Reference Citation Analysis]
|
| 146 |
Tao ZL, Wu W, Liang LC, Pan JF, Cao JZ, Jia XL, Fang L, Ma Q. Case report: Complete response of a bladder cancer patient with multiple hepatic and pelvic metastases treated by nab-paclitaxel combined with sintilimab. Front Oncol 2022;12:1020793. [PMID: 36578927 DOI: 10.3389/fonc.2022.1020793] [Reference Citation Analysis]
|
| 147 |
Luque M, Sanz-Álvarez M, Morales-Gallego M, Madoz-Gúrpide J, Zazo S, Domínguez C, Cazorla A, Izarzugaza Y, Arranz JL, Cristóbal I, Rojo F. Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. Cancers (Basel) 2022;14. [PMID: 36551522 DOI: 10.3390/cancers14246034] [Reference Citation Analysis]
|
| 148 |
Spira A, Awada A, Isambert N, Lorente D, Penel N, Zhang Y, Ojalvo LS, Hicking C, Rolfe PA, Ihling C, Dussault I, Locke G, Borel C. Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer. Front Oncol 2022;12:981940. [PMID: 36568239 DOI: 10.3389/fonc.2022.981940] [Reference Citation Analysis]
|
| 149 |
Monteiro FL, Stepanauskaite L, Williams C, Helguero LA. SETD7 Expression Is Associated with Breast Cancer Survival Outcomes for Specific Molecular Subtypes: A Systematic Analysis of Publicly Available Datasets. Cancers (Basel) 2022;14. [PMID: 36551516 DOI: 10.3390/cancers14246029] [Reference Citation Analysis]
|
| 150 |
Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, Pavlick D, Gjoerup O, Ross JS, Harmon R, Chung J, Decker B, Dennis L, Frampton GM, Molinero L, Oesterreich S, Venstrom JM, Oxnard GR, Hegde PS, Sokol ES. Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nat Commun 2022;13:7495. [PMID: 36470901 DOI: 10.1038/s41467-022-35245-x] [Reference Citation Analysis]
|
| 151 |
Zhang X, Wen J, Zhang G, Fan W, Tan J, Liu H, Li J. Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma. Transl Oncol 2022;27:101600. [PMID: 36481605 DOI: 10.1016/j.tranon.2022.101600] [Reference Citation Analysis]
|
| 152 |
Takasu C, Nishi M, Yoshikawa K, Tokunaga T, Nakao T, Kashihara H, Wada Y, Yoshimoto T, Okikawa S, Yamashita S, Shimada M. Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. BMC Cancer 2022;22:1263. [PMID: 36471264 DOI: 10.1186/s12885-022-10357-1] [Reference Citation Analysis]
|
| 153 |
Barsoumian HB, Sheth RA, Ramapriyan R, Hsu E, Gagea M, Crowley K, Sezen D, Williams M, Welsh JW. Radiation Therapy Modulates Tumor Physical Characteristics to Reduce Intratumoral Pressure and Enhance Intratumoral Drug Delivery and Retention. Adv Radiat Oncol 2023;8:101137. [PMID: 36632088 DOI: 10.1016/j.adro.2022.101137] [Reference Citation Analysis]
|
| 154 |
de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F, Andrés R, Santisteban M, Ramos M, Holgado E, Cortés J, López-Miranda E, Cortés A, Henao F, Palazón-Carrión N, Rodriguez LM, Ceballos I, Soto A, Puertes A, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study. BMC Cancer 2022;22:1258. [PMID: 36463104 DOI: 10.1186/s12885-022-10363-3] [Reference Citation Analysis]
|
| 155 |
Zhao H, Liang Y, Sun C, Zhai Y, Li X, Jiang M, Yang R, Li X, Shu Q, Kai G, Han B. Dihydrotanshinone I Inhibits the Lung Metastasis of Breast Cancer by Suppressing Neutrophil Extracellular Traps Formation. Int J Mol Sci 2022;23. [PMID: 36499502 DOI: 10.3390/ijms232315180] [Reference Citation Analysis]
|
| 156 |
Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
|
| 157 |
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T. Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in Brief 2022;45:108558. [DOI: 10.1016/j.dib.2022.108558] [Reference Citation Analysis]
|
| 158 |
Shahbandi A, Chiu FY, Ungerleider NA, Kvadas R, Mheidly Z, Sun MJS, Tian D, Waizman DA, Anderson AY, Machado HL, Pursell ZF, Rao SG, Jackson JG. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat Cancer 2022;3:1513-33. [PMID: 36482233 DOI: 10.1038/s43018-022-00466-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 159 |
Jia Y, Jia Y, Shi Y, Zhao W, Martin J, Wang X, Tong Z, Song Y. Integrative analysis of LncRNA-mRNA signature reveals a functional LincRNA in triple-negative breast cancer. Holist Integ Oncol 2022;1:9. [DOI: 10.1007/s44178-022-00009-6] [Reference Citation Analysis]
|
| 160 |
He R, Yuan X, Chen Z, Zheng Y. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. International Immunopharmacology 2022;113:109444. [DOI: 10.1016/j.intimp.2022.109444] [Reference Citation Analysis]
|
| 161 |
Rijcken CJF, De Lorenzi F, Biancacci I, Hanssen RGJM, Thewissen M, Hu Q, Atrafi F, Liskamp RMJ, Mathijssen RHJ, Miedema IHC, Menke-van der Houven van Oordt CW, van Dongen GAMS, Vugts DJ, Timmers M, Hennink WE, Lammers T. Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles. Adv Drug Deliv Rev 2022;191:114613. [PMID: 36343757 DOI: 10.1016/j.addr.2022.114613] [Reference Citation Analysis]
|
| 162 |
Passalacqua MI, Rizzo G, Santarpia M, Curigliano G. 'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research'. Expert Opin Investig Drugs 2022;31:1291-310. [PMID: 36522800 DOI: 10.1080/13543784.2022.2159805] [Reference Citation Analysis]
|
| 163 |
Barros EM, Mcintosh SA, Savage KI. The DNA damage induced immune response: Implications for cancer therapy. DNA Repair 2022;120:103409. [DOI: 10.1016/j.dnarep.2022.103409] [Reference Citation Analysis]
|
| 164 |
Cejuela M, Vethencourt A, Pernas S. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. Curr Oncol Rep 2022;24:1801-19. [PMID: 36255603 DOI: 10.1007/s11912-022-01339-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 165 |
Furukawa N, Stearns V, Santa-Maria CA, Popel AS. The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting. Expert Opin Ther Targets 2022;26:1041-56. [PMID: 36657483 DOI: 10.1080/14728222.2022.2170779] [Reference Citation Analysis]
|
| 166 |
de Oliveira Andrade F, Verma V, Hilakivi-Clarke L. Maternal obesity and resistance to breast cancer treatments among offspring: Link to gut dysbiosis. Cancer Rep (Hoboken) 2022;5:e1752. [PMID: 36411524 DOI: 10.1002/cnr2.1752] [Reference Citation Analysis]
|
| 167 |
Tan WK, Segal BD, Curtis MD, Baxi SS, Capra WB, Garrett-Mayer E, Hobbs BP, Hong DS, Hubbard RA, Zhu J, Sarkar S, Samant M. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations. Contemp Clin Trials Commun 2022;30:101000. [PMID: 36186544 DOI: 10.1016/j.conctc.2022.101000] [Reference Citation Analysis]
|
| 168 |
Zheng D, Li Y, Song L, Xu T, Jiang X, Yin X, He Y, Xu J, Ma X, Chai L, Xu J, Hu J, Mi P, Jing J, Shi H. Improvement of radiotherapy with an ozone-carried liposome nano-system for synergizing cancer immune checkpoint blockade. Nano Today 2022;47:101675. [DOI: 10.1016/j.nantod.2022.101675] [Reference Citation Analysis]
|
| 169 |
Cuzzubbo S, Carpentier AF. Neurological adverse events of immune checkpoint blockade: from pathophysiology to treatment. Curr Opin Neurol 2022;35:814-22. [PMID: 36226705 DOI: 10.1097/WCO.0000000000001113] [Reference Citation Analysis]
|
| 170 |
Ameri A, Tavakoli-far B, Rostami M, Abedi kiasari B, Sakhaei D, Saad Ahmed O, Forouzani F, Fazli Y. Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer. International Immunopharmacology 2022;113:109334. [DOI: 10.1016/j.intimp.2022.109334] [Reference Citation Analysis]
|
| 171 |
Wu J, Fan D, Shao Z, Xu B, Ren G, Jiang Z, Wang Y, Jin F, Zhang J, Zhang Q, Ma F, Ma J, Wang Z, Wang S, Wang X, Wang S, Wang H, Wang T, Wang X, Wang J, Wang J, Wang B, Fu L, Li H, Shi Y, Gan L, Liu Y, Liu J, Liu Z, Liu Q, Sun Q, Cheng W, Yu K, Tong Z, Wu X, Song C, Zhang J, Zhang J, Li J, Li B, Li M, Li H, Yang W, Yang H, Yang B, Bu H, Shen J, Shen Z, Chen Y, Chen C, Pang D, Fan Z, Zheng Y, Yu X, Liu G, Hu X, Ling Y, Tang J, Yin Y, Geng C, Yuan P, Gu Y, Chang C, Cao X, Sheng Y, Huang Y, Huang J, Peng W, Zeng X, Xie Y, Liao N, Daiming F, Zhimin S, Binghe X, Guosheng R, Jiong W, Zefei J, Yongsheng W, Feng J, Jin Z, Qingyuan Z, Fei M, Jinli M, Zhonghua W, Yongsheng W, Shusen W, Xiaojia W, Shu W, Haibo W, Tao W, Xiang W, Jing W, Jia W, Biyun W, Li F, Hongyuan L, Yehui S, Lu G, Guosheng R, Yunjiang L, Jian L, Zhenzhen L, Qiang L, Wenwu C, Zefei J, Keda Y, Zhongsheng T, Xinhong W, Chuangui S, Jianguo Z, Jian Z, Qingyuan Z, Jin Z, Junjie L, Bin L, Man L, Huiping L, Wentao Y, Hongjian Y, Benlong Y, Hong B, Juping S, Zhenzhou S, Zhimin S, Yiding C, Ceshi C, Da P, Zhimin F, Ying Z, Feng J, Xiaoli Y, Guangyu L, Xichun H, Yiqun L, Jinhai T, Binghe X, Yongmei Y, Cuizhi G, Cuizhi G, Cuizhi G, Peng Y, Yajia G, Cai C, Xuchen C, Yuan S, Yuanxi H, Jian H, Jian H, Weijun P, Xiaohua Z, Yuntao X, Ning L, Committee of Breast Cancer Society, Chinese Anti-Cancer Association. CACA Guidelines for Holistic Integrative Management of Breast Cancer. Holist Integ Oncol 2022;1:7. [DOI: 10.1007/s44178-022-00007-8] [Reference Citation Analysis]
|
| 172 |
Liang F, Peng L, Wu Z, Giamas G, Stebbing J. Design and reporting of phase III oncology trials with prospective biomarker validation. J Natl Cancer Inst 2023;115:174-80. [PMID: 36448689 DOI: 10.1093/jnci/djac210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 173 |
Xu Z, Hou J, Ma H, Zhao Y, Fei F, Sun R, Li J. DLDH-containing extracellular vesicles from CAFs reduced DOX sensitivity in triple-negative breast cancer.. [DOI: 10.21203/rs.3.rs-2262675/v1] [Reference Citation Analysis]
|
| 174 |
Tan S, Yu J, Huang Q, Zhou N, Xiong X, Gou H. Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1037646] [Reference Citation Analysis]
|
| 175 |
Cohen IJ, Pareja F, Socci ND, Shen R, Doane AS, Schwartz J, Khanin R, Morris EA, Sutton EJ, Blasberg RG. Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. Front Immunol 2022;13:880959. [PMID: 36505421 DOI: 10.3389/fimmu.2022.880959] [Reference Citation Analysis]
|
| 176 |
Kast V, Nadernezhad A, Pette D, Gabrielyan A, Fusenig M, Honselmann KC, Stange DE, Werner C, Loessner D. A Tumor Microenvironment Model of Pancreatic Cancer to Elucidate Responses toward Immunotherapy. Adv Healthc Mater 2022;:e2201907. [PMID: 36417691 DOI: 10.1002/adhm.202201907] [Reference Citation Analysis]
|
| 177 |
Zalpoor H, Aziziyan F, Liaghat M, Bakhtiyari M, Akbari A, Nabi-Afjadi M, Forghaniesfidvajani R, Rezaei N. The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. Cell Commun Signal 2022;20:186. [PMID: 36419156 DOI: 10.1186/s12964-022-00951-y] [Reference Citation Analysis]
|
| 178 |
Eltarhoni K, Kamel F, Ihebunezie K, Nisar P, Soloviev M. Therapeutic Antibodies in Cancer Treatment in the UK. Int J Mol Sci 2022;23. [PMID: 36498915 DOI: 10.3390/ijms232314589] [Reference Citation Analysis]
|
| 179 |
Pang L, Gan C, Xu J, Jia Y, Chai J, Huang R, Li A, Ge H, Yu S, Cheng H. Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. Cancers (Basel) 2022;14. [PMID: 36497209 DOI: 10.3390/cancers14235727] [Reference Citation Analysis]
|
| 180 |
Kundu M, Greer YE, Dine JL, Lipkowitz S. Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy. Cells 2022;11. [PMID: 36496977 DOI: 10.3390/cells11233717] [Reference Citation Analysis]
|
| 181 |
Panagi M, Mpekris F, Chen P, Voutouri C, Nakagawa Y, Martin JD, Hiroi T, Hashimoto H, Demetriou P, Pierides C, Samuel R, Stylianou A, Michael C, Fukushima S, Georgiou P, Papageorgis P, Papaphilippou PC, Koumas L, Costeas P, Ishii G, Kojima M, Kataoka K, Cabral H, Stylianopoulos T. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models. Nat Commun 2022;13:7165. [PMID: 36418896 DOI: 10.1038/s41467-022-34744-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 182 |
Inoue T, Narukawa M. Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Control 2022;29:10732748221140694. [PMID: 36748438 DOI: 10.1177/10732748221140694] [Reference Citation Analysis]
|
| 183 |
Ke L, Li S, Cui H. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis. BMC Cancer 2022;22:1185. [DOI: 10.1186/s12885-022-10284-1] [Reference Citation Analysis]
|
| 184 |
Luo K, Liu S, Shen X, Xu J, Shi C, Chao Y, Wen Z, Zhang K, Wang R, Liu B, Jiang Y. Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1003656] [Reference Citation Analysis]
|
| 185 |
Tan S, Yu J, Huang Q, Zhou N, Gou H. PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1006075] [Reference Citation Analysis]
|
| 186 |
Uceda-Castro R, Margarido AS, Cornet L, Vegna S, Hahn K, Song JY, Putavet DA, van Geldorp M, Çitirikkaya CH, de Keizer PLJ, Ter Beek LC, Borst GR, Akkari L, van Tellingen O, Broekman MLD, Vennin C, van Rheenen J. Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis. Cell Rep Med 2022;3:100821. [PMID: 36384097 DOI: 10.1016/j.xcrm.2022.100821] [Reference Citation Analysis]
|
| 187 |
Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, Jóźwiak K, Zu Eulenburg C, Kreipe HH, Harbeck N; ADAPT TN investigators. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clin Cancer Res 2022;28:4995-5003. [PMID: 35797219 DOI: 10.1158/1078-0432.CCR-22-0482] [Reference Citation Analysis]
|
| 188 |
Tower H, Dall G, Davey A, Stewart M, Lanteri P, Ruppert M, Lambouras M, Nasir I, Yeow S, Darcy PK, Ingman WV, Parker B, Haynes NM, Britt KL. Estrogen-induced immune changes within the normal mammary gland. Sci Rep 2022;12:18986. [PMID: 36347875 DOI: 10.1038/s41598-022-21871-4] [Reference Citation Analysis]
|
| 189 |
Uliano J, Nicolò E, Corvaja C, Taurelli Salimbeni B, Trapani D, Curigliano G. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. Expert Review of Clinical Pharmacology 2022. [DOI: 10.1080/17512433.2022.2142559] [Reference Citation Analysis]
|
| 190 |
Baldwin LA, Bartonicek N, Yang J, Wu SZ, Deng N, Roden DL, Chan CL, Al-Eryani G, Zanker DJ, Parker BS, Swarbrick A, Junankar S. DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. Nat Commun 2022;13:6539. [PMID: 36344500 DOI: 10.1038/s41467-022-34041-x] [Reference Citation Analysis]
|
| 191 |
Sharmni Vishnu K, Win TT, Aye SN, Basavaraj AK. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. BMC Cancer 2022;22:1139. [DOI: 10.1186/s12885-022-10225-y] [Reference Citation Analysis]
|
| 192 |
Shen X, Chen T, Liu N, Yang B, Feng G, Yu P, Zhan C, Yin N, Wang Y, Huang B, Chen S. MRI-guided microwave ablation and albumin-bound paclitaxel for lung tumors: Initial experience. Front Bioeng Biotechnol 2022;10. [DOI: 10.3389/fbioe.2022.1011753] [Reference Citation Analysis]
|
| 193 |
Aparicio B, Repáraz D, Ruiz M, Llopiz D, Silva L, Vercher E, Theunissen P, Tamayo I, Smerdou C, Igea A, Santisteban M, Gónzalez-deza C, Lasarte JJ, Hervás-stubbs S, Sarobe P. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.985886] [Reference Citation Analysis]
|
| 194 |
Torregrosa C, Chorin F, Beltran EEM, Neuzillet C, Cardot-ruffino V. Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s Perspectives. Cancers 2022;14:5402. [DOI: 10.3390/cancers14215402] [Reference Citation Analysis]
|
| 195 |
Huang C, Li C, Cai J, Chen J, Wang B, Li M, Zhou W, Wang J, Zhang P, Zhang JV. Chondroitin Sulfate Targeting Nanodrug Achieves Near-Infrared Fluorescence-Guided Chemotherapy Against Triple-Negative Breast Primary and Lung Metastatic Cancer. IJN 2022;Volume 17:5547-5563. [DOI: 10.2147/ijn.s380358] [Reference Citation Analysis]
|
| 196 |
Liu S, Li J, Gu L, Wu K, Xing H. Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer. IJN 2022;Volume 17:5209-5227. [DOI: 10.2147/ijn.s388075] [Reference Citation Analysis]
|
| 197 |
Taurelli Salimbeni B, Corvaja C, Valenza C, Zagami P, Curigliano G. The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. Expert Opin Investig Drugs 2022;31:1203-26. [PMID: 36413823 DOI: 10.1080/13543784.2022.2151433] [Reference Citation Analysis]
|
| 198 |
Vlajnic T, Baur F, Soysal SD, Weber WP, Piscuoglio S, Muenst S. PD-L1 Expression in Triple-negative Breast Cancer-a Comparative Study of 3 Different Antibodies. Appl Immunohistochem Mol Morphol 2022;30:726-30. [PMID: 36165931 DOI: 10.1097/PAI.0000000000001062] [Reference Citation Analysis]
|
| 199 |
Minegishi S, Kinguchi S, Horita N, Namkoong H, Briasoulis A, Ishigami T, Tamura K, Nishiyama A, Yano Y, Japanese Society of Hypertension working group “Onco-Hypertension”. Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. Hypertension 2022;79:2611-2621. [DOI: 10.1161/hypertensionaha.122.19865] [Reference Citation Analysis]
|
| 200 |
Nelczyk AT, Ma L, Gupta AD, Gamage HEV, McHenry MT, Henn MA, Kadiri M, Wang Y, Krawczynska N, Bendre S, He S, Shahoei SH, Madak-Erdogan Z, Hsiao SH, Saleh T, Carpenter V, Gewirtz DA, Spinella MJ, Nelson ER. The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer. Biochim Biophys Acta Mol Basis Dis 2022;1868:166515. [PMID: 35932893 DOI: 10.1016/j.bbadis.2022.166515] [Reference Citation Analysis]
|
| 201 |
Eugene B. Cone, Lorine Haeuser, Stephen W. Reese, Maya Marchese, David-Dan Nguyen, Junaid Nabi, Wesley H. Chou, Joachim Noldus, Rana R. McKay, Kerry Laing Kilbridge, Quoc-Dien Trinh. Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS One 2022;17:e0272022. [PMID: 36318537 DOI: 10.1371/journal.pone.0272022] [Reference Citation Analysis]
|
| 202 |
Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Semin Cancer Biol 2022;86:981-96. [PMID: 35149179 DOI: 10.1016/j.semcancer.2022.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 203 |
Ismail A, El-mahdy HA, Abulsoud AI, Sallam AM, Eldeib MG, Elsakka EG, Zaki MB, Doghish AS. Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review. International Journal of Biological Macromolecules 2022. [DOI: 10.1016/j.ijbiomac.2022.10.241] [Reference Citation Analysis]
|
| 204 |
Liang Y, Min D, Fan H, Liu K, Tu J, He X, Liu B, Zhou L, Liu S, Sun X. Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.023] [Reference Citation Analysis]
|
| 205 |
Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, Koo KM, Tan PH, Tan DS, Dent RA. Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing? JCO Precision Oncology 2022. [DOI: 10.1200/po.22.00309] [Reference Citation Analysis]
|
| 206 |
Ahmed Khalil A, Rauf A, Alhumaydhi FA, Aljohani ASM, Javed MS, Khan MA, Khan IA, El-Esawi MA, Bawazeer S, Bouyahya A, Rebezov M, Shariati MA, Thiruvengadam M. Recent Developments and Anticancer Therapeutics of Paclitaxel: An Update. Curr Pharm Des 2022;28:3363-73. [PMID: 36330627 DOI: 10.2174/1381612829666221102155212] [Reference Citation Analysis]
|
| 207 |
Shi W, Chen Z, Liu H, Miao C, Feng R, Wang G, Chen G, Chen Z, Fan P, Pang W, Li C. COL11A1 as an novel biomarker for breast cancer with machine learning and immunohistochemistry validation. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.937125] [Reference Citation Analysis]
|
| 208 |
Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Delle Piane C, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. Breast 2022;66:293-304. [PMID: 36379199 DOI: 10.1016/j.breast.2022.10.014] [Reference Citation Analysis]
|
| 209 |
Jake G Maule, Lani K Clinton, Ryon P Graf, Jinpeng Xiao, Geoffrey R Oxnard, Jeffrey S Ross, Richard S P Huang. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. J Immunother Cancer 2022;10:e005573. [PMID: 36302564 DOI: 10.1136/jitc-2022-005573] [Reference Citation Analysis]
|
| 210 |
Jungles KM, Holcomb EA, Pearson AN, Jungles KR, Bishop CR, Pierce LJ, Green MD, Speers CW. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1022542] [Reference Citation Analysis]
|
| 211 |
Deutschmann C, Bartsch R, Singer CF, Gschwantler-Kaulich D, Seifert M, Leser C, Marhold M, Bago-Horvath Z, Pfeiler G. Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. BMC Cancer 2022;22:1099. [PMID: 36289467 DOI: 10.1186/s12885-022-10168-4] [Reference Citation Analysis]
|
| 212 |
Tsimberidou AM, Fountzilas E, Kurzrock R. Precision Medicine in Oncology Drug Development. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm052.pub3] [Reference Citation Analysis]
|
| 213 |
Sharma P, Anandhan S, Siddiqui BA, Goswami S, Subudhi SK, Gao J, Peggs K, Quezada S, Allison JP. Cancer Immunotherapy. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm068.pub2] [Reference Citation Analysis]
|
| 214 |
Heimes AS, Almstedt K, Krajnak S, Runkel A, Droste A, Schwab R, Stewen K, Lebrecht A, Battista MJ, Brenner W, Hasenburg A, Gehrmann M, Hengstler JG, Schmidt M. Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer. Biomedicines 2022;10. [PMID: 36289918 DOI: 10.3390/biomedicines10102656] [Reference Citation Analysis]
|
| 215 |
Tripathy D, Makhnoon S, Arun B, Sahin A, Kettner NM, Damodaran S, Keyomarsi K, Yang W, Hunt KK, Clemens M, Woodward WA, Mitchell MP, Layman R, Hobbs EA, Lim B, Dupuis M, Murthy R, Alhalabi O, Ibrahim N, Subbiah IM, Barcenas C. Neoplasms of the Breast. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm109.pub2] [Reference Citation Analysis]
|
| 216 |
Corvaja C, Taurelli Salimbeni B, Nicolò E, Puglisi F, Curigliano G. Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance. Expert Opin Pharmacother 2022. [PMID: 36268855 DOI: 10.1080/14656566.2022.2139176] [Reference Citation Analysis]
|
| 217 |
Rahmy S, Mishra SJ, Murphy S, Blagg BSJ, Lu X. Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors. Front Immunol 2022;13:1005045. [PMID: 36341371 DOI: 10.3389/fimmu.2022.1005045] [Reference Citation Analysis]
|
| 218 |
Li X, Tang L, Chen Q, Cheng X, Liu Y, Wang C, Zhu C, Xu K, Gao F, Huang J, Wang R, Guan X. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer. Chin Med J (Engl) 2022;135:2436-45. [PMID: 36583862 DOI: 10.1097/CM9.0000000000002329] [Reference Citation Analysis]
|
| 219 |
Avila J, Leone JP. Advances in the Management of Central Nervous System Metastases from Breast Cancer. IJMS 2022;23:12525. [DOI: 10.3390/ijms232012525] [Reference Citation Analysis]
|
| 220 |
Zhong Y, Ren X, Cao X, Xu Y, Song Y, Zhou Y, Mao F, Shen S, Wang Z, Sun Q. Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis. Front Oncol 2022;12:871786. [DOI: 10.3389/fonc.2022.871786] [Reference Citation Analysis]
|
| 221 |
Turri G, Caligola S, Ugel S, Conti C, Zenuni S, Barresi V, Ruzzenente A, Lippi G, Scarpa A, Guglielmi A, Pedrazzani C. Analysis of pre-diagnostic values of leukocytes count and neutrophil-to-lymphocyte ratio in patients who develop colorectal cancer.. [DOI: 10.21203/rs.3.rs-2146681/v1] [Reference Citation Analysis]
|
| 222 |
Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET 3rd, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer 2022;10:e005119. [PMID: 36252998 DOI: 10.1136/jitc-2022-005119] [Reference Citation Analysis]
|
| 223 |
Sun X, Lu Z, Liang Z, Deng B, Zhu Y, Shi J, Lu X. Transcriptomics and Proteomics Characterizing the Anticancer Mechanisms of Natural Rebeccamycin Analog Loonamycin in Breast Cancer Cells. Molecules 2022;27:6958. [DOI: 10.3390/molecules27206958] [Reference Citation Analysis]
|
| 224 |
Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H. A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630. Clin Cancer Res 2022;28:4402-9. [PMID: 35980349 DOI: 10.1158/1078-0432.CCR-22-1687] [Reference Citation Analysis]
|
| 225 |
Wang J, Li J, Wu Y, Xu X, Qian X, Lei Y, Liu H, Zhang Z, Li Y. ROS-Responsive Nanocomplex of aPD-L1 and Cabazitaxel Improves Intratumor Delivery and Potentiates Radiation-Mediated Antitumor Immunity. Nano Lett 2022. [PMID: 36226914 DOI: 10.1021/acs.nanolett.2c03227] [Reference Citation Analysis]
|
| 226 |
Giannopoulos S, Bozkus CC, Zografos E, Athanasiou A, Bongiovanni AM, Doulaveris G, Bakoyiannis CN, Theodoropoulos GE, Zografos GC, Witkin SS, Orfanelli T. Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment. Metabolites 2022;12:966. [DOI: 10.3390/metabo12100966] [Reference Citation Analysis]
|
| 227 |
Sasaki E, Iwakoshi A, Satake T, Nakajima K, Kobayashi M, Ando Y, Koshikawa T, Masago K, Honma N, Nishimura R, Kato Y, Ichihara S. The Diagnostic Utility of IDH2 R172 Immunohistochemistry in Tall Cell Carcinoma With Reversed Polarity of the Breast. Appl Immunohistochem Mol Morphol 2022. [PMID: 36222504 DOI: 10.1097/PAI.0000000000001074] [Reference Citation Analysis]
|
| 228 |
Paratore C, Zichi C, Audisio M, Bungaro M, Caglio A, Di Liello R, Gamba T, Gargiulo P, Mariniello A, Reale ML, Perrone F, Di Maio M. Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. ESMO Open 2022;7:100593. [PMID: 36228332 DOI: 10.1016/j.esmoop.2022.100593] [Reference Citation Analysis]
|
| 229 |
Liu J, Yu Y, Liu C, Gao C, Zhuang J, Liu L, Wu Q, Ma W, Zhang Q, Sun C. Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment. Front Pharmacol 2022;13:1035954. [DOI: 10.3389/fphar.2022.1035954] [Reference Citation Analysis]
|
| 230 |
Onagi H, Horimoto Y, Sakaguchi A, Ikarashi D, Yanagisawa N, Nakayama T, Nakatsura T, Ishizuka Y, Sasaki R, Watanabe J, Saito M, Saeki H, Hayashi T, Arakawa A, Yao T, Kitano S. High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. Breast Cancer Res 2022;24:67. [PMID: 36217150 DOI: 10.1186/s13058-022-01563-7] [Reference Citation Analysis]
|
| 231 |
Nicolini A, Ferrari P, Carpi A. Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. Biomedicines 2022;10:2511. [PMID: 36289773 DOI: 10.3390/biomedicines10102511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 232 |
Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol 2022;15:143. [PMID: 36209184 DOI: 10.1186/s13045-022-01362-9] [Reference Citation Analysis]
|
| 233 |
Makrantonakis AE, Zografos E, Gazouli M, Dimitrakakis K, Toutouzas KG, Zografos CG, Kalapanida D, Tsiakou A, Samelis G, Zagouri F. PD-L1 Gene Polymorphisms rs822336 G>C and rs822337 T>A: Promising Prognostic Markers in Triple Negative Breast Cancer Patients. Medicina (Kaunas) 2022;58. [PMID: 36295559 DOI: 10.3390/medicina58101399] [Reference Citation Analysis]
|
| 234 |
Lin PH, Laliotis G. The Present and Future of Clinical Management in Metastatic Breast Cancer. JCM 2022;11:5891. [DOI: 10.3390/jcm11195891] [Reference Citation Analysis]
|
| 235 |
Huo Y, Shao S, Liu E, Li J, Tian Z, Wu X, Zhang S, Stover D, Wu H, Cheng L, Li L. Subpathway Analysis of Transcriptome Profiles Reveals New Molecular Mechanisms of Acquired Chemotherapy Resistance in Breast Cancer. Cancers (Basel) 2022;14. [PMID: 36230801 DOI: 10.3390/cancers14194878] [Reference Citation Analysis]
|
| 236 |
Pousette J, Johansson A, Jönsson C, Fornander T, Lindström LS, Olsson H, Perez-Tenorio G. Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients. Cancers (Basel) 2022;14. [PMID: 36230767 DOI: 10.3390/cancers14194844] [Reference Citation Analysis]
|
| 237 |
Qu J, Sun F, Guan H, Hou Y, Qi H, Sun X, Xing L. The immune-related gene-based prognostic index predicts the prognosis and effect of immune checkpoint inhibitors in hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2092544/v1] [Reference Citation Analysis]
|
| 238 |
Bobrie A, Massol O, Ramos J, Mollevi C, Lopez-Crapez E, Bonnefoy N, Boissière-Michot F, Jacot W. Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. Cancers (Basel) 2022;14. [PMID: 36230752 DOI: 10.3390/cancers14194829] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 239 |
Tang X, Yang ZZ, Kim HJ, Anagnostou T, Yu Y, Wu X, Chen J, Krull JE, Wenzl K, Mondello P, Bhardwaj V, Wang J, Novak AJ, Ansell SM. Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma. Clin Cancer Res 2022;28:4322-35. [PMID: 35686915 DOI: 10.1158/1078-0432.CCR-22-0977] [Reference Citation Analysis]
|
| 240 |
Fu WD, Wang XH, Lu KK, Lu YQ, Zhou JY, Huang QD, Guo GL. Real-world outcomes for Chinese breast cancer patients with tumor location of central and nipple portion. Front Surg 2022;9:993263. [PMID: 36263089 DOI: 10.3389/fsurg.2022.993263] [Reference Citation Analysis]
|
| 241 |
Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Lab Invest 2022;102:1143-9. [PMID: 35581307 DOI: 10.1038/s41374-022-00796-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 242 |
Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Restuccia E, Schmid P. ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future Oncol 2022;18:3563-72. [PMID: 36382554 DOI: 10.2217/fon-2022-0485] [Reference Citation Analysis]
|
| 243 |
Untch M, Fasching PA, Haidinger R, Harbeck N, Jackisch C, Lüftner D, Müller V, Schumacher-Wulf E, Würstlein R, Thomssen C. Advanced Breast Cancer: AGO Recommendations 2022 - Focus on ABC6 Consensus. Geburtshilfe Frauenheilkd 2022;82:1044-54. [PMID: 36186150 DOI: 10.1055/a-1904-6100] [Reference Citation Analysis]
|
| 244 |
Kawaguchi K, Maeshima Y, Toi M. Tumor immune microenvironment and systemic response in breast cancer. Med Oncol 2022;39:208. [PMID: 36175677 DOI: 10.1007/s12032-022-01782-0] [Reference Citation Analysis]
|
| 245 |
Xu Z, Shi T, Mo F, Yu W, Shen Y, Jiang Q, Wang F, Liu X. Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy. Angew Chem Int Ed 2022. [DOI: 10.1002/anie.202211505] [Reference Citation Analysis]
|
| 246 |
Gou Q, Liu Z, Xie Y, Deng Y, Ma J, Li J, Zheng H. Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation. Front Pharmacol 2022;13:995555. [DOI: 10.3389/fphar.2022.995555] [Reference Citation Analysis]
|
| 247 |
. Breast Cancer. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch6] [Reference Citation Analysis]
|
| 248 |
Altena R, Bajalica-lagercrantz S, Papakonstantinou A. Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies. Cancers 2022;14:4665. [DOI: 10.3390/cancers14194665] [Reference Citation Analysis]
|
| 249 |
Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2022;101:e30830. [PMID: 36197237 DOI: 10.1097/MD.0000000000030830] [Reference Citation Analysis]
|
| 250 |
Li W, Zhang X, Chen Y, Pang D. Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer. Front Oncol 2022;12:966511. [DOI: 10.3389/fonc.2022.966511] [Reference Citation Analysis]
|
| 251 |
Kalot G, Godard A, Busser B, Bendellaa M, Dalonneau F, Paul C, Le Guével X, Josserand V, Coll JL, Denat F, Bodio E, Goze C, Gautier T, Sancey L. Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting. Biomater Sci 2022. [PMID: 36149672 DOI: 10.1039/d2bm01271e] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 252 |
Kim CM, Lee JB, Shin SJ, Ahn JB, Lee M, Kim HS. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO Open 2022;7:100577. [PMID: 36156450 DOI: 10.1016/j.esmoop.2022.100577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 253 |
Stanowska O, Kuczkiewicz-Siemion O, Dębowska M, Olszewski WP, Jagiełło-Gruszfeld A, Tysarowski A, Prochorec-Sobieszek M. PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment-A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters. J Clin Med 2022;11. [PMID: 36233396 DOI: 10.3390/jcm11195524] [Reference Citation Analysis]
|
| 254 |
Ke L, Li S, Cui H. The Predictive Effect of Tumor Mutation Burden on prognosis in Breast cancer: A Systematic Review and Meta-Analysis.. [DOI: 10.21203/rs.3.rs-2043934/v1] [Reference Citation Analysis]
|
| 255 |
Wang Y, Minden A. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. IJMS 2022;23:11046. [DOI: 10.3390/ijms231911046] [Reference Citation Analysis]
|
| 256 |
Chen C, Ma X, Li Y, Ma J, Yang W, Shui R. Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study. Pathol Res Pract 2022;238:154137. [PMID: 36152566 DOI: 10.1016/j.prp.2022.154137] [Reference Citation Analysis]
|
| 257 |
Gámez-Chiachio M, Sarrió D, Moreno-Bueno G. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers (Basel) 2022;14:4543. [PMID: 36139701 DOI: 10.3390/cancers14184543] [Reference Citation Analysis]
|
| 258 |
Luo L, Wei Q, Xu C, Dong M, Zhao W. Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer. Front Immunol 2022;13:933703. [DOI: 10.3389/fimmu.2022.933703] [Reference Citation Analysis]
|
| 259 |
Irabor OC, Nelson N, Shah Y, Niazi MK, Poiset S, Storozynsky E, Singla DK, Hooper DC, Lu B. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Front Oncol 2022;12:940127. [DOI: 10.3389/fonc.2022.940127] [Reference Citation Analysis]
|
| 260 |
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 2022;13:964442. [DOI: 10.3389/fimmu.2022.964442] [Reference Citation Analysis]
|
| 261 |
Alonso-miguel D, Fiering S, Arias-pulido H. Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes. Cells 2022;11:2850. [DOI: 10.3390/cells11182850] [Reference Citation Analysis]
|
| 262 |
López Flores M, Honrado Franco E, Sánchez Cousido LF, Minguito-Carazo C, Sanz Guadarrama O, López González L, Vallejo Pascual ME, Molina de la Torre AJ, García Palomo A, López González A. Relationship between Aldehyde Dehydrogenase, PD-L1 and Tumor-Infiltrating Lymphocytes with Pathologic Response and Survival in Breast Cancer. Cancers (Basel) 2022;14. [PMID: 36139578 DOI: 10.3390/cancers14184418] [Reference Citation Analysis]
|
| 263 |
Yuan K, Wu J, Zhao Y, Lyu S, Zhou Q, Shi F, Li Y, Song Q. Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test. Diagn Pathol 2022;17. [DOI: 10.1186/s13000-022-01249-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 264 |
Tian Y, Huang A, Tian M, Wang K, Dang Q, Zhang C, Liu H, Zhao J, Yang X, Zhang C, Guo L, Chen F. Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e30151. [PMID: 36086680 DOI: 10.1097/MD.0000000000030151] [Reference Citation Analysis]
|
| 265 |
Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Front Immunol 2022;13:982026. [DOI: 10.3389/fimmu.2022.982026] [Reference Citation Analysis]
|
| 266 |
Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun (Lond) 2022. [PMID: 36074908 DOI: 10.1002/cac2.12358] [Reference Citation Analysis]
|
| 267 |
van der Noord VE, van de Water B, Le Dévédec SE. Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery. Cancers 2022;14:4353. [DOI: 10.3390/cancers14184353] [Reference Citation Analysis]
|
| 268 |
Miglietta F, Visani L, Marini S, Griguolo G, Vernaci GM, Bottosso M, Dieci MV, Meattini I, Guarneri V. Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? Cancer Treat Rev 2022;110:102462. [PMID: 36087503 DOI: 10.1016/j.ctrv.2022.102462] [Reference Citation Analysis]
|
| 269 |
Zhang T, Wang Y, Shi C, Liu X, Lv S, Wang X, Li W. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Front Pharmacol 2022;13:955701. [DOI: 10.3389/fphar.2022.955701] [Reference Citation Analysis]
|
| 270 |
Song YM, Qian XL, Xia XQ, Li YQ, Sun YY, Jia YM, Wang J, Xue HQ, Gao GS, Wang XZ, Zhang XM, Guo XJ. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression. Breast Cancer Res Treat 2022. [PMID: 36056297 DOI: 10.1007/s10549-022-06679-0] [Reference Citation Analysis]
|
| 271 |
Manspeaker MP, O'Melia MJ, Thomas SN. Elicitation of stem-like CD8+ T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control. J Immunother Cancer 2022;10:e005079. [PMID: 36100312 DOI: 10.1136/jitc-2022-005079] [Reference Citation Analysis]
|
| 272 |
Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J Exp Clin Cancer Res 2022;41:265. [DOI: 10.1186/s13046-022-02476-1] [Reference Citation Analysis]
|
| 273 |
Maier AM, Hester A, Harbeck N, Würstlein R. Therapie des triple-negativen Mammakarzinoms. InFo Hämatol Onkol 2022;25:42-55. [DOI: 10.1007/s15004-022-9153-9] [Reference Citation Analysis]
|
| 274 |
Sun X, Li T, Wang P, Shang L, Niu M, Meng X, Shao H. Nanomaterials and Advances in Tumor Immune-Related Therapy: A Bibliometric Analysis. j biomed nanotechnol 2022;18:2154-2170. [DOI: 10.1166/jbn.2022.3415] [Reference Citation Analysis]
|
| 275 |
Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). J Immunother Cancer 2022;10. [PMID: 36175037 DOI: 10.1136/jitc-2022-005413] [Reference Citation Analysis]
|
| 276 |
Bronger H, Ettl J. Immunonkologie: Neues zum Endometrium‑, Zervix- und triple-negativen Mammakarzinom. Gynäkologie 2022;55:660-667. [DOI: 10.1007/s00129-022-04986-7] [Reference Citation Analysis]
|
| 277 |
Mezni E, Behi K, Gonçalves A. Immunotherapy and breast cancer: an overview. Curr Opin Oncol 2022;34:587-94. [PMID: 35838204 DOI: 10.1097/CCO.0000000000000878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 278 |
Kadono T, Yamamoto S, Kato K. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Jpn J Clin Oncol 2022:hyac138. [PMID: 36047845 DOI: 10.1093/jjco/hyac138] [Reference Citation Analysis]
|
| 279 |
Zhu J, Luo M, Liang D, Gao S, Zheng Y, He Z, Zhao W, Yu X, Qiu K, Wu J. Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data. International Immunopharmacology 2022;110:109053. [DOI: 10.1016/j.intimp.2022.109053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 280 |
Ge X, Yost SE, Lee JS, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Chung S, Yeon C, Stewart D, Li D, Rajurkar S, Somlo G, Mortimer J, Waisman J, Yuan Y. Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. Cancers (Basel) 2022;14. [PMID: 36077811 DOI: 10.3390/cancers14174279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 281 |
Yildirim HC, Guven DC, Aktepe OH, Taban H, Yilmaz F, Yasar S, Aksoy S, Erman M, Kilickap S, Yalcin S. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. J Clin Med 2022;11. [PMID: 36079101 DOI: 10.3390/jcm11175171] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 282 |
Friebe V, Fehm T, Ruckhäberle E. Immuntherapien bei gynäkologischen Tumoren. best practice onkologie 2022;17:386-394. [DOI: 10.1007/s11654-022-00418-z] [Reference Citation Analysis]
|
| 283 |
Kosaka Y, Saeki T, Takano T, Aruga T, Yamashita T, Masuda N, Koibuchi Y, Osaki A, Watanabe J, Suzuki R. . IJN 2022;Volume 17:4567-78. [DOI: 10.2147/ijn.s372477] [Reference Citation Analysis]
|
| 284 |
Kaneko K, Acharya CR, Nagata H, Yang X, Hartman ZC, Hobeika A, Hughes PF, Haystead TAJ, Morse MA, Lyerly HK, Osada T. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers. J Immunother Cancer 2022;10. [PMID: 36171008 DOI: 10.1136/jitc-2022-004793] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 285 |
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Elisa Onesti C, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D. Multiple Bayesian Network Meta-Analyses to Establish Therapeutic Algorithms for Metastatic Triple Negative Breast Cancer. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 286 |
So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. Pharmacology & Therapeutics 2022;237:108253. [DOI: 10.1016/j.pharmthera.2022.108253] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 287 |
Huang Q, Mei Z, Han X. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials. Front Oncol 2022;12:972767. [DOI: 10.3389/fonc.2022.972767] [Reference Citation Analysis]
|
| 288 |
Verret B, Bottosso M, Hervais S, Pistilli B. The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. Cancers 2022;14:4203. [DOI: 10.3390/cancers14174203] [Reference Citation Analysis]
|
| 289 |
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 2022;15:121. [PMID: 36038913 DOI: 10.1186/s13045-022-01341-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 290 |
Chen MS, Liu PC, Yi JZ, Xu L, He T, Wu H, Yang JQ, Lv Q. Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer. Sci Rep 2022;12:14659. [PMID: 36038627 DOI: 10.1038/s41598-022-18727-2] [Reference Citation Analysis]
|
| 291 |
Lee YJ, Kim JY, Jeon SH, Nam H, Jung JH, Jeon M, Kim ES, Bae SJ, Ahn J, Yoo TK, Sun WY, Ahn SG, Jeong J, Park SH, Park WC, Kim SI, Shin EC. CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. Sci Immunol 2022;7:eabn8390. [PMID: 36026440 DOI: 10.1126/sciimmunol.abn8390] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 292 |
Lucas MW, Kelly CM. Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights. Cancer Manag Res 2022;14:2493-506. [PMID: 35999966 DOI: 10.2147/CMAR.S341466] [Reference Citation Analysis]
|
| 293 |
File DM, Pascual T, Deal AM, Wheless A, Perou CM, Claire Dees E, Carey LA. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. Breast Cancer Res Treat 2022. [PMID: 36008651 DOI: 10.1007/s10549-022-06700-6] [Reference Citation Analysis]
|
| 294 |
Deng H, Wang L, Wang N, Zhang K, Zhao Y, Qiu P, Qi X, Zhang D, Xu F, Liu J. Neoadjuvant Checkpoint Blockade in Combination with Chemotherapy in Patients with Tripe-Negative Breast Cancer: Exploratory Analysis of Real-World, Multicenter Data.. [DOI: 10.21203/rs.3.rs-1941236/v1] [Reference Citation Analysis]
|
| 295 |
Garufi G, Carbognin L, Schettini F, Seguí E, Di Leone A, Franco A, Paris I, Scambia G, Tortora G, Fabi A. Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. Cancers 2022;14:4064. [DOI: 10.3390/cancers14174064] [Reference Citation Analysis]
|
| 296 |
Dobritoiu F, Baltan A, Chefani A, Billingham K, Chenard MP, Vaziri R, Lacroix-Triki M, Waydelich A, Erb G, Andersson E, Cañamero M, Toro P, Wedden S, D'Arrigo C. Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC). Appl Immunohistochem Mol Morphol 2022. [PMID: 36036647 DOI: 10.1097/PAI.0000000000001053] [Reference Citation Analysis]
|
| 297 |
Li L, Li L, Sun Q. High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases. BMC Bioinformatics 2022;23:350. [PMID: 35996075 DOI: 10.1186/s12859-022-04894-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 298 |
Wang H, Zhao C, Santa-Maria CA, Emens LA, Popel AS. Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. iScience 2022;25:104702. [PMID: 35856032 DOI: 10.1016/j.isci.2022.104702] [Reference Citation Analysis]
|
| 299 |
Ribeiro R, Carvalho MJ, Goncalves J, Moreira JN. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. Front Mol Biosci 2022;9:903065. [DOI: 10.3389/fmolb.2022.903065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 300 |
Hong K, Zhang Y, Yao L, Zhang J, Sheng X, Song L, Guo Y, Guo Y. Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer. Front Cell Dev Biol 2022;10:913684. [DOI: 10.3389/fcell.2022.913684] [Reference Citation Analysis]
|
| 301 |
Azim HA, Shohdy KS, Elghazawy H, Salib MM, Almeldin D, Kassem L. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis. Biomarkers 2022;:1-15. [PMID: 35980714 DOI: 10.1080/1354750X.2022.2112614] [Reference Citation Analysis]
|
| 302 |
Kwon MJ. Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. Arch Pharm Res 2022. [PMID: 35982262 DOI: 10.1007/s12272-022-01402-5] [Reference Citation Analysis]
|
| 303 |
Mandapati A, Lukong KE. Triple negative breast cancer: approved treatment options and their mechanisms of action. J Cancer Res Clin Oncol 2022. [PMID: 35976445 DOI: 10.1007/s00432-022-04189-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 304 |
Zhang F. Immune checkpoint inhibitors: the mechanisms, limitations, and improvements. HSET 2022;8:14-22. [DOI: 10.54097/hset.v8i.1105] [Reference Citation Analysis]
|
| 305 |
Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ Precis Oncol 2022;6:56. [PMID: 35974168 DOI: 10.1038/s41698-022-00297-1] [Reference Citation Analysis]
|
| 306 |
Yang X, Tang W, He Y, An H, Wang J. Development of a novel lipid metabolism-based signature to predict survival and immune response in triple negative breast cancer.. [DOI: 10.21203/rs.3.rs-1941091/v1] [Reference Citation Analysis]
|
| 307 |
Chung C, Yeung VTY, Wong KCW. Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. J Oncol Pharm Pract 2022;:10781552221119797. [PMID: 35971313 DOI: 10.1177/10781552221119797] [Reference Citation Analysis]
|
| 308 |
Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly L. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol 2022;204:115209. [PMID: 35973582 DOI: 10.1016/j.bcp.2022.115209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 309 |
Hamada K, Tsunoda T, Yoshimura K. Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. Life (Basel) 2022;12:1229. [PMID: 36013407 DOI: 10.3390/life12081229] [Reference Citation Analysis]
|
| 310 |
Koni M, Castellano I, Venturelli E, Sarcinella A, Lopatina T, Grange C, Cedrino M, Femminò S, Cossu-Rocca P, Orrù S, D'Ascenzo F, Cotellessa I, Tampieri C, Debernardi C, Cugliari G, Matullo G, Camussi G, De Miglio MR, Brizzi MF. Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target. Cancers (Basel) 2022;14:3918. [PMID: 36010912 DOI: 10.3390/cancers14163918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 311 |
Hooda-nehra A, L. Smith T, I. Ferrer A, I. Staquicini F, Arap W, Pasqualini R, Rameshwar P. Targeted Regulation and Cellular Imaging of Tumor-Associated Macrophages in Triple-Negative Breast Cancer: From New Mechanistic Insights to Candidate Translational Applications. Macrophages celebrating 140 years of discovery [Working Title] 2022. [DOI: 10.5772/intechopen.105654] [Reference Citation Analysis]
|
| 312 |
Korlimarla A, Ps H, Prabhu J, Ragulan C, Patil Y, Vp S, Desai K, Mathews A, Appachu S, Diwakar RB, Bs S, Melcher A, Cheang M, Sadanandam A. Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. Transl Oncol 2022;25:101511. [PMID: 35964339 DOI: 10.1016/j.tranon.2022.101511] [Reference Citation Analysis]
|
| 313 |
Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell 2022;5. [DOI: 10.3389/frai.2022.876100] [Reference Citation Analysis]
|
| 314 |
Liang T, Lu L, Song X, Qi J, Wang J. Combination of microtubule targeting agents with other antineoplastics for cancer treatment. Biochim Biophys Acta Rev Cancer 2022;1877:188777. [PMID: 35963551 DOI: 10.1016/j.bbcan.2022.188777] [Reference Citation Analysis]
|
| 315 |
Wesolowski J, Tankiewicz-kwedlo A, Pawlak D. Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. Cancers 2022;14:3860. [DOI: 10.3390/cancers14163860] [Reference Citation Analysis]
|
| 316 |
Qian X, Hu W, Yan J. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option? Front Immunol 2022;13:963533. [DOI: 10.3389/fimmu.2022.963533] [Reference Citation Analysis]
|
| 317 |
Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching PA, Nekljudova V, Denkert C, Untch M; GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022:S0923-7534(22)03791-7. [PMID: 35961599 DOI: 10.1016/j.annonc.2022.07.1940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 318 |
Tahir IM, Rauf A, Mehboob H, Sadaf S, Alam MS, Kalsoom F, Bouyahya A, El Allam A, El Omari N, Bakrim S, Akram M, Raza SK, Emran TB, Mabkhot YN, Zengin G, Derkho M, Natalya S, Shariati MA. Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. Hum Antibodies 2022;30:131-50. [PMID: 35938242 DOI: 10.3233/HAB-220001] [Reference Citation Analysis]
|
| 319 |
Kuczkiewicz-Siemion O, Sokół K, Puton B, Borkowska A, Szumera-Ciećkiewicz A. The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. Cancers (Basel) 2022;14:3833. [PMID: 35954496 DOI: 10.3390/cancers14153833] [Reference Citation Analysis]
|
| 320 |
Clarke S, Chin SN, Dodds L, George SHL, Badal S. Racial disparities in breast cancer preclinical and clinical models. Breast Cancer Res 2022;24:56. [PMID: 35932017 DOI: 10.1186/s13058-022-01551-x] [Reference Citation Analysis]
|
| 321 |
Yang M, Olaoba OT, Zhang C, Kimchi ET, Staveley-o’carroll KF, Li G. Cancer Immunotherapy and Delivery System: An Update. Pharmaceutics 2022;14:1630. [DOI: 10.3390/pharmaceutics14081630] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 322 |
Zhang J, Tang Z, Guo X, Wang Y, Zhou Y, Cai W. Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the Serpinc1 gene. Front Oncol 2022;12:933646. [DOI: 10.3389/fonc.2022.933646] [Reference Citation Analysis]
|
| 323 |
Kiss I, Kuhn M, Hrusak K, Buchler B, Boublikova L, Buchler T. Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. Front Oncol 2022;12:946307. [DOI: 10.3389/fonc.2022.946307] [Reference Citation Analysis]
|
| 324 |
Punekar SR, Shum E, Grello CM, Lau SC, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol 2022;12:877594. [DOI: 10.3389/fonc.2022.877594] [Reference Citation Analysis]
|
| 325 |
Cao J, Wang B, Zhang J, Tao Z, Wang L, Hu X. Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer. Front Oncol 2022;12:837963. [DOI: 10.3389/fonc.2022.837963] [Reference Citation Analysis]
|
| 326 |
Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, Navarro EA, Pasetto A, Nascimento Silva D, Ancarani V, Sambri V, Calabrò L, Martinelli G, Mazza M. T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. IJMS 2022;23:8590. [DOI: 10.3390/ijms23158590] [Reference Citation Analysis]
|
| 327 |
Gong J, Cao J, Zhang Q, Xu N, Zhao Y, Xing B, Miao Z, Wu Y, Pan H, Gao Q, Li X, Liu B, Li W, Pei Z, Xia H, Qi Q, Dai H, Shi Q, Yang J, Li J, Shen L. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. Cancer Immunol Immunother 2022;71:1897-1908. [DOI: 10.1007/s00262-021-03102-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 328 |
Li Z, Sun Y, Lai M, Zhou Y, Qiu M. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis. International Immunopharmacology 2022;109:108790. [DOI: 10.1016/j.intimp.2022.108790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 329 |
Azami T, Takano Y, Noda J, Yamawaki M, Yoshida E, Niiya F, Maruoka N, Ogawa T, Ichikawa W, Nagahama M. Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis. Clin J Gastroenterol 2022;15:818-821. [DOI: 10.1007/s12328-022-01651-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 330 |
Zhou L, Chen Q, Chen H, Wang L, Zhang J, Li Q. Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-11. [DOI: 10.1155/2022/4097576] [Reference Citation Analysis]
|
| 331 |
Presti D, Dall'Olio FG, Besse B, Ribeiro JM, Di Meglio A, Soldato D. Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: a systematic review. Crit Rev Oncol Hematol 2022;:103773. [PMID: 35917885 DOI: 10.1016/j.critrevonc.2022.103773] [Reference Citation Analysis]
|
| 332 |
Pleiko K, Haugas M, Parfejevs V, Pantelejevs T, Parisini E, Teesalu T, Riekstina U. Targeting triple-negative breast cancer with β1-integrin binding aptamer.. [DOI: 10.1101/2022.07.28.501822] [Reference Citation Analysis]
|
| 333 |
Ma Y, Ma X, Wang J, Wu S, Wang J, Cao B. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J Surg Oncol 2022;20:242. [PMID: 35897018 DOI: 10.1186/s12957-022-02695-y] [Reference Citation Analysis]
|
| 334 |
Righini M, Mollica V, Rizzo A, La Manna G, Massari F. Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. J Clin Med 2022;11. [PMID: 35955989 DOI: 10.3390/jcm11154373] [Reference Citation Analysis]
|
| 335 |
Yamashita N, Kufe D. Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression. Int J Mol Sci 2022;23:8219. [PMID: 35897789 DOI: 10.3390/ijms23158219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 336 |
Marczyk M, Qing T, O'Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. NPJ Breast Cancer 2022;8:88. [PMID: 35869114 DOI: 10.1038/s41523-022-00449-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 337 |
Zheng D, Hou X, Yu J, He X. Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. Front Pharmacol 2022;13:928369. [DOI: 10.3389/fphar.2022.928369] [Reference Citation Analysis]
|
| 338 |
Cortes J, Rugo HS, Cescon DW, Im S, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 2022;387:217-226. [DOI: 10.1056/nejmoa2202809] [Cited by in Crossref: 59] [Cited by in F6Publishing: 16] [Article Influence: 59.0] [Reference Citation Analysis]
|
| 339 |
Ahmad MZ, Alasiri AS, Alasmary MY, Abdullah MM, Ahmad J, Abdel Wahab BA, M Alqahtani SA, Pathak K, Mustafa G, Khan MA, Saikia R, Gogoi U. Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges. Immunotherapy 2022. [PMID: 35852105 DOI: 10.2217/imt-2021-0348] [Reference Citation Analysis]
|
| 340 |
Baram T, Oren N, Erlichman N, Meshel T, Ben-baruch A. Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer. Cancers 2022;14:3513. [DOI: 10.3390/cancers14143513] [Reference Citation Analysis]
|
| 341 |
Tian Y, Zhang C, Dang Q, Wang K, Liu Q, Liu H, Shang H, Zhao J, Xu Y, Wu T, Liu W, Yang X, Safi M, Wu YS. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4976032] [Reference Citation Analysis]
|
| 342 |
Lee JY, Kannan B, Lim BY, Li Z, Lim AH, Loh JW, Ko TK, Ng CC, Chan JY. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. Int J Mol Sci 2022;23:7839. [PMID: 35887186 DOI: 10.3390/ijms23147839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 343 |
Rodrigues-Ferreira S, Nahmias C. Predictive biomarkers for personalized medicine in breast cancer. Cancer Lett 2022;545:215828. [PMID: 35853538 DOI: 10.1016/j.canlet.2022.215828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 344 |
Mahmoud AS, Zakaria ZA, Hamzah HH, F.t.a. TA. An Overview of Breast Cancer Therapy. Breast Cancer: Current Trends in Molecular Research 2022. [DOI: 10.2174/9781681089522112010014] [Reference Citation Analysis]
|
| 345 |
Howard FM, Pearson AT, Nanda R. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2022. [PMID: 35834065 DOI: 10.1007/s10549-022-06665-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 346 |
Ou S, Luo J, Wei H, Qin X, Du S, Wang S, Jiang Q. Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews. Front Immunol 2022;13:953761. [DOI: 10.3389/fimmu.2022.953761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 347 |
Wang B, Sun T, Zhao Y, Wang S, Zhang J, Wang Z, Teng YE, Cai L, Yan M, Wang X, Jiang Z, Pan Y, Luo J, Shao Z, Wu J, Guo X, Hu X. A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun 2022;13:4025. [PMID: 35821019 DOI: 10.1038/s41467-022-31704-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 348 |
Silva M, Martins D, Mendes F. The Role of Immune Checkpoint Blockade in Acute Myeloid Leukemia. Onco 2022;2:164-180. [DOI: 10.3390/onco2030011] [Reference Citation Analysis]
|
| 349 |
Cheung A, Chenoweth AM, Quist J, Sow HS, Malaktou C, Ferro R, Hoffmann RM, Osborn G, Sachouli E, French E, Marlow R, Lacy KE, Papa S, Grigoriadis A, Karagiannis SN. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. Cancers (Basel) 2022;14. [PMID: 35884422 DOI: 10.3390/cancers14143361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 350 |
Liu C, Zhao Z, Gao R, Zhang X, Sun Y, Wu J, Liu J, Chen C. Matrix Metalloproteinase-2-Responsive Surface-Changeable Liposomes Decorated by Multifunctional Peptides to Overcome the Drug Resistance of Triple-Negative Breast Cancer through Enhanced Targeting and Penetrability. ACS Biomater Sci Eng 2022;8:2979-94. [PMID: 35666956 DOI: 10.1021/acsbiomaterials.2c00295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 351 |
Xie F, Zhou X, Li H, Su P, Liu S, Li R, Zou J, Wei X, Pan C, Zhang Z, Zheng M, Liu Z, Meng X, Ovaa H, Ten Dijke P, Zhou F, Zhang L. USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-β receptor TβRII. EMBO J 2022;:e108791. [PMID: 35811497 DOI: 10.15252/embj.2021108791] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 352 |
Antony GR, Augustine P, Parambil ST, Littleflower AB, Kattoor J, Krishna KMJ, Subhadradevi L. Immunohistochemical expression of PD-L1 and MDR1 in breast tumors: association with clinico-pathological parameters and treatment outcome. Clin Exp Med 2022. [PMID: 35810258 DOI: 10.1007/s10238-022-00852-x] [Reference Citation Analysis]
|
| 353 |
Yin J, Zhu C, Wang G, Gu J. Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses. Int J Gen Med 2022;15:5901-14. [PMID: 35795302 DOI: 10.2147/IJGM.S370351] [Reference Citation Analysis]
|
| 354 |
Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, Chaudhuri M, Bailly De Tilleghem CL, Cappoen N, O'Shaughnessy J. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. Immunotherapy 2022. [PMID: 35796042 DOI: 10.2217/imt-2022-0082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 355 |
Borgovan T, Yanamandra N, Schmidt H. INNATE IMMUNITY AS A TARGET FOR NOVEL THERAPEUTICS IN TRIPLE NEGATIVE BREAST CANCER. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2096005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 356 |
Yan W, Tang X, Wang L, He C, Cui X, Yuan S, Zhang H. Applicability analysis of immunotherapy for lung cancer patients based on deep learning. Methods 2022;205:149-56. [PMID: 35809770 DOI: 10.1016/j.ymeth.2022.07.004] [Reference Citation Analysis]
|
| 357 |
Wu B, Song M, Dong Q, Xiang G, Li J, Ma X, Wei F. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. Theranostics 2022;12:5086-102. [PMID: 35836797 DOI: 10.7150/thno.74989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 358 |
Méndez-lópez LF. Revisiting Epithelial Carcinogenesis. IJMS 2022;23:7437. [DOI: 10.3390/ijms23137437] [Reference Citation Analysis]
|
| 359 |
Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET 3rd, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen EM, Rodig S, Winer EP, Mittendorf EA, Wu CJ, Wagle N, Stover DG, Shukla SA, Tolaney SM. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precis Oncol 2022;6:e2100413. [PMID: 35797509 DOI: 10.1200/PO.21.00413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 360 |
Santa-maria CA, Dunn SA, Ho AY. Immunotherapy Combined with Radiation Therapy in Breast Cancer: A Rapidly Evolving Landscape. Seminars in Radiation Oncology 2022;32:291-7. [DOI: 10.1016/j.semradonc.2022.01.001] [Reference Citation Analysis]
|
| 361 |
Espié M, Bonnet-bensimon C, De Castelbajac V, Cuvier C, Giacchetti S, Teixeira L. Cáncer de mama metastásico. EMC - Ginecología-Obstetricia 2022;58:1-9. [DOI: 10.1016/s1283-081x(22)46717-8] [Reference Citation Analysis]
|
| 362 |
Dacosta PE, Naranjo L, Peg V. Immunologic determinants of mammary tumors: PD-L1 and TILS. Revista de Senología y Patología Mamaria 2022;35:S60-S66. [DOI: 10.1016/j.senol.2022.05.004] [Reference Citation Analysis]
|
| 363 |
Yang K, Li J, Zhao L, Sun Z, Bai C. Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors. Front Med 2022. [PMID: 35776405 DOI: 10.1007/s11684-021-0902-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 364 |
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial. Clin Cancer Res 2022;28:2807-17. [PMID: 35247906 DOI: 10.1158/1078-0432.CCR-21-4313] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 365 |
Jin L, Guo Y, Mao W, Wang J, Jin L, Liu X, Shou Q, Fu H. Total glucosides of paeony inhibit breast cancer growth by inhibiting TAMs infiltration through NF-κB/CCL2 signaling. Phytomedicine 2022. [DOI: 10.1016/j.phymed.2022.154307] [Reference Citation Analysis]
|
| 366 |
Tarantino D, Walker C, Weekes D, Pemberton H, Davidson K, Torga G, Frankum J, Mendes-Pereira AM, Prince C, Ferro R, Brough R, Pettitt SJ, Lord CJ, Grigoriadis A, Nj Tutt A. Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance. Oncogene 2022. [PMID: 35768547 DOI: 10.1038/s41388-022-02369-9] [Reference Citation Analysis]
|
| 367 |
Huober J, Barrios CH, Niikura N, Jarząb M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol 2022;:JCO2102772. [PMID: 35763704 DOI: 10.1200/JCO.21.02772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 368 |
Giugliano F, Valenza C, Tarantino P, Curigliano G. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced? Expert Opin Investig Drugs 2022. [PMID: 35762248 DOI: 10.1080/13543784.2022.2095260] [Reference Citation Analysis]
|
| 369 |
Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep 2022. [PMID: 35759082 DOI: 10.1007/s11033-022-07525-8] [Reference Citation Analysis]
|
| 370 |
Cserni G, Francz M, Járay B, Kálmán E, Kovács I, Krenács T, Tóth E, Udvarhelyi N, Vass L, Vörös A, Krivokuca A, Kajo K, Kajová Macháleková K, Kulka J. Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res 2022;28:1610373. [DOI: 10.3389/pore.2022.1610373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 371 |
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nat Commun 2022;13:3671. [PMID: 35760778 DOI: 10.1038/s41467-022-31238-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 372 |
De Francesco EM, Cirillo F, Vella V, Belfiore A, Maggiolini M, Lappano R. Triple-negative breast cancer drug resistance, durable efficacy, and cure: How advanced biological insights and emerging drug modalities could transform progress. Expert Opin Ther Targets 2022. [PMID: 35761781 DOI: 10.1080/14728222.2022.2094762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 373 |
Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 2022;:JCO2201063. [PMID: 35759724 DOI: 10.1200/JCO.22.01063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 374 |
Silva D, Mesquita A. Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer. Breast Cancer�(Auckl) 2022;16:117822342211075. [DOI: 10.1177/11782234221107580] [Reference Citation Analysis]
|
| 375 |
Saji S, Ohsumi S, Ito M, Hayashi N, Kobayashi K, Masuda N, Niikura N, Yamashita T, Kiyama K, Hasegawa A, Nakagawa S, Hattori M. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031). Jpn J Clin Oncol 2022:hyac098. [PMID: 35750038 DOI: 10.1093/jjco/hyac098] [Reference Citation Analysis]
|
| 376 |
Shi Y, Li Y, Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Lv C, Han S, Yu Y, Xu F, Tian Y. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. Int Immunopharmacol 2022;110:108968. [PMID: 35764018 DOI: 10.1016/j.intimp.2022.108968] [Reference Citation Analysis]
|
| 377 |
Zhao Q, He X, Qin X, Liu Y, Jiang H, Wang J, Wu S, Zhou R, Yu C, Liu S, Zhang H, Tian M. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer. Front Immunol 2022;13:938439. [DOI: 10.3389/fimmu.2022.938439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 378 |
Ning WJ, Liu X, Zeng HY, An ZQ, Luo WX, Xia NS. Recent progress in antibody-based therapeutics for triple-negative breast cancer. Expert Opin Drug Deliv 2022. [PMID: 35738312 DOI: 10.1080/17425247.2022.2093853] [Reference Citation Analysis]
|
| 379 |
Kim JM. Molecular Link between DNA Damage Response and Microtubule Dynamics. IJMS 2022;23:6986. [DOI: 10.3390/ijms23136986] [Reference Citation Analysis]
|
| 380 |
Zheng K, Luo Z, Zhou Y, Zhang L, Wang Y, Chen X, Yao S, Xiong H, Yuan X, Zou Y, Wang Y, Xiong H. A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration. Comput Math Methods Med 2022;2022:4635806. [PMID: 35720039 DOI: 10.1155/2022/4635806] [Reference Citation Analysis]
|
| 381 |
Baek SH, Kim JH, Bae SJ, Ji JH, Lee Y, Jeong J, Cha YJ, Ahn SG. SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer. Cancers 2022;14:3042. [DOI: 10.3390/cancers14133042] [Reference Citation Analysis]
|
| 382 |
Prasanna T, Malik L, McCuaig RD, Tu WJ, Wu F, Lim PS, Tan AHY, Dahlstrom JE, Clingan P, Moylan E, Chrisp J, Fuller D, Rao S, Yip D. A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED). Front Oncol 2022;12:862427. [PMID: 35719960 DOI: 10.3389/fonc.2022.862427] [Reference Citation Analysis]
|
| 383 |
Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Front Oncol 2022;12:919072. [DOI: 10.3389/fonc.2022.919072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 384 |
Glazkova EV, Frolova MA, Israelyan ER. Therapy options for metastatic triple negative breast cancer. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-9-201-206] [Reference Citation Analysis]
|
| 385 |
Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci 2022;23:6806. [PMID: 35743249 DOI: 10.3390/ijms23126806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 386 |
Hou Y, Peng Y, Li Z. Update on prognostic and predictive biomarkers of breast cancer. Semin Diagn Pathol 2022:S0740-2570(22)00053-3. [PMID: 35752515 DOI: 10.1053/j.semdp.2022.06.015] [Reference Citation Analysis]
|
| 387 |
Berrino E, Miglio U, Bellomo SE, Debernardi C, Bragoni A, Petrelli A, Cascardi E, Giordano S, Montemurro F, Marchiò C, Venesio T, Sapino A. The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients. Cells 2022;11:1944. [PMID: 35741073 DOI: 10.3390/cells11121944] [Reference Citation Analysis]
|
| 388 |
Haist M, Mailänder V, Bros M. Nanodrugs Targeting T Cells in Tumor Therapy. Front Immunol 2022;13:912594. [PMID: 35693776 DOI: 10.3389/fimmu.2022.912594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 389 |
Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med 2022;20:271. [PMID: 35706041 DOI: 10.1186/s12967-022-03472-x] [Reference Citation Analysis]
|
| 390 |
Zha H, Xu Z, Xu X, Lu X, Shi P, Xiao Y, Tsai HI, Su D, Cheng F, Cheng X, Chen H. PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell. Pharmaceutics 2022;14:1263. [PMID: 35745835 DOI: 10.3390/pharmaceutics14061263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 391 |
Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov 2022. [PMID: 35701637 DOI: 10.1038/s41573-022-00493-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 392 |
Liu C, Li Y, Xing X, Zhuang J, Wang J, Wang C, Zhang L, Liu L, Feng F, Li H, Gao C, Yu Y, Liu J, Sun C. Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer. Mol Ther Nucleic Acids 2022;28:670-84. [PMID: 35614988 DOI: 10.1016/j.omtn.2022.04.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 393 |
Emens LA, Cimino-Mathews A. Quiescent cancer cells: Therapeutic targets to overcome immunotherapy resistance? Med (N Y) 2022;3:358-60. [PMID: 35690055 DOI: 10.1016/j.medj.2022.05.013] [Reference Citation Analysis]
|
| 394 |
Čeprnja T, Mrklić I, Perić Balja M, Marušić Z, Blažićević V, Spagnoli GC, Juretić A, Čapkun V, Tečić Vuger A, Vrdoljak E, Tomić S. Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer. J Pers Med 2022;12. [PMID: 35743725 DOI: 10.3390/jpm12060941] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 395 |
Zambelli A, Sgarra R, De Sanctis R, Agostinetto E, Santoro A, Manfioletti G. Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. Expert Opin Ther Targets 2022;:1-17. [PMID: 35638300 DOI: 10.1080/14728222.2022.2084380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 396 |
Jing D, Wu W, Chen X, Xiao H, Zhang Z, Chen F, Zhang Z, Liu J, Shao Z, Pu F. Quercetin encapsulated in Folic Acid-Modified Liposomes is therapeutic against osteosarcoma by non-Covalent binding to the JH2 Domain of JAK2 Via the JAK2-STAT3-PDL1. Pharmacol Res 2022;:106287. [PMID: 35671921 DOI: 10.1016/j.phrs.2022.106287] [Reference Citation Analysis]
|
| 397 |
Rigiracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Adame-Garcia SR, Arang N, Lubrano S, De Francesco EM, Belfiore A, Gutkind JS, Maggiolini M. Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC). J Exp Clin Cancer Res 2022;41:193. [PMID: 35655319 DOI: 10.1186/s13046-022-02396-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 398 |
Lin J, Zhao A, Fu D. Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer. Sci Rep 2022;12:9311. [PMID: 35665772 DOI: 10.1038/s41598-022-13499-1] [Reference Citation Analysis]
|
| 399 |
Xu Y, Shu D, Shen M, Wu Q, Peng Y, Liu L, Tang Z, Gao S, Wang Y, Liu S, Cui D. Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer. Journal of Immunology Research 2022;2022:1-22. [DOI: 10.1155/2022/9412119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 400 |
Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H, Gu Z, Ma X, Luo K. Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. Adv Sci (Weinh) 2022;:e2201734. [PMID: 35652198 DOI: 10.1002/advs.202201734] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 401 |
Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. Am Soc Clin Oncol Educ Book 2022;42:1-13. [PMID: 35649211 DOI: 10.1200/EDBK_351186] [Reference Citation Analysis]
|
| 402 |
Zhou W, Yu M, Mao X, Pan H, Tang X, Wang J, Che N, Xie H, Ling L, Zhao Y, Liu X, Wang C, Zhang K, Qiu W, Ding Q, Wang S. Landscape of the Peripheral Immune Response Induced by Local Microwave Ablation in Patients with Breast Cancer. Adv Sci (Weinh) 2022;9:e2200033. [PMID: 35403824 DOI: 10.1002/advs.202200033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 403 |
Sanmamed MF, Berraondo P, Rodriguez-ruiz ME, Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer 2022;3:665-680. [DOI: 10.1038/s43018-022-00401-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 404 |
Kiss I, Kuhn M, Hrusak K, Buchler T. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. ESMO Open 2022;7:100474. [DOI: 10.1016/j.esmoop.2022.100474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 405 |
Marhold M. Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer. memo 2022;15:129-32. [DOI: 10.1007/s12254-021-00781-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 406 |
Qayoom H, Mehraj U, Aisha S, Sofi S, Ahmad Mir M. Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing. Drug Repurposing - Molecular Aspects and Therapeutic Applications 2022. [DOI: 10.5772/intechopen.100183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 407 |
Chebib I, Mino-Kenudson M. PD-L1 immunohistochemistry: Clones, cutoffs, and controversies. APMIS 2022;130:295-313. [PMID: 35332576 DOI: 10.1111/apm.13223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 408 |
Mo H, Breitling R, Francavilla C, Schwartz J. Data integration and mechanistic modelling for breast cancer biology: Current state and future directions. Current Opinion in Endocrine and Metabolic Research 2022;24:100350. [DOI: 10.1016/j.coemr.2022.100350] [Reference Citation Analysis]
|
| 409 |
Lepland A, Malfanti A, Haljasorg U, Asciutto EK, Pickholz M, Bringas M, Đorđević S, Salumäe L, Peterson P, Teesalu T, Vicent MJ, Scodeller P. Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice. Cancer Res Commun 2022;2:533-51. [PMID: 36923553 DOI: 10.1158/2767-9764.CRC-22-0043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 410 |
Mehlich D, Marusiak AA. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 411 |
Zhao S, Yan C, Lv H, Yang J, You C, Li Z, Ma D, Xiao Y, Hu J, Yang W, Jiang Y, Xu J, Shao Z. Deep learning framework for comprehensive molecular and prognostic stratifications of triple-negative breast cancer. Fundamental Research 2022. [DOI: 10.1016/j.fmre.2022.06.008] [Reference Citation Analysis]
|
| 412 |
Vittori C, Jeansonne D, Yousefi H, Faia C, Lin Z, Reiss K, Peruzzi F. Mechanisms of miR-3189-3p-mediated inhibition of c-MYC translation in triple negative breast cancer. Cancer Cell Int 2022;22:204. [PMID: 35642054 DOI: 10.1186/s12935-022-02620-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 413 |
Xiong J, Sheng J, Wei Y, Sun Z, Xiao X, Zhang L. Sesamol Augments Paclitaxel-Induced Apoptosis in Human Cervical Cancer Cell Lines. Nutr Cancer 2022;:1-9. [PMID: 35639488 DOI: 10.1080/01635581.2022.2079684] [Reference Citation Analysis]
|
| 414 |
Han MG, Wee CW, Kang MH, Kim MJ, Jeon SH, Kim IA. Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model. Cancers (Basel) 2022;14:2692. [PMID: 35681672 DOI: 10.3390/cancers14112692] [Reference Citation Analysis]
|
| 415 |
Ben Dori S, Aizic A, Zubkov A, Tsuriel S, Sabo E, Hershkovitz D. The risk of PD-L1 expression misclassification in triple-negative breast cancer. Breast Cancer Res Treat 2022. [PMID: 35622241 DOI: 10.1007/s10549-022-06630-3] [Reference Citation Analysis]
|
| 416 |
Boulos M, Moujaes E, Nsouli G, Tfayli A, Kourie HR. Talazoparib in BRCA-mutated advanced breast cancer: is earlier better? Pharmacogenomics 2022;23:487-92. [PMID: 35607887 DOI: 10.2217/pgs-2022-0011] [Reference Citation Analysis]
|
| 417 |
Shafi S, Parwani AV, Li Z. PD-L1 (SP142 and 22C3) Immunohistochemistry in Clinical Metastatic Triple Negative or Low Hormone Receptor Breast Carcinomas: Experience from a Large Academic Institution. Hum Pathol 2022:S0046-8177(22)00139-3. [PMID: 35623466 DOI: 10.1016/j.humpath.2022.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 418 |
Cherri S, Oneda E, Noventa S, Melocchi L, Zaniboni A. Microsatellite instability and chemosensitivity in solid tumours. Ther Adv Med Oncol 2022;14:175883592210993. [DOI: 10.1177/17588359221099347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 419 |
Yamaguchi H, Wang SC, Hung MC. Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy. Clin Transl Med 2022;12:e803. [PMID: 35588146 DOI: 10.1002/ctm2.803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 420 |
Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Tsuda B, Okamura T, Kumaki N, Hozumi K, Harada N, Iwamoto T, Honda C, Kurozumi S, Niikura N. Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression. Sci Rep 2022;12:8098. [PMID: 35577913 DOI: 10.1038/s41598-022-11578-x] [Reference Citation Analysis]
|
| 421 |
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J Immunother Cancer 2022;10. [PMID: 35577503 DOI: 10.1136/jitc-2021-004076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 422 |
Semiglazov V, Tseluiko A, Kudaybergenova A, Artemyeva A, Krivorotko P, Donskih R. Immunology and immunotherapy in breast cancer. Cancer Biol Med 2022;19:609-18. [PMID: 35676750 DOI: 10.20892/j.issn.2095-3941.2021.0597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 423 |
Larsson A, Nordström O, Johansson A, Rydén L, Leandersson K, Bergenfelz C. Peripheral Blood Mononuclear Cell Populations Correlate with Outcome in Patients with Metastatic Breast Cancer. Cells 2022;11:1639. [DOI: 10.3390/cells11101639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 424 |
Meng Z, Ye Z, Zhu P, Zhu J, Fang S, Qiu T, Li Y, Meng L. New Developments and Opportunities of Microbiota in Treating Breast Cancers. Front Microbiol 2022;13:818793. [DOI: 10.3389/fmicb.2022.818793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 425 |
Suppan C. ESMO 2021-my top three abstracts in breast cancer. Memo 2022;15:111-3. [PMID: 35540707 DOI: 10.1007/s12254-022-00810-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 426 |
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Barroso-Sousa R, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpfennig KW, Hemberg M, Agudo J. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell 2022;185:1694-1708.e19. [PMID: 35447074 DOI: 10.1016/j.cell.2022.03.033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 427 |
Alvarez-Breckenridge C, Remon J, Piña Y, Nieblas-Bedolla E, Forsyth P, Hendriks L, Brastianos PK. Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients. Am Soc Clin Oncol Educ Book 2022;42:1-19. [PMID: 35522917 DOI: 10.1200/EDBK_352320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 428 |
Glass EB, Hoover AA, Bullock KK, Madden MZ, Reinfeld BI, Harris W, Parker D, Hufnagel DH, Crispens MA, Khabele D, Rathmell WK, Rathmell JC, Wilson AJ, Giorgio TD, Yull FE. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. BMC Cancer 2022;22:497. [PMID: 35513776 DOI: 10.1186/s12885-022-09612-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 429 |
Long Y, Chen R, Yu X, Tong Y, Peng X, Li F, Hu C, Sun J, Gong L. Suppression of tumor/host intrinsic CMTM6 drives anti-tumor cytotoxicity in a PD-L1 independent manner.. [DOI: 10.1101/2022.05.06.490847] [Reference Citation Analysis]
|
| 430 |
Zhao H, Han B, Li X, Sun C, Zhai Y, Li M, Jiang M, Zhang W, Liang Y, Kai G. Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms. Front Pharmacol 2022;13:872085. [DOI: 10.3389/fphar.2022.872085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 431 |
Meng Y, Wu J. Facile and One-step Direct Synthesis of Poly(valine) as a Robust Drug Nanocarrier for Enhanced Breast Cancer Therapy. Chin J Polym Sci. [DOI: 10.1007/s10118-022-2701-9] [Reference Citation Analysis]
|
| 432 |
Song Y, Bugada L, Li R, Hu H, Zhang L, Li C, Yuan H, Rajanayake KK, Truchan NA, Wen F, Gao W, Sun D. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. Sci Transl Med 2022;14:eabl3649. [PMID: 35507675 DOI: 10.1126/scitranslmed.abl3649] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 433 |
Dannehl D, Hartkopf AD. Personalisierte Medizin – innovative Therapiemöglichkeiten für das metastasierte Mammakarzinom. Gynäkologe 2022;55:335-343. [DOI: 10.1007/s00129-022-04934-5] [Reference Citation Analysis]
|
| 434 |
Choo JRE, Jan YH, Ow SGW, Wong A, Lee MX, Ngoi N, Yadav K, Lim JSJ, Lim SE, Chan CW, Hartman M, Tang SW, Goh BC, Tan HL, Chong WQ, Yvonne ALE, Chan GHJ, Chen SJ, Tan KT, Lee SC. Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. Target Oncol 2022;17:355-68. [PMID: 35699834 DOI: 10.1007/s11523-022-00886-x] [Reference Citation Analysis]
|
| 435 |
Kirwan CC, Blower EL. Contemporary breast cancer treatment-associated thrombosis. Thrombosis Research 2022;213:S8-S15. [DOI: 10.1016/j.thromres.2021.12.025] [Reference Citation Analysis]
|
| 436 |
Montagna G, Ferraro E, Pilewskie ML. Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer. Advances in Oncology 2022;2:47-61. [DOI: 10.1016/j.yao.2022.01.004] [Reference Citation Analysis]
|
| 437 |
Hu D, Zhang W, Xiang J, Li D, Chen Y, Yuan P, Shao S, Zhou Z, Shen Y, Tang J. A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 438 |
Ebrahimi N, Kharazmi K, Ghanaatian M, Miraghel SA, Amiri Y, Seyedebrahimi SS, Mobarak H, Yazdani E, Parkhideh S, Hamblin MR, Aref AR. Role of the Wnt and GTPase pathways in breast cancer tumorigenesis and treatment. Cytokine & Growth Factor Reviews 2022. [DOI: 10.1016/j.cytogfr.2022.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 439 |
Meattini I, Livi L, Lorito N, Becherini C, Bacci M, Visani L, Fozza A, Belgioia L, Loi M, Mangoni M, Lambertini M, Morandi A. Integrating radiation therapy with targeted treatments for breast cancer: from bench to bedside. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 440 |
Tan Q, Yin S, Zhou D, Chi Y, Man X, Li H. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer. Front Oncol 2022;12:779786. [DOI: 10.3389/fonc.2022.779786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 441 |
Stimes N, Stanbery L, Albrethsen M, Trivedi C, Hamouda D, Dworkin L, Nemunaitis J. Small-cell breast carcinoma with response to atezolizumab: a case report. Immunotherapy 2022. [PMID: 35481350 DOI: 10.2217/imt-2021-0100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 442 |
Cherny NI. An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed? Nat Rev Clin Oncol 2022. [PMID: 35484286 DOI: 10.1038/s41571-022-00636-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 443 |
Chaudhuri A, Kumar DN, Dehari D, Singh S, Kumar P, Bolla PK, Kumar D, Agrawal AK. Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). Pharmaceuticals 2022;15:542. [DOI: 10.3390/ph15050542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 444 |
Lian J, Ma HX, Xu EW, Bu P, Yun KM, Xi YF. Subclassifying triple-negative breast cancers and its potential clinical utility. Virchows Arch 2022. [PMID: 35471664 DOI: 10.1007/s00428-022-03329-0] [Reference Citation Analysis]
|
| 445 |
Pruteanu LL, Braicu C, Módos D, Jurj MA, Raduly LZ, Zănoagă O, Magdo L, Cojocneanu R, Paşca S, Moldovan C, Moldovan AI, Ţigu AB, Gurzău E, Jäntschi L, Bender A, Berindan-Neagoe I. Targeting Cell Death Mechanism Specifically in Triple Negative Breast Cancer Cell Lines. Int J Mol Sci 2022;23:4784. [PMID: 35563174 DOI: 10.3390/ijms23094784] [Reference Citation Analysis]
|
| 446 |
Goda N, Nakashima C, Nagamine I, Otagaki S. The Effect of Intratumoral Interrelation among FOXP3+ Regulatory T Cells on Treatment Response and Survival in Triple-Negative Breast Cancer. Cancers (Basel) 2022;14. [PMID: 35565267 DOI: 10.3390/cancers14092138] [Reference Citation Analysis]
|
| 447 |
Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study. Breast Cancer 2022. [PMID: 35460066 DOI: 10.1007/s12282-022-01357-x] [Reference Citation Analysis]
|
| 448 |
Sawaki M, Shimomura A, Shien T, Iwata H. Management of breast cancer in older patients. Japanese Journal of Clinical Oncology 2022. [DOI: 10.1093/jjco/hyac054] [Reference Citation Analysis]
|
| 449 |
Carlino F, Diana A, Piccolo A, Ventriglia A, Bruno V, De Santo I, Letizia O, De Vita F, Daniele B, Ciardiello F, Orditura M. Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice. Cancers (Basel) 2022;14:2102. [PMID: 35565233 DOI: 10.3390/cancers14092102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 450 |
Hu L, Sun J, Li Z, Qu Z, Liu Y, Wan Q, Liu J, Ding X, Zang F, Zhang J, Yao L, Xu Y, Wang Y, Xie Y. Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients. NPJ Breast Cancer 2022;8:52. [PMID: 35449176 DOI: 10.1038/s41523-022-00417-x] [Reference Citation Analysis]
|
| 451 |
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol 2022;40:1312-22. [PMID: 35089812 DOI: 10.1200/JCO.21.01485] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 452 |
Wang XH, Zhang J, Wu J, He XH, Shen YR, Peng YG, An YZ. Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer. Front Oncol 2022;12:840453. [PMID: 35433492 DOI: 10.3389/fonc.2022.840453] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 453 |
Bruijnen CP, Koldenhof JJ, Verheijden RJ, van den Bos F, Emmelot-Vonk MH, Witteveen PO, Suijkerbuijk KPM. Frailty and checkpoint inhibitor toxicity in older patients with melanoma. Cancer 2022. [PMID: 35439334 DOI: 10.1002/cncr.34230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 454 |
Qian X, Xu X, Wu Y, Wang J, Li J, Chen S, Wen J, Li Y, Zhang Z. Strategies of engineering nanomedicines for tumor retention. J Control Release 2022:S0168-3659(22)00200-0. [PMID: 35447297 DOI: 10.1016/j.jconrel.2022.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 455 |
Tzoras E, Zerdes I, Tsiknakis N, Manikis GC, Mezheyeuski A, Bergh J, Matikas A, Foukakis T. Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. Cancers 2022;14:1999. [DOI: 10.3390/cancers14081999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 456 |
Huang Y, Chen P, Peng B, Liao R, Huang H, Huang M, Chen Q, Li S, Guo S, Zheng S. The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis. Clin Exp Med 2022. [PMID: 35416524 DOI: 10.1007/s10238-022-00800-9] [Reference Citation Analysis]
|
| 457 |
Buch SA, Baba MR. Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. Indian J Med Paediatr Oncol. [DOI: 10.1055/s-0042-1742442] [Reference Citation Analysis]
|
| 458 |
Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H, Zhang Z, Lu L, Zhang X. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Front Immunol 2022;13:862084. [DOI: 10.3389/fimmu.2022.862084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 459 |
Saha T, Lukong KE. Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance. Front Oncol 2022;12:856974. [PMID: 35392236 DOI: 10.3389/fonc.2022.856974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 460 |
Li C, Pan J, Jiang Y, Wu Y, Jin Z, Chen X. Characterization of Pyroptosis-Related Subtypes via RNA-Seq and ScRNA-Seq to Predict Chemo-Immunotherapy Response in Triple-Negative Breast Cancer. Front Genet 2022;13:788670. [PMID: 35386285 DOI: 10.3389/fgene.2022.788670] [Reference Citation Analysis]
|
| 461 |
Thompson KJ, Leon-ferre RA, Sinnwell JP, Zahrieh D, Suman V, Metzger F, Asad S, Stover D, Carey L, Sikov W, Ingle J, Liu M, Carter J, Klee E, Weinshilboum R, Boughey J, Wang L, Couch F, Goetz M, Kalari K. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer 2022;4. [DOI: 10.1093/narcan/zcac018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 462 |
Huppert LA, Gumusay O, Rugo HS. Emerging treatment strategies for metastatic triple-negative breast cancer. Ther Adv Med Oncol 2022;14:175883592210869. [DOI: 10.1177/17588359221086916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 463 |
Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD, Adili A, Noroozi-Aghideh A, Razeghian E. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 2022;20:44. [PMID: 35392976 DOI: 10.1186/s12964-022-00854-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 464 |
Blatnik A, Ribnikar D, Šetrajčič Dragoš V, Novaković S, Stegel V, Grčar Kuzmanov B, Boc N, Perić B, Škerl P, Klančar G, Krajc M. BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome. Breast Cancer 2022. [PMID: 35381901 DOI: 10.1007/s12282-022-01354-0] [Reference Citation Analysis]
|
| 465 |
Magbanua MJM, Gumusay O, Kurzrock R, van 't Veer LJ, Rugo HS. Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. Front Oncol 2022;12:802579. [PMID: 35372077 DOI: 10.3389/fonc.2022.802579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 466 |
Wang H, Rong X, Zhao G, Zhou Y, Xiao Y, Ma D, Jin X, Wu Y, Yan Y, Yang H, Zhou Y, Qian M, Niu C, Hu X, Li DQ, Liu Q, Wen Y, Jiang YZ, Zhao C, Shao ZM. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab 2022;34:581-594.e8. [PMID: 35278352 DOI: 10.1016/j.cmet.2022.02.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 37.0] [Reference Citation Analysis]
|
| 467 |
Zhu J, Wu G, Zhao Y, Yang B, Chen Q, Jiang J, Meng Y, Ji S, Gu K. Epidemiology, Treatment and Prognosis Analysis of Small Cell Breast Carcinoma: A Population-Based Study. Front Endocrinol 2022;13:802339. [DOI: 10.3389/fendo.2022.802339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 468 |
Lopatina T, Koni M, Grange C, Cedrino M, Femminò S, Lombardo G, Favaro E, Brizzi MF. IL-3 signalling in the tumour microenvironment shapes the immune response via tumour endothelial cell-derived extracellular vesicles. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 469 |
Miglietta F, Bottosso M, Griguolo G, Dieci M, Guarneri V. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open 2022;7:100409. [DOI: 10.1016/j.esmoop.2022.100409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 470 |
Miguel Cejalvo J, Falato C, Villanueva L, Tolosa P, González X, Pascal M, Canes J, Gavilá J, Manso L, Pascual T, Prat A, Salvador F. Oncolytic Viruses: a new immunotherapeutic approach for breast cancer treatment? Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 471 |
Liu Z, Wang C, Chen X, Zhu J, Sun X, Xia Q, Lu Z, Qiao J, Zhou Y, Wang H, Wang Y, Yan M. Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial. European Journal of Cancer 2022;165:157-68. [DOI: 10.1016/j.ejca.2022.01.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 472 |
Kyriazoglou A, Beuselinck B. Equivocal evaluation of progressive disease in patients treated with immune checkpoint inhibitors: a challenge for clinical trials and biomarker research. Acta Clin Belg 2022;77:406-9. [PMID: 33308043 DOI: 10.1080/17843286.2020.1853886] [Reference Citation Analysis]
|
| 473 |
Mittendorf EA, Burgers F, Haanen J, Cascone T. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. Am Soc Clin Oncol Educ Book 2022;42:1-15. [PMID: 35714302 DOI: 10.1200/EDBK_349411] [Reference Citation Analysis]
|
| 474 |
Bagegni NA, Davis AA, Clifton KK, Ademuyiwa FO. Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. BCTT 2022;Volume 14:113-123. [DOI: 10.2147/bctt.s293597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 475 |
Kok VC, Wang CC, Liao S, Chen D. Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer. BCTT 2022;Volume 14:85-99. [DOI: 10.2147/bctt.s359346] [Reference Citation Analysis]
|
| 476 |
David S, Tan J, Siva S, Karroum L, Savas P, Loi S. Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. Biomedicines 2022;10:821. [DOI: 10.3390/biomedicines10040821] [Reference Citation Analysis]
|
| 477 |
Zhu SY, Yu KD. Breast Cancer Vaccines: Disappointing or Promising? Front Immunol 2022;13:828386. [PMID: 35154149 DOI: 10.3389/fimmu.2022.828386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 478 |
Orillard E, Henriques J, Vernerey D, Almotlak H, Calcagno F, Fein F, Fratté S, Jary M, Klajer E, Vienot A, Borg C, Kim S. Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients. Front Oncol 2022;12:763926. [PMID: 35340264 DOI: 10.3389/fonc.2022.763926] [Reference Citation Analysis]
|
| 479 |
Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? Cancers (Basel) 2022;14:1710. [PMID: 35406483 DOI: 10.3390/cancers14071710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 480 |
Alamoudi MK, Chipman M, Deieso-frechette F, Bogis AM, Alqurashi RS, Li K, Zhang R, Castañer M, Triafallou G, Herbosa CG, Carland C, Lee AJ, Gillani K, Paulson KE, Yee AS. CHA1: A New Combinatorial Therapy That Reciprocally Regulates Wnt and JAK/STAT/Interferon Signaling to Re-program Breast Tumors and the Tumor-Resident Landscape.. [DOI: 10.1101/2022.03.25.485706] [Reference Citation Analysis]
|
| 481 |
Starzer AM, Heller G, Tomasich E, Melchardt T, Feldmann K, Hatziioannou T, Traint S, Minichsdorfer C, Schwarz-Nemec U, Nackenhorst M, Müllauer L, Preusser M, Berghoff AS, Fuereder T. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e003420. [PMID: 35338086 DOI: 10.1136/jitc-2021-003420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 482 |
Yap TA, Bessudo A, Hamilton E, Sachdev J, Patel MR, Rodon J, Evilevitch L, Duncan M, Guo W, Kumar S, Lu S, Dezube BJ, Gabrail N. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. J Immunother Cancer 2022;10:e003924. [PMID: 35332062 DOI: 10.1136/jitc-2021-003924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 483 |
Li AY, Gaebe K, Jerzak KJ, Cheema PK, Sahgal A, Das S. Intracranial Metastatic Disease: Present Challenges, Future Opportunities. Front Oncol 2022;12:855182. [PMID: 35330715 DOI: 10.3389/fonc.2022.855182] [Reference Citation Analysis]
|
| 484 |
Filippi S, Paccosi E, Balzerano A, Ferretti M, Poli G, Taborri J, Brancorsini S, Proietti-de-santis L. CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype. Cancers 2022;14:1687. [DOI: 10.3390/cancers14071687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 485 |
Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, Song XQ, Hu X, Yang WT, Chai WJ, Guo XM, Chen XZ, Xu YH, Zhu XY, Zou JJ, Wang ZH, Jiang YZ, Shao ZM. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer 2022;21:84. [PMID: 35337339 DOI: 10.1186/s12943-022-01536-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 486 |
Deng S, Leong HC, Datta A, Gopal V, Kumar AP, Yap CT. PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. Cancers (Basel) 2022;14:1652. [PMID: 35406424 DOI: 10.3390/cancers14071652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 487 |
Valencia GA, Rioja P, Morante Z, Ruiz R, Fuentes H, Castaneda CA, Vidaurre T, Neciosup S, Gomez HL. Immunotherapy in triple-negative breast cancer: A literature review and new advances. World J Clin Oncol 2022; 13(3): 219-236 [DOI: 10.5306/wjco.v13.i3.219] [Reference Citation Analysis]
|
| 488 |
Tian Z, Yu C, Zhang W, Wu KL, Wang C, Gupta R, Xu Z, Wu L, Chen Y, Zhang XH, Xiao H. Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone. ACS Cent Sci 2022;8:312-21. [PMID: 35355817 DOI: 10.1021/acscentsci.1c01024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 489 |
Montero JC, Calvo-Jiménez E, Del Carmen S, Abad M, Ocaña A, Pandiella A. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer. J Exp Clin Cancer Res 2022;41:106. [PMID: 35317825 DOI: 10.1186/s13046-022-02330-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 490 |
Zhang K, Kong X, Li Y, Wang Z, Zhang L, Xuan L. PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. Front Pharmacol 2022;13:854967. [DOI: 10.3389/fphar.2022.854967] [Reference Citation Analysis]
|
| 491 |
Li C, Zhang C, Zhang G, Chen B, Li X, Li K, Ren C, Wen L, Liao N. YTHDF1 amplification is correlated with worse outcome and lower immune cell infiltrations in breast cancer. Cancer Biomark 2022. [PMID: 35342079 DOI: 10.3233/CBM-203103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 492 |
Fang C, Zhong R, Qiu C, Zou BB. The Prognostic Value of GNG7 in Colorectal Cancer and Its Relationship With Immune Infiltration. Front Genet 2022;13:833013. [PMID: 35281820 DOI: 10.3389/fgene.2022.833013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 493 |
Hu ZY, Zheng C, Yang J, Ding S, Tian C, Xie N, Xue L, Wu M, Fu S, Rao Z, Price MA, McCarthy JB, Ouyang Q, Lin J, Deng X. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer. Front Oncol 2022;12:804466. [PMID: 35280756 DOI: 10.3389/fonc.2022.804466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 494 |
Wang C, Zhou Y, Lin Y, Mao F, Guan J, Zhang X, Shen S, Wang X, Zhang Y, Pan B, Zhong Y, Peng L, Cao X, Yao R, Zhou X, Xu C, Xu Y, Sun Q. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA). BMC Cancer 2022;22:269. [PMID: 35287613 DOI: 10.1186/s12885-022-09346-1] [Reference Citation Analysis]
|
| 495 |
Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol 2022;15:24. [PMID: 35279217 DOI: 10.1186/s13045-022-01242-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 46.0] [Reference Citation Analysis]
|
| 496 |
Cattolico C, Bailey P, Barry ST. Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. Front Cell Dev Biol 2022;10:816517. [PMID: 35273962 DOI: 10.3389/fcell.2022.816517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 497 |
Chung AW, Kozielski AJ, Qian W, Zhou J, Anselme AC, Chan AA, Pan PY, Lee DJ, Chang JC. Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6. NPJ Breast Cancer 2022;8:30. [PMID: 35260569 DOI: 10.1038/s41523-021-00371-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 498 |
Mpekris F, Voutouri C, Panagi M, Baish JW, Jain RK, Stylianopoulos T. Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy. J Control Release 2022:S0168-3659(22)00119-5. [PMID: 35271911 DOI: 10.1016/j.jconrel.2022.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 499 |
Korlimarla A, Hari P, Prabhu J, Ragulan C, Patil Y, Snijesh V, Desai K, Mathews A, Appachu S, Diwakar RB, Srinath B, Cheang M, Sadanandam A. A comprehensive analysis of immune landscape of Indian triple negative breast cancer.. [DOI: 10.1101/2022.03.06.483159] [Reference Citation Analysis]
|
| 500 |
Amin S, Tolaney SM, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Mulvihill E, Shinde R, McLaurin K. Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives. Future Oncol 2022. [PMID: 35249366 DOI: 10.2217/fon-2021-0761] [Reference Citation Analysis]
|
| 501 |
Zhang J, Pan S, Jian C, Hao L, Dong J, Sun Q, Jin H, Han X. Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice. Front Immunol 2021;12:819405. [PMID: 35069604 DOI: 10.3389/fimmu.2021.819405] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 502 |
Chang H, Yang X, Moore J, Liu XP, Jen KY, Snijders AM, Ma L, Chou W, Corchado-Cobos R, García-Sancha N, Mendiburu-Eliçabe M, Pérez-Losada J, Barcellos-Hoff MH, Mao JH. From Mouse to Human: Cellular Morphometric Subtype Learned From Mouse Mammary Tumors Provides Prognostic Value in Human Breast Cancer. Front Oncol 2021;11:819565. [PMID: 35242697 DOI: 10.3389/fonc.2021.819565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 503 |
Muhammed A, D'Alessio A, Enica A, Talbot T, Fulgenzi CAM, Nteliopoulos G, Goldin RD, Cortellini A, Pinato DJ. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35236211 DOI: 10.1080/14737159.2022.2049244] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 504 |
Salloum A, Habre M, Chebl JA, Chebl KA, Atallah C, Medawar G, Kourie HR. Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. Immunotherapy 2022. [PMID: 35232283 DOI: 10.2217/imt-2021-0244] [Reference Citation Analysis]
|
| 505 |
O'Melia MJ, Mulero-Russe A, Kim J, Pybus A, DeRyckere D, Wood L, Graham DK, Botchwey E, García AJ, Thomas SN. Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening. Adv Mater 2022;34:e2108084. [PMID: 34989049 DOI: 10.1002/adma.202108084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 506 |
Vetter M, Rothgiesser KM, Li Q, Hawle H, Schönfeld W, Ribi K, Riniker S, von Moos R, Trojan A, Kralidis E, Fehr M, Müller A, Thürlimann B, _ _. SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. Endocrine Oncology 2022;2:9-18. [DOI: 10.1530/eo-21-0009] [Reference Citation Analysis]
|
| 507 |
Ocaña A, Chacón JI, Calvo L, Antón A, Mansutti M, Albanell J, Martínez MT, Lahuerta A, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chan A, Morales S, Herranz J, Tusquets I, Chiesa M, Caballero R, Valagussa P, Bianchini G, Alba E, Gianni L. Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Front Oncol 2021;11:827625. [PMID: 35223459 DOI: 10.3389/fonc.2021.827625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 508 |
Tian Z, Yao W. Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas. Front Oncol 2022;12:815900. [PMID: 35223497 DOI: 10.3389/fonc.2022.815900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 509 |
Brown LC, Loi S. Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update. Breast 2022;62 Suppl 1:S29-33. [PMID: 34996667 DOI: 10.1016/j.breast.2021.12.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 510 |
Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-liedtke C, Kolberg H, Lüftner D, Müller V, Schütz F, Thomssen C, Belleville E, Behrens A, Bader S, Untch M, Welslau M, Würstlein R, Thill M, Krug D, Hartkopf AD. Update Mammakarzinom 2021 Teil 3 – aktuelle Entwicklungen bei der Behandlung von Brustkrebspatientinnen mit frühen Krankheitsstadien: Übersicht und Beurteilung von speziellen Therapiesituationen durch ein internationales Expertenpanel. Senologie - Zeitschrift für Mammadiagnostik und -therapie 2022;19:75-87. [DOI: 10.1055/a-1755-5749] [Reference Citation Analysis]
|
| 511 |
Cardin DB, Gilbert J, Whisenant JG, Ayers GD, Jalikis F, Dahlman KB, O'neal JF, Revetta F, Shi C, Berlin J. Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 512 |
Ditsch N, Stickeler E, Behrens A, Belleville E, Fasching PA, Fehm TN, Hartkopf AD, Jackisch C, Janni W, Kolberg-liedtke C, Kolberg H, Lüftner D, Lux MP, Müller V, Schneeweiss A, Schütz F, Schulmeyer CE, Tesch H, Thomssen C, Uleer C, Untch M, Welslau M, Wöckel A, Wurmthaler LA, Würstlein R, Thill M, Aktas B. Update Mammakarzinom 2021 Teil 2 – fortgeschrittene Stadien, Langzeitfolgen und Biomarker. Senologie - Zeitschrift für Mammadiagnostik und -therapie 2022;19:65-74. [DOI: 10.1055/a-1755-5626] [Reference Citation Analysis]
|
| 513 |
Würstlein R, Harbeck N. Immuntherapie bei Brustkrebs. Deutsche Zeitschrift für Onkologie 2022;54:4-8. [DOI: 10.1055/a-1745-5354] [Reference Citation Analysis]
|
| 514 |
Cao X, Chen J, Li B, Dang J, Zhang W, Zhong X, Wang C, Raoof M, Sun Z, Yu J, Fakih MG, Feng M. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. Sci Adv 2022;8:eabl9171. [PMID: 35302839 DOI: 10.1126/sciadv.abl9171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 515 |
Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z. Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. Cancers (Basel) 2022;14:1253. [PMID: 35267561 DOI: 10.3390/cancers14051253] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 516 |
Fertal SA, Poterala JE, Ponik SM, Wisinski KB. Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. Cancers (Basel) 2022;14. [PMID: 35267548 DOI: 10.3390/cancers14051238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 517 |
Pellerino A, Soffietti R, Bruno F, Manna R, Muscolino E, Botta P, Palmiero R, Rudà R. Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program. Cancers 2022;14:1192. [DOI: 10.3390/cancers14051192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 518 |
Goh PK, Wiede F, Zeissig MN, Britt KL, Liang S, Molloy T, Goode N, Xu R, Loi S, Muller M, Humbert PO, McLean C, Tiganis T. PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer. Sci Adv 2022;8:eabk3338. [PMID: 35196085 DOI: 10.1126/sciadv.abk3338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 519 |
Fraguas-sánchez AI, Lozza I, Torres-suárez AI. Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic. Cancers 2022;14:1198. [DOI: 10.3390/cancers14051198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 520 |
Studentova H, Zemankova A, Spisarova M, Skanderova D, Tudos Z, Melichar B, Student V. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma. Medicina 2022;58:336. [DOI: 10.3390/medicina58030336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 521 |
Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W, Guo W, Wu X, Pu C, Hu X, Li Z, Yao M, Luo D, Xu X. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer 2022;21:60. [PMID: 35197058 DOI: 10.1186/s12943-021-01447-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 522 |
Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer 2022;8:23. [PMID: 35181659 DOI: 10.1038/s41523-022-00386-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 523 |
Erlichman N, Baram T, Meshel T, Morein D, Da'adoosh B, Ben-Baruch A. Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. Cancers (Basel) 2022;14:1042. [PMID: 35205789 DOI: 10.3390/cancers14041042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 524 |
Altei WF, Pachane BC, Souza C, Marques MMC, Selistre-de-Araújo H. New insights into the discovery of drugs for triple-negative breast cancer metastasis. Expert Opin Drug Discov 2022;:1-12. [PMID: 35179448 DOI: 10.1080/17460441.2022.2039619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 525 |
Hsu FT, Tsai CL, Chiang IT, Lan KH, Yueh PF, Liang WY, Lin CS, Chao Y, Lan KL. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. J Cell Mol Med 2022. [PMID: 35174623 DOI: 10.1111/jcmm.17220] [Reference Citation Analysis]
|
| 526 |
Kurozumi S, Kaira K, Matsumoto H, Kurosumi M, Yokobori T, Kanai Y, Sekine C, Honda C, Katayama A, Furuya M, Shiino S, Makiguchi T, Mongan NP, Rakha EA, Oyama T, Fujii T, Shirabe K, Horiguchi J. Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Sci Rep 2022;12:2742. [PMID: 35177712 DOI: 10.1038/s41598-022-06615-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 527 |
Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffeis I, Valagussa P, Viale G. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study. Ann Oncol 2022:S0923-7534(22)00113-2. [PMID: 35182721 DOI: 10.1016/j.annonc.2022.02.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 528 |
Niwinska A, Pogoda K, Jagiello-Gruszfeld A, Duchnowska R. Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy. Cancers (Basel) 2022;14:965. [PMID: 35205723 DOI: 10.3390/cancers14040965] [Reference Citation Analysis]
|
| 529 |
Sahay A, Patil A, Desai SB. How We Use Immunohistochemistry to Arrive at a Diagnosis in Breast Lesions. Indian J Med Paediatr Oncol. [DOI: 10.1055/s-0042-1742439] [Reference Citation Analysis]
|
| 530 |
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022;386:556-67. [PMID: 35139274 DOI: 10.1056/NEJMoa2112651] [Cited by in Crossref: 182] [Cited by in F6Publishing: 107] [Article Influence: 182.0] [Reference Citation Analysis]
|
| 531 |
Sabbatino F, Liguori L, Pepe S, Ferrone S. Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther 2022. [PMID: 35130816 DOI: 10.1080/14712598.2022.2038132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 532 |
O'sullivan H, Conroy M, Power D, Bambury R, O’mahony D, Collins D, O’leary M, O’reilly S. Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study. J Palliat Care. [DOI: 10.1177/08258597221078391] [Reference Citation Analysis]
|
| 533 |
Anders CK, Woodcock MG, Van Swearingen AED, Moore DT, Sambade MJ, Laurie S, Robeson A, Kolupaev O, Cuaboy LA, Garrett AL, McKinnon K, Cowens K, Bortone D, Calhoun BC, Wilkinson AD, Carey L, Jolly T, Muss H, Reeder-Hayes K, Kaltman R, Jankowitz R, Gudena V, Olajide O, Perou C, Dees EC, Vincent BG, Serody JS. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. J Immunother Cancer 2022;10:e003427. [PMID: 35121644 DOI: 10.1136/jitc-2021-003427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 534 |
Felcher CM, Bogni ES, Kordon EC. IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment. IJMS 2022;23:1809. [DOI: 10.3390/ijms23031809] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 535 |
Cao K, Du Y, Bao X, Han M, Su R, Pang J, Liu S, Shi Z, Yan F, Feng S. Glutathione-Bioimprinted Nanoparticles Targeting of N6-methyladenosine FTO Demethylase as a Strategy against Leukemic Stem Cells. Small 2022;:e2106558. [PMID: 35119204 DOI: 10.1002/smll.202106558] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 536 |
Okines A, Irfan T, Asare B, Mohammed K, Osin P, Nerurkar A, Smith IE, Parton M, Ring A, Johnston S, Turner NC. Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience. Breast Cancer Res Treat 2022. [PMID: 35119530 DOI: 10.1007/s10549-021-06432-z] [Reference Citation Analysis]
|
| 537 |
Qiu D, Zhang G, Yan X, Xiao X, Ma X, Lin S, Wu J, Li X, Wang W, Liu J, Ma Y, Ma M. Prospects of Immunotherapy for Triple-Negative Breast Cancer. Front Oncol 2021;11:797092. [PMID: 35111680 DOI: 10.3389/fonc.2021.797092] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 538 |
Peddi PF. Triple negative breast cancer: any closer to cracking the code? Curr Opin Obstet Gynecol 2022;34:52-5. [PMID: 34967815 DOI: 10.1097/GCO.0000000000000769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 539 |
Zacharakis N, Huq LM, Seitter SJ, Kim SP, Gartner JJ, Sindiri S, Hill VK, Li YF, Paria BC, Ray S, Gasmi B, Lee C, Prickett TD, Parkhurst MR, Robbins PF, Langhan MM, Shelton TE, Parikh AY, Levi ST, Hernandez JM, Hoang CD, Sherry RM, Yang JC, Feldman SA, Goff SL, Rosenberg SA. Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. JCO. [DOI: 10.1200/jco.21.02170] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 540 |
Villacampa G, Tolosa P, Salvador F, Sánchez-bayona R, Villanueva L, Dienstmann R, Ciruelos E, Pascual T. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: a systematic review and meta-analysis. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 541 |
Zheng C, Zhang W, Wang J, Zhai Y, Xiong F, Cai Y, Gong X, Zhu B, Zhu HH, Wang H, Li Y, Zhang P. Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 542 |
Zhang F, Wang Y, Yang F, Zhang Y, Jiang M, Zhang X. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study. CMAR 2022;Volume 14:535-46. [DOI: 10.2147/cmar.s349442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 543 |
Yu DL, Lou ZP, Ma FY, Najafi M. The interactions of paclitaxel with tumour microenvironment. Int Immunopharmacol 2022;105:108555. [PMID: 35121223 DOI: 10.1016/j.intimp.2022.108555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 544 |
Satcher RL, Zhang XH. Evolving cancer-niche interactions and therapeutic targets during bone metastasis. Nat Rev Cancer 2022;22:85-101. [PMID: 34611349 DOI: 10.1038/s41568-021-00406-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 545 |
Kyriazoglou A, Kaparelou M, Goumas G, Liontos M, Zakopoulou R, Zografos E, Zygogianni A, Dimopoulos MA, Zagouri F. Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. Breast Care (Basel) 2022;17:63-70. [PMID: 35355696 DOI: 10.1159/000514860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 546 |
Sieluk J, Song Y, Freimark J, Huang M, Haiderali A, Berman R, Wang T, Signorovitch J, Hirshfield KM. The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States. Adv Ther 2022;39:943-58. [PMID: 34918193 DOI: 10.1007/s12325-021-01913-5] [Reference Citation Analysis]
|
| 547 |
Saleh RR, Scott JL, Meti N, Perlon D, Fazelzad R, Ocana A, Amir E. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. Mol Diagn Ther 2022. [PMID: 35106739 DOI: 10.1007/s40291-022-00576-4] [Reference Citation Analysis]
|
| 548 |
Chun B, Pucilowska J, Chang S, Kim I, Nikitin B, Koguchi Y, Redmond WL, Bernard B, Rajamanickam V, Polaske N, Fields PA, Conrad V, Schmidt M, Urba WJ, Conlin AK, McArthur HL, Page DB. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer. J Immunother Cancer 2022;10:e004033. [PMID: 35086949 DOI: 10.1136/jitc-2021-004033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 549 |
Lv ZD, Song HM, Niu ZH, Nie G, Zheng S, Xu YY, Gong W, Wang HB. Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. Front Oncol 2021;11:760655. [PMID: 35087749 DOI: 10.3389/fonc.2021.760655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 550 |
van Rossum AGJ, Mandjes IAM, van Werkhoven E, van Tinteren H, van Leeuwen-Stok AE, Nederlof P, Portielje JEA, van Alphen RJ, Platte E, van den Broek D, Huitema A, Kok M, Linn SC, Oosterkamp HM. Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). Breast Care (Basel) 2021;16:598-606. [PMID: 35087363 DOI: 10.1159/000512200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 551 |
Kulasinghe A, Monkman J, Shah ET, Matigian N, Adams MN, O'Byrne K. Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC). Front Oncol 2021;11:798296. [PMID: 35083152 DOI: 10.3389/fonc.2021.798296] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 552 |
Tsunoda A, Mizuno T, Iida S, Uchida K, Yamashita M, Sukeno K, Oka H, Tono Y, Ishihara M, Saito K, Tamaru S, Yamanaka K, Tawara I, Tanaka K. Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer. Case Reports in Oncological Medicine 2022;2022:1-4. [DOI: 10.1155/2022/2709062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 553 |
Kessler AJ, Sparano JA. Systemic therapy for triple-negative breast cancer: A changing landscape. Crit Rev Oncol Hematol 2022;:103608. [PMID: 35093499 DOI: 10.1016/j.critrevonc.2022.103608] [Reference Citation Analysis]
|
| 554 |
Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci 2022;9:836417. [DOI: 10.3389/fmolb.2022.836417] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 555 |
Chen F, Chen N, Gao Y, Jia L, Lyu Z, Cui J. Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy. Front Oncol 2021;11:724424. [PMID: 35070955 DOI: 10.3389/fonc.2021.724424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 556 |
Kadamkulam Syriac A, Nandu NS, Leone JP. Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective. Breast Cancer (Dove Med Press) 2022;14:1-13. [PMID: 35046721 DOI: 10.2147/BCTT.S274514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 557 |
Laenkholm AV, Callagy G, Balancin M, Bartlett JMS, Sotiriou C, Marchio C, Kok M, Dos Anjos CH, Salgado R. Incorporation of TILs in daily breast cancer care: how much evidence can we bear? Virchows Arch 2022. [PMID: 35043236 DOI: 10.1007/s00428-022-03276-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 558 |
Brown LJ, Achinger-kawecka J, Portman N, Clark S, Stirzaker C, Lim E. Epigenetic Therapies and Biomarkers in Breast Cancer. Cancers 2022;14:474. [DOI: 10.3390/cancers14030474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 559 |
Dong X, Yang Y, Xu G, Tian Z, Yang Q, Gong Y, Wu G. The initial expression alterations occurring to transcription factors during the formation of breast cancer: Evidence from bioinformatics. Cancer Med 2022. [PMID: 35037412 DOI: 10.1002/cam4.4545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 560 |
Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 561 |
Lin YZ, Liu SH, Wu WR, Shen YC, Wang YL, Liao CC, Lin PL, Chang H, Liu LC, Cheng WC, Wang SC. miR-4759 suppresses breast cancer through immune checkpoint blockade. Comput Struct Biotechnol J 2022;20:241-51. [PMID: 35024096 DOI: 10.1016/j.csbj.2021.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 562 |
Najjar S, Allison KH. Updates on breast biomarkers. Virchows Arch 2022. [PMID: 35029776 DOI: 10.1007/s00428-022-03267-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 563 |
Shu C, Zheng X, Wuhafu A, Cicka D, Doyle S, Niu Q, Fan D, Qian K, Ivanov AA, Du Y, Mo X, Fu H. Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. Acta Pharmacol Sin 2022. [PMID: 35031699 DOI: 10.1038/s41401-021-00847-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 564 |
Samuels M, Cilibrasi C, Papanastasopoulos P, Giamas G. Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. Biomolecules 2022;12:132. [DOI: 10.3390/biom12010132] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 565 |
Meegdes M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, Kooreman LFS, Erdkamp FLG, Dercksen MW, Vriens BEPJ, Aaldering KNA, Pepels MJAE, van de Winkel LMH, Tol J, Heijns JB, van de Wouw AJ, Peters NAJB, Hochstenbach-Waelen A, Smidt ML, Geurts SME, Tjan-Heijnen VCG. The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Res Treat 2022. [PMID: 35025003 DOI: 10.1007/s10549-021-06472-5] [Reference Citation Analysis]
|
| 566 |
Yoo TK, Kang J, Lee A, Chae BJ. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes. Breast Cancer Res Treat 2022. [PMID: 35018542 DOI: 10.1007/s10549-021-06437-8] [Reference Citation Analysis]
|
| 567 |
Carter ME, Koch A, Lauer UM, Hartkopf AD. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol 2021;11:803050. [PMID: 35004328 DOI: 10.3389/fonc.2021.803050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 568 |
Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer 2022;8:3. [PMID: 35017545 DOI: 10.1038/s41523-021-00362-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 569 |
Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. Breast Cancer Res Treat 2022. [PMID: 35015209 DOI: 10.1007/s10549-021-06480-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 570 |
Principe DR, Kamath SD, Korc M, Munshi HG. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther 2022;236:108111. [PMID: 35016920 DOI: 10.1016/j.pharmthera.2022.108111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 571 |
Li A, Goodyear S, Fuss C, Mitri Z. Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. JCO Precis Oncol 2021;5:904-9. [PMID: 34994619 DOI: 10.1200/PO.20.00361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 572 |
Schlauch D, Fu X, Jones SF, Burris HA 3rd, Spigel DR, Reeves J, McKenzie AJ. Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precis Oncol 2021;5:1625-38. [PMID: 34994650 DOI: 10.1200/PO.21.00008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 573 |
Núñez Abad M, Calabuig-Fariñas S, Lobo de Mena M, Torres-Martínez S, García González C, García García JÁ, Iranzo González-Cruz V, Camps Herrero C. Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. Cancers (Basel) 2022;14:307. [PMID: 35053471 DOI: 10.3390/cancers14020307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 574 |
Gardner A, de Mingo Pulido Á, Hänggi K, Bazargan S, Onimus A, Kasprzak A, Conejo-Garcia JR, Rejniak KA, Ruffell B. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization. J Immunother Cancer 2022;10:e003571. [PMID: 34987021 DOI: 10.1136/jitc-2021-003571] [Reference Citation Analysis]
|
| 575 |
Reich LA, Moerland JA, Leal AS, Zhang D, Carapellucci S, Lockwood B, Jurutka PW, Marshall PA, Wagner CE, Liby KT. The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer. Sci Rep 2022;12:293. [PMID: 34997154 DOI: 10.1038/s41598-021-04415-0] [Reference Citation Analysis]
|
| 576 |
Mu QG, Lin G, Jeon M, Wang H, Chang FC, Revia RA, Yu J, Zhang M. Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer. Mater Today (Kidlington) 2021;50:149-69. [PMID: 34987308 DOI: 10.1016/j.mattod.2021.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 577 |
Wu Y, Dutta P, Clayton S, McCloud A, Vadgama JV. Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women. J Clin Med 2022;11:283. [PMID: 35053979 DOI: 10.3390/jcm11020283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 578 |
Haider S, Penfornis P, Claudio PP, McChesney JD, Chittiboyina AG. Balancing the efficacy vs. the toxicity of promiscuous natural products: Paclitaxel-based acid-labile lipophilic prodrugs as promising chemotherapeutics. Eur J Med Chem 2022;227:113891. [PMID: 34656042 DOI: 10.1016/j.ejmech.2021.113891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 579 |
Ji Q, Ding J, Hao M, Luo N, Huang J, Zhang W. Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:795650. [PMID: 34976837 DOI: 10.3389/fonc.2021.795650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 580 |
Sankaranarayanan RA, Peil J, Vogg ATJ, Bolm C, Terhorst S, Classen A, Bauwens M, Maurer J, Mottaghy F, Morgenroth A. Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. Cancers (Basel) 2022;14:230. [PMID: 35008392 DOI: 10.3390/cancers14010230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 581 |
Tu J, Xu H, Ma L, Li C, Qin W, Chen X, Yi M, Sun L, Liu B, Yuan X. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics 2022;12:747-66. [PMID: 34976211 DOI: 10.7150/thno.65828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 582 |
Saleh L, Wilson C, Holen I. CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. MedComm (2020) 2021;2:514-30. [PMID: 34977868 DOI: 10.1002/mco2.97] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 583 |
Waks A. Molecular Testing and Personalized Neoadjuvant Treatment. Management of the Breast and Axilla in the Neoadjuvant Setting 2022. [DOI: 10.1007/978-3-030-88020-0_8] [Reference Citation Analysis]
|
| 584 |
Geng C, Thompson TC. DNA damage response inhibitor and anti-PD-L1 therapy for prostate cancer: Development of predictive biomarkers. Engineering 2022. [DOI: 10.1016/j.eng.2022.01.002] [Reference Citation Analysis]
|
| 585 |
Wu L, Wang W, Tian J, Qi C, Cai Z, Yan W, Xuan S, Shang A. Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer. Bioengineered 2022;13:1942-51. [PMID: 35019820 DOI: 10.1080/21655979.2021.2023997] [Reference Citation Analysis]
|
| 586 |
Dar TB, Bhat AR, Biteghe FAN, Bhat AR, Malindi Z. Nanotechnology and Nanomedicine. Fundamentals and Advances in Medical Biotechnology 2022. [DOI: 10.1007/978-3-030-98554-7_11] [Reference Citation Analysis]
|
| 587 |
Fernandes RCM. Molecular Basis of Breast Cancer. Modern Breast Cancer Imaging 2022. [DOI: 10.1007/978-3-030-84546-9_1] [Reference Citation Analysis]
|
| 588 |
Arole V, Shafi S, Challa B, Parwani AV, Tozbikian G, Li Z. Evaluating mismatch repair status to screen clinical advanced breast carcinomas for immunotherapy: experience from a large academic institution. Clinical Breast Cancer 2022. [DOI: 10.1016/j.clbc.2022.01.010] [Reference Citation Analysis]
|
| 589 |
Nasrazadani A, Marti JLG, Hyder T, Gorantla V, Brufsky AM. Ongoing Clinical Studies and Future Directions. Management of the Breast and Axilla in the Neoadjuvant Setting 2022. [DOI: 10.1007/978-3-030-88020-0_15] [Reference Citation Analysis]
|
| 590 |
Liu H, Mehr CR. Breast. Handbook of Practical Immunohistochemistry 2022. [DOI: 10.1007/978-3-030-83328-2_14] [Reference Citation Analysis]
|
| 591 |
Nasser TA, Abdelhamid AS, Teleb M, Khattab SN, Bekhit AA, Elkhodairy KA, Elzoghby AO. Concluding remarks and future perspective of combination drug delivery systems. Combination Drug Delivery Approach as an Effective Therapy for Various Diseases 2022. [DOI: 10.1016/b978-0-323-85873-1.00004-6] [Reference Citation Analysis]
|
| 592 |
Serrano Olvera JA, Osorio Pérez D, Noguez Ramos A, Ramírez Medina RG, Jiménez Cantero A, Manríquez Cedillo de la Borbolla LF. Aspectos clínicos y terapéuticos del carcinoma de mama metastásico triple negativo. Anales Médicos de la Asociación Médica del Centro Médico ABC 2022;67:119-130. [DOI: 10.35366/106027] [Reference Citation Analysis]
|
| 593 |
Lago LD, de Caluwe A, Borghgraef C, Dumont L, Pepersack T. Breast Cancer in Older Adults with Frailty. Frailty in Older Adults with Cancer 2022. [DOI: 10.1007/978-3-030-89162-6_17] [Reference Citation Analysis]
|
| 594 |
Mir MA, Haq BU. Targeting tumor microenvironment for breast cancer treatment. Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies 2022. [DOI: 10.1016/b978-0-443-18696-7.00008-7] [Reference Citation Analysis]
|
| 595 |
Kwapisz D. Cancer Immunotherapy Clinical Trials. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_205-2] [Reference Citation Analysis]
|
| 596 |
Baxi V, Lee G, Duan C, Pandya D, Cohen DN, Edwards R, Chang H, Li J, Elliott H, Pokkalla H, Glass B, Agrawal N, Lahiri A, Wang D, Khosla A, Wapinski I, Beck A, Montalto M. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Mod Pathol 2022;35:1529-39. [PMID: 35840720 DOI: 10.1038/s41379-022-01119-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 597 |
Castaneda CA. Molecular and Cellular Analyses of Breast Cancers in Real Life. Improving Oncology Worldwide 2022. [DOI: 10.1007/978-3-030-96053-7_10] [Reference Citation Analysis]
|
| 598 |
Zhong Y, Peng F, Luo X, Wang X, Yang B, Tang X, Xu Z, Ren L, Wang Z, Peng C, Wang N. A pyroptosis-related gene signature for prognostic and immunological evaluation in breast cancer. Front Oncol 2022;12:964508. [PMID: 36936274 DOI: 10.3389/fonc.2022.964508] [Reference Citation Analysis]
|
| 599 |
Keenan JC, Ryan PK, Medford AJ, Spring LM, Bardia A, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies. Oncology & Haematology 2022;18:98. [DOI: 10.17925/ohr.2022.18.2.98] [Reference Citation Analysis]
|
| 600 |
Gristina V, Iacono F, Lisanti C, La Mantia M, Galvano A. Available Immunotherapy Drugs in Oncology. Current Clinical Pathology 2022. [DOI: 10.1007/978-3-030-97744-3_2] [Reference Citation Analysis]
|
| 601 |
Keshavarz-fathi M, Keshavarz-fathi M, Rezaei N. Cancer Immunology. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00083-5] [Reference Citation Analysis]
|
| 602 |
Steiger HJ, Vollmer K, Rogers S, Schwyzer L. State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain. Neurosurg Rev 2022;45:3119-38. [PMID: 35902427 DOI: 10.1007/s10143-022-01839-8] [Reference Citation Analysis]
|
| 603 |
Khoury T. Metaplastic Breast Carcinoma Revisited; Subtypes Determine Outcomes. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2021.11.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 604 |
Kok VC, Wang CCN, Liao SH, Chen DL. Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer. Breast Cancer (Dove Med Press) 2022;14:85-99. [PMID: 35437353 DOI: 10.2147/BCTT.S359346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 605 |
Mir MA, Sofi S, Qayoom H. The interplay of immunotherapy, chemotherapy, and targeted therapy in tripple negative breast cancer (TNBC). Combinational Therapy in Triple Negative Breast Cancer 2022. [DOI: 10.1016/b978-0-323-96136-3.00001-7] [Reference Citation Analysis]
|
| 606 |
Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med 2022;28:2573-83. [PMID: 36482103 DOI: 10.1038/s41591-022-02126-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 607 |
Kwan JM, Oikonomou EK, Henry ML, Sinusas AJ. Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. Front Cardiovasc Med 2022;9:829553. [PMID: 35369354 DOI: 10.3389/fcvm.2022.829553] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 608 |
Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in translational medicine and clinical practice. Mod Pathol 2022;35:23-32. [PMID: 34611303 DOI: 10.1038/s41379-021-00919-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 55.0] [Reference Citation Analysis]
|
| 609 |
Bohm MS, Sipe LM, Pye ME, Davis MJ, Pierre JF, Makowski L. The role of obesity and bariatric surgery-induced weight loss in breast cancer. Cancer Metastasis Rev 2022;41:673-95. [PMID: 35870055 DOI: 10.1007/s10555-022-10050-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 610 |
Vohra P, Chen Y, Krings G. Less Common Triple-Negative Breast Cancers. A Comprehensive Guide to Core Needle Biopsies of the Breast 2022. [DOI: 10.1007/978-3-031-05532-4_12] [Reference Citation Analysis]
|
| 611 |
Allison KH. Current Standard Clinical Predictive Markers. A Comprehensive Guide to Core Needle Biopsies of the Breast 2022. [DOI: 10.1007/978-3-031-05532-4_22] [Reference Citation Analysis]
|
| 612 |
Chan W, Marinho J, Chavarri-guerra Y, Hincapie-echeverri J, Velasco RN, Akagunduz B, Roy M, Kwong WTG, Wu W, Battisti NML, Soto-perez-de-celis E. Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper. Journal of Geriatric Oncology 2022. [DOI: 10.1016/j.jgo.2022.01.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 613 |
Sikov WM. Neoadjuvant Systemic Therapy for Breast Cancer Based on Underlying Tumor Biology. Management of the Breast and Axilla in the Neoadjuvant Setting 2022. [DOI: 10.1007/978-3-030-88020-0_6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 614 |
Kumar S, Gupta S, Maurya AP, Singh R, Nigam S. Hormonal and Targeted Treatments in Breast Cancer. Breast Cancer 2022. [DOI: 10.1007/978-981-16-4546-4_21] [Reference Citation Analysis]
|
| 615 |
Julka PK, Gupta I, Tiwari R. Role of Chemotherapy in Breast Cancer. Breast Cancer 2022. [DOI: 10.1007/978-981-16-4546-4_20] [Reference Citation Analysis]
|
| 616 |
Floris G, Broeckx G, Antoranz A, De Schepper M, Salgado R, Desmedt C, Peeters DJE, Van den Eynden GGGM. Tumor Infiltrating Lymphocytes in Breast Cancer: Implementation of a New Histopathological Biomarker. Biomarkers of the Tumor Microenvironment 2022. [DOI: 10.1007/978-3-030-98950-7_13] [Reference Citation Analysis]
|
| 617 |
Ratosa I, Visani L. Concomitant Radiation and Systemic Therapy in the Adjuvant and Metastatic Setting. Breast Cancer Radiation Therapy 2022. [DOI: 10.1007/978-3-030-91170-6_53] [Reference Citation Analysis]
|
| 618 |
Vallejo-ardila DL, Parra-medina R, Combita A, Cardona AF, Paquet-fifield S. The Effects of Angiotensin-Converting Enzyme Inhibitors on Metastasis-Associated Myeloid Cells. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_91] [Reference Citation Analysis]
|
| 619 |
Montemagno C, Luciano F, Pagès G. Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2217-9_1] [Reference Citation Analysis]
|
| 620 |
Luo J, Zou H, Guo Y, Tong T, Ye L, Zhu C, Deng L, Wang B, Pan Y, Li P. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Res 2022;24:99. [PMID: 36581908 DOI: 10.1186/s13058-022-01596-y] [Reference Citation Analysis]
|
| 621 |
Liu X, Mai J, Meng C, Spiegel AJ, Wei W, Shen H. Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine. IJN 2022;Volume 17:203-12. [DOI: 10.2147/ijn.s341394] [Reference Citation Analysis]
|
| 622 |
Opyrchal M. T-Cell Receptor (TCR) Engineered Cells and Their Transition to the Clinic. Cancer Drug Discovery and Development 2022. [DOI: 10.1007/978-3-030-87849-8_14] [Reference Citation Analysis]
|
| 623 |
Jagannathan G, White MJ, Xian RR, Emens LA, Cimino-mathews A. A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2021.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 624 |
Dong X, Yang Y, Yuan Q, Hou J, Wu G. High Expression of CEMIP Correlates Poor Prognosis and the Tumur Microenvironment in Breast Cancer as a Promisingly Prognostic Biomarker. Front Genet 2021;12:768140. [PMID: 34966410 DOI: 10.3389/fgene.2021.768140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 625 |
Ozaki Y, Miura S, Oki R, Morikawa T, Uchino K. Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. Cancers (Basel) 2021;14:196. [PMID: 35008357 DOI: 10.3390/cancers14010196] [Reference Citation Analysis]
|
| 626 |
Lepland A, Malfanti A, Haljasorg U, Asciutto EK, Pickholz M, Bringas M, Đorđević S, Salumäe L, Peterson P, Teesalu T, Vicent MJ, Scodeller P. Depletion of CD206+ Tumour Macrophages via a Peptide-Targeted Star-Shaped Polyglutamate Inhibits Tumourigenesis and Metastatic Dissemination in Breast Cancer Models.. [DOI: 10.1101/2021.12.29.474487] [Reference Citation Analysis]
|
| 627 |
Giugliano F, Antonarelli G, Tarantino P, Cortes J, Rugo HS, Curigliano G. Harmonizing PD-L1 testing in metastatic triple negative breast cancer. Expert Opin Biol Ther 2021;:1-4. [PMID: 34930070 DOI: 10.1080/14712598.2022.2021180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 628 |
Vishwakarma GK, Kumari P, Bhattacharjee A. Thresholding of prominent biomarkers of breast cancer on overall survival using classification and regression tree. Cancer Biomark 2021. [PMID: 35001879 DOI: 10.3233/CBM-210470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 629 |
He F, Liu J, Shen X, Wang Z, Li Q, Li G. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Ann Pharmacother 2021;:10600280211058385. [PMID: 34963337 DOI: 10.1177/10600280211058385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 630 |
Tarantino P, Barroso-Sousa R, Garrido-Castro AC, McAllister SS, Guerriero JL, Mittendorf E, Curigliano G, Tolaney SM. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Rev Anticancer Ther 2021;:1-13. [PMID: 34919490 DOI: 10.1080/14737140.2022.2020650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 631 |
Kiely M, Lord B, Ambs S. Immune response and inflammation in cancer health disparities. Trends Cancer 2021:S2405-8033(21)00240-5. [PMID: 34965905 DOI: 10.1016/j.trecan.2021.11.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 632 |
Barca C, Foray C, Hermann S, Herrlinger U, Remory I, Laoui D, Schäfers M, Grauer OM, Zinnhardt B, Jacobs AH. The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). Front Immunol 2021;12:787307. [PMID: 34950148 DOI: 10.3389/fimmu.2021.787307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 633 |
Li X, Sun H, Liu Q, Liu Y, Hou Y, Jin W. Conjoint analysis of circulating tumor cells and solid tumors for exploring potential prognostic markers and constructing a robust novel predictive signature for breast cancer. Cancer Cell Int 2021;21:708. [PMID: 34953500 DOI: 10.1186/s12935-021-02415-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 634 |
Wang Y, Yu J, Li D, Zhao L, Sun B, Wang J, Wang Z, Zhou S, Wang M, Yang Y, Liu H, Zhang H, Lv Q, Jiang Q, He Z, Wang Y. Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy. J Control Release 2021;341:812-27. [PMID: 34953979 DOI: 10.1016/j.jconrel.2021.12.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 635 |
Latif F, Bint Abdul Jabbar H, Malik H, Sadaf H, Sarfraz A, Sarfraz Z, Cherrez-Ojeda I. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Expert Rev Anticancer Ther 2021. [PMID: 34949142 DOI: 10.1080/14737140.2022.2023011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 636 |
Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer 2021;162:22-33. [PMID: 34952480 DOI: 10.1016/j.ejca.2021.11.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 637 |
Zhai Y, Ma Y, Pang B, Zhang J, Li Y, Rui Y, Xu T, Zhao Y, Qian Z, Gu Y, Li S. A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy. J Nanobiotechnology 2021;19:434. [PMID: 34930285 DOI: 10.1186/s12951-021-01193-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 638 |
Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, Shparyk Y, Jakobsen EH, Wu M, Bach BA, Feng D, Ratajczak CK, Maag D, Diéras V. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. Ther Adv Med Oncol 2021;13:17588359211059601. [PMID: 34917174 DOI: 10.1177/17588359211059601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 639 |
Shen Y, Zhang B, Wei X, Guan X, Zhang W. CXCL8 is a prognostic biomarker and correlated with TNBC brain metastasis and immune infiltration. Int Immunopharmacol 2021;103:108454. [PMID: 34929481 DOI: 10.1016/j.intimp.2021.108454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 640 |
Wang Z, Wang F, Ding XY, Li TE, Wang HY, Gao YH, Wang WJ, Liu YF, Chen XS, Shen KW. Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis. Cancer Lett 2021;527:174-90. [PMID: 34929335 DOI: 10.1016/j.canlet.2021.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 641 |
Wu TN, Chen HM, Shyur LF. Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment. Int J Mol Sci 2021;22:13571. [PMID: 34948368 DOI: 10.3390/ijms222413571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 642 |
Li Y, Xing L, Li F, Liu H, Gan L, Yang D, Wang M, Yin X, Li H, Ren G. Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Oncol 2021;11:657634. [PMID: 34912699 DOI: 10.3389/fonc.2021.657634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 643 |
Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. Cancer Treat Rev 2021;103:102324. [PMID: 34953200 DOI: 10.1016/j.ctrv.2021.102324] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 644 |
Kasherman L, Karakasis K, Oza AM. With Our Powers Combined: Exploring PARP Inhibitors and Immunotherapy. Cancer J 2021;27:511-20. [PMID: 34904815 DOI: 10.1097/PPO.0000000000000557] [Reference Citation Analysis]
|
| 645 |
Wang L, Zhang X, Wang M, Li Y, Xu J, Wei J, Li H, Ren G, Yin X. AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer. Front Oncol 2021;11:749135. [PMID: 34900696 DOI: 10.3389/fonc.2021.749135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 646 |
Yaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O'Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study. Breast Cancer Res 2021;23:113. [PMID: 34906209 DOI: 10.1186/s13058-021-01493-w] [Reference Citation Analysis]
|
| 647 |
Lo Gullo R, Wen H, Reiner JS, Hoda R, Sevilimedu V, Martinez DF, Thakur SB, Jochelson MS, Gibbs P, Pinker K. Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. Cancers 2021;13:6273. [DOI: 10.3390/cancers13246273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 648 |
Skala MC, Ayuso JM, Burkard ME, Deming DA. Breast cancer immunotherapy: current biomarkers and the potential of in vitro assays. Curr Opin Biomed Eng 2021;21:100348. [PMID: 34901585 DOI: 10.1016/j.cobme.2021.100348] [Reference Citation Analysis]
|
| 649 |
Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F. Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. Front Oncol 2021;11:769280. [PMID: 34900718 DOI: 10.3389/fonc.2021.769280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 650 |
Tolba MF, Santa-Maria CA, Albini A, Chimusa ER, Al-Ramadi BK, Tolaney SM. Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer. Front Oncol 2021;11:752689. [PMID: 34900701 DOI: 10.3389/fonc.2021.752689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 651 |
Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther 2021;6:412. [PMID: 34897277 DOI: 10.1038/s41392-021-00823-w] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 652 |
Koh SB, Ellisen LW. Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer. Cancer Cell 2021;39:1562-4. [PMID: 34767761 DOI: 10.1016/j.ccell.2021.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 653 |
Rodríguez-Bautista R, Caro-Sánchez CH, Cabrera-Galeana P, Alanis-Funes GJ, Gutierrez-Millán E, Ávila-Ríos S, Matías-Florentino M, Reyes-Terán G, Díaz-Chávez J, Villarreal-Garza C, Hernández-Pedro NY, Ortega-Gómez A, Lara-Mejía L, Rangel-Escareño C, Arrieta O. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers (Basel) 2021;13:6256. [PMID: 34944876 DOI: 10.3390/cancers13246256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 654 |
Han G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL. Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies. Stat Med 2021. [PMID: 34897773 DOI: 10.1002/sim.9282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 655 |
Vaikundaraja IM, Dhanushkodi M, Radhakrishnan V, Kalaiarasi JP, Mehra N, Selvarajan G, Rajan AK, Kesana SS, Ananthi B, Iyer P, Rao M, Krishnamurthy A, Velusamy S, Ranganathan R, Sagar TG. Real-World Outcome of Platinum-Based Chemotherapy in Advanced Breast Cancer (ABC): A Retrospective Study from a Tertiary Cancer Center in India. Indian J Med Paediatr Oncol. [DOI: 10.1055/s-0041-1735597] [Reference Citation Analysis]
|
| 656 |
Zong Y, Pegram M. Research advances and new challenges in overcoming triple-negative breast cancer. Cancer Drug Resist 2021;4:517-42. [PMID: 34888495 DOI: 10.20517/cdr.2021.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 657 |
Noer JB, Talman MM, Moreira JMA. HLA Class II Histocompatibility Antigen γ Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer. Cancers 2021;13:6179. [DOI: 10.3390/cancers13246179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 658 |
Chen N, Higashiyama N, Hoyos V. Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1. Biomedicines 2021;9:1863. [PMID: 34944679 DOI: 10.3390/biomedicines9121863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 659 |
Bhat V, Pellizzari S, Allan AL, Wong E, Lock M, Brackstone M, Lohmann AE, Cescon DW, Parsyan A. Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications. Crit Rev Oncol Hematol 2021;169:103566. [PMID: 34890802 DOI: 10.1016/j.critrevonc.2021.103566] [Reference Citation Analysis]
|
| 660 |
Wong SK, Nebhan CA, Johnson DB. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. Front Immunol 2021;12:786046. [PMID: 34868071 DOI: 10.3389/fimmu.2021.786046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 661 |
Li Z, Sun G, Sun G, Cheng Y, Wu L, Wang Q, Lv C, Zhou Y, Xia Y, Tang W. Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. Front Oncol 2021;11:771335. [PMID: 34869005 DOI: 10.3389/fonc.2021.771335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 662 |
Ye H, Zhang N. Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer. Comput Math Methods Med 2021;2021:1498924. [PMID: 34868337 DOI: 10.1155/2021/1498924] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 663 |
Qiu X, Qu Y, Guo B, Zheng H, Meng F, Zhong Z. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer. J Control Release 2021;341:498-510. [PMID: 34883139 DOI: 10.1016/j.jconrel.2021.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 664 |
Kalugin MV, Ivanova KA, Borisova EI, Nakhapetyan SS, Gutorov SL. Effectiveness of combination with eribulin in third line of chemotherapy for triple negative breast cancer (case report). Medicinskij alfavit 2021;1:20-24. [DOI: 10.33667/2078-5631-2021-31-20-24] [Reference Citation Analysis]
|
| 665 |
Nadesh R, Menon KN, Biswas L, Mony U, Subramania Iyer K, Vijayaraghavan S, Nambiar A, Nair S. Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer. Sci Rep 2021;11:23435. [PMID: 34873206 DOI: 10.1038/s41598-021-01878-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 666 |
Sammons S, Van Swearingen AED, Chung C, Anders CK. Advances in the management of breast cancer brain metastases. Neurooncol Adv 2021;3:v63-74. [PMID: 34859234 DOI: 10.1093/noajnl/vdab119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 667 |
Radziuviene G, Rasmusson A, Augulis R, Grineviciute RB, Zilenaite D, Laurinaviciene A, Ostapenko V, Laurinavicius A. Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients. Front Oncol 2021;11:774088. [PMID: 34858854 DOI: 10.3389/fonc.2021.774088] [Reference Citation Analysis]
|
| 668 |
Steindl A, Brastianos PK, Preusser M, Berghoff AS. Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. Neurooncol Adv 2021;3:v35-42. [PMID: 34859231 DOI: 10.1093/noajnl/vdab105] [Reference Citation Analysis]
|
| 669 |
Li Y, Tan Y, Wen L, Xing Z, Wang C, Zhang L, Wu K, Sun H, Li Y, Lei Q, Wu S. Overexpression of BIRC6 driven by EGF-JNK-HECTD1 signaling is a potential therapeutic target for triple-negative breast cancer. Mol Ther Nucleic Acids 2021;26:798-812. [PMID: 34729249 DOI: 10.1016/j.omtn.2021.09.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 670 |
Tian T, Zhao Y, Zheng J, Jin S, Liu Z, Wang T. Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer. Mol Ther Nucleic Acids 2021;26:63-80. [PMID: 34513294 DOI: 10.1016/j.omtn.2021.06.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 671 |
Eteshola EOU, Landa K, Rempel RE, Naqvi IA, Hwang ES, Nair SK, Sullenger BA. Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects. Mol Ther Nucleic Acids 2021;26:1-10. [PMID: 34513289 DOI: 10.1016/j.omtn.2021.06.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 672 |
Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 673 |
Collier KA, Asad S, Tallman D, Jenison J, Rajkovic A, Mardis ER, Parsons HA, Tolaney SM, Winer EP, Lin NU, Ha G, Adalsteinsson VA, Stover DG. Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34849445 DOI: 10.1200/PO.21.00104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 674 |
Blohmer J, Schneeweiss A, Bauerfeind I, Fehm T, Müller V, Thomssen C, Witzel I, Wöckel A, Janni W. Therapiealgorithmen für das Mammakarzinom. Onkologe 2021;27:1165-1174. [DOI: 10.1007/s00761-021-01060-0] [Reference Citation Analysis]
|
| 675 |
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer 2021;7:150. [PMID: 34853355 DOI: 10.1038/s41523-021-00346-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 676 |
Bai X, Ni J, Beretov J, Wang S, Dong X, Graham P, Li Y. THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple-Negative Breast Cancer. Adv Sci (Weinh) 2021;8:e2102658. [PMID: 34708581 DOI: 10.1002/advs.202102658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 677 |
Thomssen C. Prädiktive und prognostische Faktoren in der Therapie des frühen Mammakarzinoms. Onkologe 2021;27:1175-1190. [DOI: 10.1007/s00761-021-01054-y] [Reference Citation Analysis]
|
| 678 |
Togashi Y. Cancer-immunotherapy biomarkers in the tumor microenvironment. Okayama I Z 2021;133:151-157. [DOI: 10.4044/joma.133.151] [Reference Citation Analysis]
|
| 679 |
Nakhjavani M, Shigdar S. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. Pharmacol Res 2021;175:106019. [PMID: 34861397 DOI: 10.1016/j.phrs.2021.106019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 680 |
L A, A E, A M, E M, M M. Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report. Current Problems in Cancer: Case Reports 2021;4:100097. [DOI: 10.1016/j.cpccr.2021.100097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 681 |
Li Y, Zhao X, Liu Q, Liu Y. Bioinformatics reveal macrophages marker genes signature in breast cancer to predict prognosis. Ann Med 2021;53:1019-31. [PMID: 34187256 DOI: 10.1080/07853890.2021.1914343] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 682 |
Kenny K, Broom A, Page A, Prainsack B, Wakefield CE, Itchins M, Lwin Z, Khasraw M. A sociology of precision-in-practice: The affective and temporal complexities of everyday clinical care. Sociol Health Illn 2021;43:2178-95. [PMID: 34843108 DOI: 10.1111/1467-9566.13389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 683 |
Retecki K, Seweryn M, Graczyk-Jarzynka A, Bajor M. The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers (Basel) 2021;13:6012. [PMID: 34885122 DOI: 10.3390/cancers13236012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 684 |
Ledys F, Kalfeist L, Galland L, Limagne E, Ladoire S. Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. Cancers (Basel) 2021;13:5999. [PMID: 34885109 DOI: 10.3390/cancers13235999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 685 |
Schlam I, Church SE, Hether TD, Chaldekas K, Hudson BM, White AM, Maisonet E, Harris BT, Swain SM. The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling. J Transl Med 2021;19:480. [PMID: 34838031 DOI: 10.1186/s12967-021-03113-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 686 |
Corti C, Nicolò E, Curigliano G. Novel immune targets for the treatment of triple-negative breast cancer. Expert Opin Ther Targets 2021;:1-20. [PMID: 34763593 DOI: 10.1080/14728222.2021.2006187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 687 |
Kelly AD, Murugesan K, Kuang Z, Montesion M, Ross JS, Albacker LA, Huang RSP, Lin DI, Demirci U, Creeden J. Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. J Immunother Cancer 2021;9:e003550. [PMID: 34815356 DOI: 10.1136/jitc-2021-003550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 688 |
Hacking S, Wu D, Lee L, Vitkovski T, Nasim M. Nature and Significance of Stromal Differentiation,, PD-L1, and VISTA in GIST. Pathol Res Pract 2021;229:153703. [PMID: 34929600 DOI: 10.1016/j.prp.2021.153703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 689 |
Xin Y, Shen G, Zheng Y, Guan Y, Huo X, Li J, Ren D, Zhao F, Liu Z, Li Z, Zhao J. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer 2021;21:1261. [PMID: 34814874 DOI: 10.1186/s12885-021-08997-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 690 |
Matusz-Fisher A, Tan AR. Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. Expert Opin Biol Ther 2021;:1-11. [PMID: 34806498 DOI: 10.1080/14712598.2021.1981284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 691 |
Cusano E, Wong C, Taguedong E, Vaska M, Abedin T, Nixon N, Karim S, Tang P, Heng DYC, Ezeife D. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Curr Oncol 2021;28:4894-928. [PMID: 34898590 DOI: 10.3390/curroncol28060412] [Reference Citation Analysis]
|
| 692 |
Zhang X, Goedegebuure SP, Myers NB, Vickery T, Mclellan MD, Gao F, Sturmoski MA, Chen MY, Kim SW, Chen I, Davidson JT, Sankpal NV, Hundal J, Li L, Myles S, Suresh R, Ma CX, Foluso A, Wang-gillam A, Davies S, Hagemann I, Mardis ER, Griffith M, Miller CA, Hansen TH, Fleming TP, Schreiber RD, Gillanders WE. Neoantigen DNA vaccines are safe, feasible, and capable of inducing neoantigen-specific immune responses in patients with triple negative breast cancer.. [DOI: 10.1101/2021.11.19.21266466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 693 |
Kim H, Kim HJ, Kim H, Kim HR, Jo H, Hong J, Kim R, Kim JY, Ahn JS, Im YH, Lee SK, Kim H, Shin SY, Park YH. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. Cancers (Basel) 2021;13:5835. [PMID: 34830990 DOI: 10.3390/cancers13225835] [Reference Citation Analysis]
|
| 694 |
Jaouani L, Zaimi A, Al Jarroudi O, Brahmi SA, Afqir S. Unusual Metastasis From Breast Cancer: Case Report. Cureus 2021;13:e18737. [PMID: 34796050 DOI: 10.7759/cureus.18737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 695 |
Zerdes I, Simonetti M, Matikas A, Harbers L, Acs B, Boyaci C, Zhang N, Salgkamis D, Agartz S, Moreno-Ruiz P, Bai Y, Rimm DL, Hartman J, Mezheyeuski A, Bergh J, Crosetto N, Foukakis T. Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. NPJ Breast Cancer 2021;7:144. [PMID: 34799582 DOI: 10.1038/s41523-021-00352-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 696 |
Riaz N, Burugu S, Cheng AS, Leung SCY, Gao D, Nielsen TO. Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer. Cancers (Basel) 2021;13:5769. [PMID: 34830923 DOI: 10.3390/cancers13225769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 697 |
Smrke A, Tam YB, Anderson PM, Jones RL, Huang PH. The perplexing role of immuno-oncology drugs in osteosarcoma. J Bone Oncol 2021;31:100400. [PMID: 34786332 DOI: 10.1016/j.jbo.2021.100400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 698 |
Hu Y, Burkard ME. Classes of therapeutics to amplify the immune response. Breast Cancer Res Treat 2021. [PMID: 34787761 DOI: 10.1007/s10549-021-06369-3] [Reference Citation Analysis]
|
| 699 |
Li Y, Zhan Z, Yin X, Fu S, Deng X. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer. Front Oncol 2021;11:731535. [PMID: 34778045 DOI: 10.3389/fonc.2021.731535] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 700 |
Liu X, Lang Y, Liao Y, Zhu Y. Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis. Front Public Health 2021;9:756899. [PMID: 34778188 DOI: 10.3389/fpubh.2021.756899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 701 |
Darga EP, Dolce EM, Fang F, Kidwell KM, Gersch CL, Kregel S, Thomas DG, Gill A, Brown ME, Gross S, Connelly M, Holinstat M, Cobain EF, Rae JM, Hayes DF, Paoletti C. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS One 2021;16:e0260124. [PMID: 34780566 DOI: 10.1371/journal.pone.0260124] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 702 |
Vick SC, Kolupaev OV, Perou CM, Serody JS. Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells. J Immunol 2021;207:2598-607. [PMID: 34607937 DOI: 10.4049/jimmunol.2001334] [Reference Citation Analysis]
|
| 703 |
Henriques B, Mendes F, Martins D. Immunotherapy in Breast Cancer: When, How, and What Challenges? Biomedicines 2021;9. [PMID: 34829916 DOI: 10.3390/biomedicines9111687] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 704 |
Zheng X, Li L, Yu C, Yang J, Zhao Y, Su C, Yu J, Xu M. Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy. Aging (Albany NY) 2021;13:24313-38. [PMID: 34762599 DOI: 10.18632/aging.203682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 705 |
Japir AAMM, Ke W, Li J, Mukerabigwi JF, Ibrahim A, Wang Y, Li X, Zhou Q, Mohammed F, Ge Z. Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy. J Control Release 2021;339:418-29. [PMID: 34662586 DOI: 10.1016/j.jconrel.2021.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 706 |
Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol 2021. [PMID: 34754128 DOI: 10.1038/s41571-021-00565-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 81] [Article Influence: 33.5] [Reference Citation Analysis]
|
| 707 |
Yokoi T, Oba T, Kajihara R, Abrams SI, Ito F. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Sci Rep 2021;11:21992. [PMID: 34754037 DOI: 10.1038/s41598-021-01455-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 708 |
Mouchemore KA, Anderson RL. Immunomodulatory effects of G-CSF in cancer: Therapeutic implications. Semin Immunol 2021;:101512. [PMID: 34763974 DOI: 10.1016/j.smim.2021.101512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 709 |
Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Clin Immunol 2021;232:108876. [PMID: 34740840 DOI: 10.1016/j.clim.2021.108876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 710 |
Noske A, Wagner DC, Schwamborn K, Foersch S, Steiger K, Kiechle M, Oettler D, Karapetyan S, Hapfelmeier A, Roth W, Weichert W. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. Breast 2021;60:238-44. [PMID: 34768219 DOI: 10.1016/j.breast.2021.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 711 |
Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. Int J Mol Sci 2021;22:12015. [PMID: 34769447 DOI: 10.3390/ijms222112015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 712 |
Bou-Dargham MJ, Draughon S, Cantrell V, Khamis ZI, Sang QA. Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy. J Cancer 2021;12:6949-63. [PMID: 34729098 DOI: 10.7150/jca.64205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 713 |
Wang J, Browne L, Slapetova I, Shang F, Lee K, Lynch J, Beretov J, Whan R, Graham PH, Millar EKA. Multiplexed immunofluorescence identifies high stromal CD68(+)PD-L1(+) macrophages as a predictor of improved survival in triple negative breast cancer. Sci Rep 2021;11:21608. [PMID: 34732817 DOI: 10.1038/s41598-021-01116-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 714 |
Williams MM, Hafeez SA, Christenson JL, O'Neill KI, Hammond NG, Richer JK. Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways. Pharmaceuticals (Basel) 2021;14:1122. [PMID: 34832904 DOI: 10.3390/ph14111122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 715 |
Cummins DD, Morshed RA, Chavez MM, Avalos LN, Sudhakar V, Chung JE, Gallagher A, Saggi S, Daras M, Braunstein S, Theodosopoulos PV, McDermott MW, Aghi MK. Salvage Surgery for Local Control of Brain Metastases After Previous Stereotactic Radiosurgery: A Single-Center Series. World Neurosurg 2021:S1878-8750(21)01690-9. [PMID: 34740830 DOI: 10.1016/j.wneu.2021.10.179] [Reference Citation Analysis]
|
| 716 |
Salvadori G, Zanardi F, Iannelli F, Lobefaro R, Vernieri C, Longo VD. Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. Cell Metab 2021;33:2247-2259.e6. [PMID: 34731655 DOI: 10.1016/j.cmet.2021.10.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 717 |
Paradiso A, Codacci-Pisanelli G, Munzone E, Rugo HS, Heudel PE. Expert Discussion: Predictive Markers. Breast Care (Basel) 2021;16:552-7. [PMID: 34720818 DOI: 10.1159/000519562] [Reference Citation Analysis]
|
| 718 |
Hilser T, Virchow I, Grünwald V. Immunkombinationstherapien. Onkologe 2021;27:1085-1093. [DOI: 10.1007/s00761-021-01033-3] [Reference Citation Analysis]
|
| 719 |
Zhou Z, Van der Jeught K, Fang Y, Yu T, Li Y, Ao Z, Liu S, Zhang L, Yang Y, Eyvani H, Cox ML, Wang X, He X, Ji G, Schneider BP, Guo F, Wan J, Zhang X, Lu X. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng 2021;5:1320-35. [PMID: 34725507 DOI: 10.1038/s41551-021-00805-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 720 |
Ahmed KA, Kim Y, Arrington JA, Kim S, Dejesus M, Soyano AE, Armaghani AJ, Costa RL, Khong HT, Loftus LS, Rosa M, Caudell JJ, Diaz R, Robinson TJ, Etame AB, Tran ND, Sahebjam S, Soliman HH, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study. Advances in Radiation Oncology 2021;6:100798. [DOI: 10.1016/j.adro.2021.100798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 721 |
Li X, Zhen Y, Li S. Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor. Materials & Design 2021;209:109958. [DOI: 10.1016/j.matdes.2021.109958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 722 |
Chabanon RM, Rouanne M, Lord CJ, Soria JC, Pasero P, Postel-Vinay S. Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat Rev Cancer 2021;21:701-17. [PMID: 34376827 DOI: 10.1038/s41568-021-00386-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 35.5] [Reference Citation Analysis]
|
| 723 |
Huang J, Yu S, Ding L, Ma L, Chen H, Zhou H, Zou Y, Yu M, Lin J, Cui Q. The Dual Role of Circular RNAs as miRNA Sponges in Breast Cancer and Colon Cancer. Biomedicines 2021;9:1590. [PMID: 34829818 DOI: 10.3390/biomedicines9111590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 724 |
Mei C, Xin L, Liu Y, Lin J, Xian H, Zhang X, Hu W, Xia Z, Wang H, Lyu Y. Establishment of a New Cell Line of Canine Mammary Tumor CMT-1026. Front Vet Sci 2021;8:744032. [PMID: 34712723 DOI: 10.3389/fvets.2021.744032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 725 |
Kim W, Cho YA, Kim DC, Jo AR, Min KH, Lee KE. Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models. Cancers (Basel) 2021;13:5465. [PMID: 34771631 DOI: 10.3390/cancers13215465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 726 |
Torres ETR, Emens LA. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. Breast Cancer Res Treat 2021. [PMID: 34716871 DOI: 10.1007/s10549-021-06423-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 727 |
Zhang S, Gong C, Ruiz-Martinez A, Wang H, Davis-Marcisak E, Deshpande A, Popel AS, Fertig EJ. Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response. Immunoinformatics (Amst) 2021;1-2:100002. [PMID: 34708216 DOI: 10.1016/j.immuno.2021.100002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 728 |
Sakaguchi A, Horimoto Y, Onagi H, Ikarashi D, Nakayama T, Nakatsura T, Shimizu H, Kojima K, Yao T, Matsumoto T, Ogura K, Kitano S. Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res 2021;23:99. [PMID: 34715905 DOI: 10.1186/s13058-021-01477-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 729 |
Du J, Dong Y, Li Y. Identification and Prognostic Value Exploration of Cyclophosphamide (Cytoxan)-Centered Chemotherapy Response-Associated Genes in Breast Cancer. DNA Cell Biol 2021;40:1356-68. [PMID: 34704810 DOI: 10.1089/dna.2021.0077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 730 |
Shin SU, Cho HM, Das R, Gil-Henn H, Ramakrishnan S, Al Bayati A, Carroll SF, Zhang Y, Sankar AP, Elledge C, Pimentel A, Blonska M, Rosenblatt JD. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases. Cells 2021;10:2904. [PMID: 34831127 DOI: 10.3390/cells10112904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 731 |
Elwakeel E, Weigert A. Breast Cancer CAFs: Spectrum of Phenotypes and Promising Targeting Avenues. Int J Mol Sci 2021;22:11636. [PMID: 34769066 DOI: 10.3390/ijms222111636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 732 |
Zhang J, Shan B, Lin L, Dong J, Sun Q, Zhou Q, Chen J, Han X. Dissecting the Role of N6-Methylandenosine-Related Long Non-coding RNAs Signature in Prognosis and Immune Microenvironment of Breast Cancer. Front Cell Dev Biol 2021;9:711859. [PMID: 34692676 DOI: 10.3389/fcell.2021.711859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 733 |
Guo XM, Yadav MB, Khan M, Hao CW, Lin CY, Huang T, Wu J, Fan BM, Bian ZX. Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer. J Med Chem 2021. [PMID: 34699215 DOI: 10.1021/acs.jmedchem.1c00705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 734 |
Duchnowska R, Saad ED, Banaszek M, Pawłowska E, Liberek H, Cichowska-Cwalińska N, Jassem J. Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review. Cancers (Basel) 2021;13:5306. [PMID: 34771468 DOI: 10.3390/cancers13215306] [Reference Citation Analysis]
|
| 735 |
Dai Q, Liu X, He T, Yang C, Jiang J, Fang Y, Fu Z, Yuan Y, Bai S, Qiu T, Yin R, Ding P, Chen J, Li Q. Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response. iScience 2021;24:103170. [PMID: 34646996 DOI: 10.1016/j.isci.2021.103170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 736 |
Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight 2021;6:e151035. [PMID: 34676831 DOI: 10.1172/jci.insight.151035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 737 |
Chic N, Brasó-Maristany F, Prat A. Biomarkers of immunotherapy response in breast cancer beyond PD-L1. Breast Cancer Res Treat 2021. [PMID: 34676466 DOI: 10.1007/s10549-021-06421-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 738 |
Qiu P, Guo Q, Yao Q, Chen J, Lin J. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer. Front Immunol 2021;12:736030. [PMID: 34659224 DOI: 10.3389/fimmu.2021.736030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 739 |
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. NPJ Precis Oncol 2021;5:92. [PMID: 34667258 DOI: 10.1038/s41698-021-00232-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 740 |
Jeong S, Lee N, Park MJ, Jeon K, Song W. Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer. Cancers (Basel) 2021;13:5225. [PMID: 34680373 DOI: 10.3390/cancers13205225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 741 |
Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A. Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. Cancers (Basel) 2021;13:5198. [PMID: 34680350 DOI: 10.3390/cancers13205198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 742 |
Schreiber AR, Andress M, Diamond JR. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Expert Rev Anticancer Ther 2021;21:1303-11. [PMID: 34651524 DOI: 10.1080/14737140.2021.1993065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 743 |
Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res 2021;27:5628-37. [PMID: 34108182 DOI: 10.1158/1078-0432.CCR-21-0343] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 744 |
Wei D, Wang H, Zeng Q, Wang W, Hao B, Feng X, Wang P, Song N, Kan W, Huang G, Zhou X, Tan M, Zhou Y, Huang R, Li J, Chen XH. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem 2021;64:14822-47. [PMID: 34538051 DOI: 10.1021/acs.jmedchem.1c01350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 745 |
Medford A, Spring LM, Moy B, Bardia A. Antibody drug conjugates for patients with breast cancer. Curr Probl Cancer 2021;45:100795. [PMID: 34635342 DOI: 10.1016/j.currproblcancer.2021.100795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 746 |
Rivier C, Mery B, Rowinski E, Sotton S, Bouleftour W, Bertoletti L, Tredan O, Magne N. Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. Expert Opin Drug Saf 2021;:1-13. [PMID: 34551666 DOI: 10.1080/14740338.2021.1983541] [Reference Citation Analysis]
|
| 747 |
Zhang W, Kong X, Ai B, Wang Z, Wang X, Wang N, Zheng S, Fang Y, Wang J. Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. Front Oncol 2021;11:582664. [PMID: 34631507 DOI: 10.3389/fonc.2021.582664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 748 |
Kos K, de Visser KE. The Multifaceted Role of Regulatory T Cells in Breast Cancer. Annu Rev Cancer Biol 2021;5:291-310. [PMID: 34632244 DOI: 10.1146/annurev-cancerbio-042920-104912] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 749 |
Clark CA, Yang ES. Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. Front Oncol 2021;11:703802. [PMID: 34631532 DOI: 10.3389/fonc.2021.703802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 750 |
McAndrew NP, Finn RS. Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer. JCO Oncol Pract 2021;:OP2100384. [PMID: 34637323 DOI: 10.1200/OP.21.00384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 751 |
Howard FM, Villamar D, He G, Pearson AT, Nanda R. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs 2021;:1-18. [PMID: 34569400 DOI: 10.1080/13543784.2022.1986002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 752 |
Yang C, Zhang Z, Tang X, Zhang X, Chen Y, Hu T, Zhang H, Guan M, Zhang X, Wu Z. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. Hum Cell 2021. [PMID: 34628623 DOI: 10.1007/s13577-021-00630-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 753 |
Zhu SY, Ma D, Shao ZM, Yu KD. Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial. Front Mol Biosci 2021;8:752154. [PMID: 34621789 DOI: 10.3389/fmolb.2021.752154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 754 |
Pan Q, Xu J, Wen CJ, Xiong YY, Gong ZT, Yang YJ. Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction. Int J Nanomedicine 2021;16:6719-47. [PMID: 34621124 DOI: 10.2147/IJN.S328723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 755 |
Hernando-Calvo A, Cescon DW, Bedard PL. Novel classes of immunotherapy for breast cancer. Breast Cancer Res Treat 2021. [PMID: 34623509 DOI: 10.1007/s10549-021-06405-2] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 756 |
Brasó-Maristany F, Sansó M, Chic N, Martínez D, González-Farré B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sánchez M, Soy D, Jares P, Peg V, Saura C, Muñoz M, Prat A, Vivancos A. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. Front Oncol 2021;11:710596. [PMID: 34616675 DOI: 10.3389/fonc.2021.710596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 757 |
Lim B, Peterson CB, Davis A, Cho E, Pearson T, Liu H, Hwang M, Ueno NT, Lee J. ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells. Biomedicines 2021;9:1410. [PMID: 34680527 DOI: 10.3390/biomedicines9101410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 758 |
Leal AS, Moerland JA, Zhang D, Carapellucci S, Lockwood B, Krieger-Burke T, Aleiwi B, Ellsworth E, Liby KT. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers (Basel) 2021;13:5004. [PMID: 34638488 DOI: 10.3390/cancers13195004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 759 |
Davey MG, Lowery AJ, Miller N, Kerin MJ. MicroRNA Expression Profiles and Breast Cancer Chemotherapy. Int J Mol Sci 2021;22:10812. [PMID: 34639152 DOI: 10.3390/ijms221910812] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 760 |
Zheng N, Zhang S, Wang L, Qi Z, Peng Q, Jian L, Bai Y, Feng Y, Shen J, Wang R, Jiao J, Xu W, Liu S. Boosting image-guiding radiation therapy through W18O49 nanospheres and the second near-infrared light irradiation. Nano Res 2022;15:2315-23. [DOI: 10.1007/s12274-021-3814-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 761 |
Xu K, Wang R, Xie H, Hu L, Wang C, Xu J, Zhu C, Liu Y, Gao F, Li X, Wang C, Huang J, Zhou W, Zhou G, Shu Y, Guan X. Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis. Oncogenesis 2021;10:66. [PMID: 34611125 DOI: 10.1038/s41389-021-00355-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 762 |
Chen Z, Wang M, De Wilde RL, Feng R, Su M, Torres-de la Roche LA, Shi W. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype. Front Immunol 2021;12:749459. [PMID: 34603338 DOI: 10.3389/fimmu.2021.749459] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 763 |
Cha YJ, Kim D, Bae SJ, Ahn SG, Jeong J, Lee HS, Jeon S, Yoo TK, Park WC, Yoon CI. PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection. Sci Rep 2021;11:19555. [PMID: 34599199 DOI: 10.1038/s41598-021-97250-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 764 |
Yu B, Luo F, Sun B, Liu W, Shi Q, Cheng SY, Chen C, Chen G, Li Y, Feng H. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer. Adv Sci (Weinh) 2021;8:e2100014. [PMID: 34392614 DOI: 10.1002/advs.202100014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 765 |
Jerzak KJ, Lipton N, Nofech-Mozes S, Boles D, Slodkowska E, Pond GR, Warner E. Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study. Breast Cancer Res Treat 2021;189:797-806. [PMID: 34318391 DOI: 10.1007/s10549-021-06327-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 766 |
Savas P, Salgado R, Loi S. Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. Breast Cancer Res Treat 2021;189:599-606. [PMID: 34487294 DOI: 10.1007/s10549-021-06287-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 767 |
Sheikh A, Kesharwani P. An insight into aptamer engineered dendrimer for cancer therapy. European Polymer Journal 2021;159:110746. [DOI: 10.1016/j.eurpolymj.2021.110746] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 768 |
Ryu WJ, Sohn JH. Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer. Pharmaceuticals (Basel) 2021;14:1008. [PMID: 34681231 DOI: 10.3390/ph14101008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 769 |
Lu YS, Yeo W, Yap YS, Park YH, Tamura K, Li H, Cheng R. An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. Target Oncol 2021;16:701-41. [PMID: 34582007 DOI: 10.1007/s11523-021-00838-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 770 |
Schmidt M, Heimes AS. Immunomodulating Therapies in Breast Cancer-From Prognosis to Clinical Practice. Cancers (Basel) 2021;13:4883. [PMID: 34638367 DOI: 10.3390/cancers13194883] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 771 |
Song HN, Jin H, Kim JH, Ha IB, Kang KM, Choi HS, Jeong HJ, Kim MY, Kim HJ, Jeong BK. Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model. Int J Mol Sci 2021;22:10476. [PMID: 34638817 DOI: 10.3390/ijms221910476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 772 |
Peters S, Galle PR, Bernaards CA, Ballinger M, Bruno R, Quarmby V, Ruppel J, Vilimovskij A, Wu B, Sternheim N, Reck M. Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). Clin Transl Sci 2021. [PMID: 34582105 DOI: 10.1111/cts.13149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 773 |
Nunnery SE, Mayer IA, Balko JM. Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis. Cancer J 2021;27:2-7. [PMID: 33475287 DOI: 10.1097/PPO.0000000000000494] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 774 |
Lee S, Shim HS, Ahn BC, Lim SM, Kim HR, Cho BC, Hong MH. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. Cancer Immunol Immunother 2021. [PMID: 34568975 DOI: 10.1007/s00262-021-03052-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 775 |
Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021;14:156. [PMID: 34579759 DOI: 10.1186/s13045-021-01164-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 776 |
Ghebeh H, Al-Sayed A, Eiada R, Cabangon L, Ajarim D, Suleman K, Tulbah A, Al-Tweigeri T. Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer. Sci Rep 2021;11:19154. [PMID: 34580336 DOI: 10.1038/s41598-021-98113-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 777 |
Tarantino P, Antonarelli G, Ascione L, Curigliano G. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opin Investig Drugs 2021;:1-15. [PMID: 34569405 DOI: 10.1080/13543784.2021.1972968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 778 |
Terceiro LEL, Edechi CA, Ikeogu NM, Nickel BE, Hombach-Klonisch S, Sharif T, Leygue E, Myal Y. The Breast Tumor Microenvironment: A Key Player in Metastatic Spread. Cancers (Basel) 2021;13:4798. [PMID: 34638283 DOI: 10.3390/cancers13194798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 779 |
Yoshikawa K, Ishida M, Yanai H, Tsuta K, Sekimoto M, Sugie T. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer. PLoS One 2021;16:e0257860. [PMID: 34559865 DOI: 10.1371/journal.pone.0257860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 780 |
Wu T, Tang C, Tao R, Yong X, Jiang Q, Feng C. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers. Front Immunol 2021;12:693881. [PMID: 34552581 DOI: 10.3389/fimmu.2021.693881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 781 |
Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12(9): 725-745 [PMID: 34631439 DOI: 10.5306/wjco.v12.i9.725] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 782 |
Kim R, Kin T. Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer. Cancers (Basel) 2021;13:4756. [PMID: 34638242 DOI: 10.3390/cancers13194756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 783 |
Cazzaniga ME, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Di Mauro P, Cogliati V, Capici S, Clivio L, Torri V; VICTOR Study Group. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Breast Cancer Res Treat 2021;190:415-24. [PMID: 34546500 DOI: 10.1007/s10549-021-06375-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 784 |
Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol 2021;12:731798. [PMID: 34539412 DOI: 10.3389/fphar.2021.731798] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 785 |
Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun 2021;12:5563. [PMID: 34548479 DOI: 10.1038/s41467-021-25769-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 786 |
Arias-Pulido H, Cimino-Mathews AM, Chaher N, Qualls CR, Joste N, Colpaert C, Marotti JD, Chamberlin MD, Foisey MG, Prossnitz ER, Emens LA, Fiering S. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients. Breast Cancer Res Treat 2021;190:477-89. [PMID: 34542773 DOI: 10.1007/s10549-021-06391-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 787 |
Jaiswal A, Murakami K, Elia A, Shibahara Y, Done SJ, Wood SA, Donato NJ, Ohashi PS, Reedijk M. Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer. Proc Natl Acad Sci U S A 2021;118:e2101592118. [PMID: 34518219 DOI: 10.1073/pnas.2101592118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 788 |
Tavares DF, Chaves Ribeiro V, Andrade MAV, Moreira Cardoso-Júnior L, Rhangel Gomes Teixeira T, Ramos Varrone G, Lopes Britto R. Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review. Oncol Rev 2021;15:497. [PMID: 35003528 DOI: 10.4081/oncol.2021.497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 789 |
Huang CS, Yu AL, Tseng LM, Chow LWC, Hou MF, Hurvitz SA, Schwab RB, L Murray J, Chang HK, Chang HT, Chen SC, Kim SB, Hung JT, Ueng SH, Lee SH, Chen CC, Rugo HS. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. J Immunother Cancer 2020;8:e000342. [PMID: 32718986 DOI: 10.1136/jitc-2019-000342] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 790 |
Miao X, Guo Q, Pan Z, Xu X, Shao X, Wang X. The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer. Ann Transl Med 2021;9:1332. [PMID: 34532469 DOI: 10.21037/atm-21-3848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 791 |
Zerdes I, Karafousia V, Mezheyeuski A, Stogiannitsi M, Kuiper R, Moreno Ruiz P, Rassidakis G, Bergh J, Hatschek T, Foukakis T, Matikas A. Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer. Cancers (Basel) 2021;13:4655. [PMID: 34572882 DOI: 10.3390/cancers13184655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 792 |
Ji L, Fan L, Zhu X, Gao Y, Wang Z. Prognostic Score for De Novo Metastatic Breast Cancer With Liver Metastasis and Its Predictive Value of Locoregional Treatment Benefit. Front Oncol 2021;11:651636. [PMID: 34513662 DOI: 10.3389/fonc.2021.651636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 793 |
Du W, Sirbu C, Lucas BD Jr, Jubelirer SJ, Khalid A, Mei L. A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors. Front Oncol 2021;11:667847. [PMID: 34513666 DOI: 10.3389/fonc.2021.667847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 794 |
Zuo S, Wang Z, An X, Wang J, Zheng X, Shao D, Zhang Y. Self-Assembly Engineering Nanodrugs Composed of Paclitaxel and Curcumin for the Combined Treatment of Triple Negative Breast Cancer. Front Bioeng Biotechnol 2021;9:747637. [PMID: 34504835 DOI: 10.3389/fbioe.2021.747637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 795 |
Bruzas S, Kuemmel S, Harrach H, Breit E, Ataseven B, Traut A, Rüland A, Kostara A, Chiari O, Dittmer-Grabowski C, Reinisch M. Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice. Cancers (Basel) 2021;13:4564. [PMID: 34572791 DOI: 10.3390/cancers13184564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 796 |
Asleh K, Riaz N, Cheng AS, Gao D, Leung SCY, Anurag M, Nielsen TO. Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. NPJ Breast Cancer 2021;7:114. [PMID: 34504086 DOI: 10.1038/s41523-021-00320-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 797 |
Reis-Sobreiro M, Teixeira da Mota A, Jardim C, Serre K. Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages. Cells 2021;10:2364. [PMID: 34572013 DOI: 10.3390/cells10092364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 798 |
Koh SA. An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam Univ J Med 2021. [PMID: 34496466 DOI: 10.12701/yujm.2021.01312] [Reference Citation Analysis]
|
| 799 |
Fleischmann M, Glatzer M, Rödel C, Tselis N. Radioimmunotherapy: future prospects from the perspective of brachytherapy. J Contemp Brachytherapy 2021;13:458-67. [PMID: 34484362 DOI: 10.5114/jcb.2021.108601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 800 |
Goldstein LJ, Mansutti M, Levy C, Chang JC, Henry S, Fernandez-Perez I, Prausovà J, Staroslawska E, Viale G, Butler B, McCanna S, Ruffini PA, Wicha MS, Schott AF; fRida Trial Investigators. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Res Treat 2021;190:265-75. [PMID: 34476645 DOI: 10.1007/s10549-021-06367-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 801 |
Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel) 2021;13:4455. [PMID: 34503265 DOI: 10.3390/cancers13174455] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 802 |
Oner G, Önder S, Karatay H, Ak N, Tükenmez M, Müslümanoğlu M, İğci A, Dincçağ A, Özmen V, Aydiner A, Yavuz E, Cabioğlu N. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. World J Surg Oncol 2021;19:264. [PMID: 34474671 DOI: 10.1186/s12957-021-02361-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 803 |
Tian Z, Yu C, Zhang W, Wu K, Gupta R, Xu Z, Wu L, Chen Y, Zhang XH-, Xiao H. Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone.. [DOI: 10.1101/2021.08.31.457412] [Reference Citation Analysis]
|
| 804 |
Zhao H, Ma W, Fragoso RC, Iv GRH, Ashok A, Li T. Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer. Journal of the National Cancer Center 2021;1:115-21. [DOI: 10.1016/j.jncc.2021.07.004] [Reference Citation Analysis]
|
| 805 |
Lux MP, Schneeweiss A, Hartkopf AD, Müller V, Janni W, Belleville E, Stickeler E, Thill M, Fasching PA, Kolberg HC, Untch M, Harbeck N, Wöckel A, Thomssen C, Schulmeyer CE, Welslau M, Overkamp F, Schütz F, Lüftner D, Ditsch N. Update Mammakarzinom 2020 Teil 5 – Einführung von Substanzen aus der metastasierten Therapiesituation in die frühe Therapiesituation. Senologie - Zeitschrift für Mammadiagnostik und -therapie 2021;18:254-265. [DOI: 10.1055/a-1491-3672] [Reference Citation Analysis]
|
| 806 |
Bai X, Ni J, Beretov J, Graham P, Li Y. Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. Journal of the National Cancer Center 2021;1:75-87. [DOI: 10.1016/j.jncc.2021.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 807 |
Kanwal B. Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies. Cureus 2021;13:e16636. [PMID: 34458041 DOI: 10.7759/cureus.16636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 808 |
Li Y, Zhang X, Zhao C. Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. Biomed Res Int 2021;2021:9800488. [PMID: 34458371 DOI: 10.1155/2021/9800488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 809 |
Kagihara JA, Shagisultanova E, Afghahi A, Diamond JR. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Curr Breast Cancer Rep 2021;13:216-26. [PMID: 34457184 DOI: 10.1007/s12609-021-00416-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 810 |
Li J, Wang S, Wang N, Zheng Y, Yang B, Wang X, Zhang J, Pan B, Wang Z. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration. Cell Commun Signal 2021;19:89. [PMID: 34461944 DOI: 10.1186/s12964-021-00775-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 811 |
Ge Y, Zhang H, Weygant N, Yao J. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol 2021;12:640099. [PMID: 34447305 DOI: 10.3389/fphar.2021.640099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 812 |
Zhu J, Yan L, Wang Q. Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. J Ovarian Res 2021;14:112. [PMID: 34454562 DOI: 10.1186/s13048-021-00862-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 813 |
Reischer A, Kruger S, von Bergwelt-Baildon M. [A decade of checkpoint inhibitors: current standard of care and future trends]. Dtsch Med Wochenschr 2021;146:1108-18. [PMID: 34448187 DOI: 10.1055/a-1303-8820] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 814 |
Lin S, Luo S, Gu D, Li M, Rao X, Wang C, Huang P, Xu X, Weng X. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis. Oncologist 2021;26:e2013-20. [PMID: 34431578 DOI: 10.1002/onco.13954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 815 |
Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SM. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer 2021;7:110. [PMID: 34433812 DOI: 10.1038/s41523-021-00287-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 816 |
Wu B, Sternheim N, Agarwal P, Suchomel J, Vadhavkar S, Bruno R, Ballinger M, Bernaards CA, Chan P, Ruppel J, Jin J, Girish S, Joshi A, Quarmby V. Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Clin Transl Sci 2021. [PMID: 34432389 DOI: 10.1111/cts.13127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 817 |
Modi ND, Abuhelwa AY, Menz BD, McKinnon RA, Sorich MJ, Hopkins AM. Commentary: Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis. Front Pharmacol 2021;12:732622. [PMID: 34421624 DOI: 10.3389/fphar.2021.732622] [Reference Citation Analysis]
|
| 818 |
Suwanvecho S, Suwanrusme H, Jirakulaporn T, Issarachai S, Taechakraichana N, Lungchukiet P, Decha W, Boonpakdee W, Thanakarn N, Wongrattananon P, Preininger AM, Solomon M, Wang S, Hekmat R, Dankwa-Mullan I, Shortliffe E, Patel VL, Arriaga Y, Jackson GP, Kiatikajornthada N. Comparison of an oncology clinical decision-support system's recommendations with actual treatment decisions. J Am Med Inform Assoc 2021;28:832-8. [PMID: 33517389 DOI: 10.1093/jamia/ocaa334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 819 |
Liu YL, Bager CL, Willumsen N, Ramchandani D, Kornhauser N, Ling L, Cobham M, Andreopoulou E, Cigler T, Moore A, LaPolla D, Fitzpatrick V, Ward M, Warren JD, Fischbach C, Mittal V, Vahdat LT. Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. NPJ Breast Cancer 2021;7:108. [PMID: 34426581 DOI: 10.1038/s41523-021-00313-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 820 |
Li JJ, Tsang JY, Tse GM. Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. Cancers (Basel) 2021;13:4233. [PMID: 34439387 DOI: 10.3390/cancers13164233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 821 |
Stüber T, Monjezi R, Wallstabe L, Kühnemundt J, Nietzer SL, Dandekar G, Wöckel A, Einsele H, Wischhusen J, Hudecek M. Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J Immunother Cancer 2020;8:e000676. [PMID: 32303620 DOI: 10.1136/jitc-2020-000676] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 20.5] [Reference Citation Analysis]
|
| 822 |
Di Nunno V, Franceschi E, Tosoni A, Mura A, Minichillo S, Di Battista M, Gatto L, Maggio I, Lodi R, Bartolini S, Brandes AA. Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? Clin Drug Investig 2021;41:757-73. [PMID: 34403132 DOI: 10.1007/s40261-021-01070-1] [Reference Citation Analysis]
|
| 823 |
Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer 2021;9:e002597. [PMID: 34389617 DOI: 10.1136/jitc-2021-002597] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 824 |
Xu P, Xiong W, Lin Y, Fan L, Pan H, Li Y. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Cell Death Dis 2021;12:779. [PMID: 34365463 DOI: 10.1038/s41419-021-04047-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 825 |
Lal JC, Townsend MG, Mehta AK, Oliwa M, Miller E, Sotayo A, Cheney E, Mittendorf EA, Letai A, Guerriero JL. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Breast Cancer Res 2021;23:83. [PMID: 34353349 DOI: 10.1186/s13058-021-01448-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 826 |
Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals (Basel) 2021;14:763. [PMID: 34451860 DOI: 10.3390/ph14080763] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 827 |
Heimes DA, Schmidt M. Update Immunonkologie beim triple-negativen Mammakarzinom. Gynäkologe 2021;54:590-595. [DOI: 10.1007/s00129-021-04807-3] [Reference Citation Analysis]
|
| 828 |
Manukian G, Kivolowitz C, DeAngelis T, Shastri AA, Savage JE, Camphausen K, Rodeck U, Zarif JC, Simone NL. Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells. Int J Radiat Oncol Biol Phys 2021;110:1341-9. [PMID: 33647370 DOI: 10.1016/j.ijrobp.2021.02.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 829 |
Sillerud LO, Neuwelt AJ, Staquicini FI, Arap W, Pasqualini R. Repurposing Ferumoxytol as a Breast Cancer-Associated Macrophage Tracer with Five-Dimensional Quantitative [Fe]MRI of SPION Dynamics. Cancers (Basel) 2021;13:3802. [PMID: 34359704 DOI: 10.3390/cancers13153802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 830 |
Chan WL, Choi HC, Ho PP, Lau JK, Tse RP, Au J, Lam V, Liu R, Ho I, Wong C, Cheung B, Lam E, Chow D, Lam KO, Yuen KK, Kwong DL. Immune-Related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-World Data. Cancers (Basel) 2021;13:3797. [PMID: 34359698 DOI: 10.3390/cancers13153797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 831 |
Wu SY, Xiao Y, Wei JL, Xu XE, Jin X, Hu X, Li DQ, Jiang YZ, Shao ZM. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer 2021;9:e002528. [PMID: 34321275 DOI: 10.1136/jitc-2021-002528] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 832 |
Hossain F, Majumder S, David J, Miele L. Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. Cancers (Basel) 2021;13:3739. [PMID: 34359640 DOI: 10.3390/cancers13153739] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 833 |
Liu SR, Yan Q, Lin HM, Shi GZ, Cao Y, Zeng H, Liu C, Zhang R. Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World J Clin Cases 2021; 9(21): 5988-5998 [PMID: 34368318 DOI: 10.12998/wjcc.v9.i21.5988] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 834 |
Palleschi M, Tedaldi G, Sirico M, Virga A, Ulivi P, De Giorgi U. Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. Int J Mol Sci 2021;22:7884. [PMID: 34360649 DOI: 10.3390/ijms22157884] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 835 |
Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, Ni C, Chen Z. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res 2021;9:59. [PMID: 34294146 DOI: 10.1186/s40364-021-00312-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 836 |
Wang S, Xie K, Liu T. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters. Front Immunol 2021;12:690112. [PMID: 34367148 DOI: 10.3389/fimmu.2021.690112] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 837 |
Schmidt M, Edlund K, Hengstler JG, Heimes AS, Almstedt K, Lebrecht A, Krajnak S, Battista MJ, Brenner W, Hasenburg A, Rahnenführer J, Gehrmann M, Kellokumpu-Lehtinen PL, Wirtz RM, Joensuu H. Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer. Cancers (Basel) 2021;13:3626. [PMID: 34298839 DOI: 10.3390/cancers13143626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 838 |
O'Shaughnessy J, Emens LA, Chui SY, Wang W, Russell K, Lin SW, Flores Avile C, Luhn P, Schneeweiss A. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. Curr Oncol 2021;28:2741-52. [PMID: 34287291 DOI: 10.3390/curroncol28040239] [Reference Citation Analysis]
|
| 839 |
Petrazzuolo A, Perez-Lanzon M, Martins I, Liu P, Kepp O, Minard-Colin V, Maiuri MC, Kroemer G. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death Dis 2021;12:713. [PMID: 34272360 DOI: 10.1038/s41419-021-03997-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 840 |
Kothari C, Clemenceau A, Ouellette G, Ennour-Idrissi K, Michaud A, C-Gaudreault R, Diorio C, Durocher F. TBC1D9: An Important Modulator of Tumorigenesis in Breast Cancer. Cancers (Basel) 2021;13:3557. [PMID: 34298771 DOI: 10.3390/cancers13143557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 841 |
Taube JM, Roman K, Engle EL, Wang C, Ballesteros-Merino C, Jensen SM, McGuire J, Jiang M, Coltharp C, Remeniuk B, Wistuba I, Locke D, Parra ER, Fox BA, Rimm DL, Hoyt C. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. J Immunother Cancer 2021;9:e002197. [PMID: 34266881 DOI: 10.1136/jitc-2020-002197] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 842 |
Palazón-Carrión N, Jiménez-Cortegana C, Sánchez-León ML, Henao-Carrasco F, Nogales-Fernández E, Chiesa M, Caballero R, Rojo F, Nieto-García MA, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. Sci Rep 2021;11:14426. [PMID: 34257359 DOI: 10.1038/s41598-021-93838-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 843 |
Kao CN, Moi SH, Hou MF, Luo CW, Chen FM, Pan MR. RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. J Pers Med 2021;11:655. [PMID: 34357122 DOI: 10.3390/jpm11070655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 844 |
Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, He B, Miller KD, Radovich M, Schneider BP, Pahl A, Zhang X, Lu X. Targeted immunotherapy for HER2-low breast cancer with 17p loss. Sci Transl Med 2021;13:eabc6894. [PMID: 33568521 DOI: 10.1126/scitranslmed.abc6894] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 845 |
Botticelli A, Pomati G, Cirillo A, Mammone G, Ciurluini F, Cerbelli B, Sciattella P, Ralli M, Romeo U, De Felice F, Catalano C, Vullo F, Della Monaca M, Amirhassankhani S, Tomao S, Valentini V, De Vincentiis M, Tombolini V, Della Rocca C, Polimeni A, di Gioia C, Corsi A, D'Amati G, Mezi S, Marchetti P. Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. J Transl Med 2021;19:303. [PMID: 34253248 DOI: 10.1186/s12967-021-02975-3] [Reference Citation Analysis]
|
| 846 |
Tian Y, Li R, Liu Y, Li M, Song Y, Zheng Y, Gao A, Wen Q, Su G, Sun Y. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:667650. [PMID: 34322382 DOI: 10.3389/fonc.2021.667650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 847 |
Vito A, Salem O, El-Sayes N, MacFawn IP, Portillo AL, Milne K, Harrington D, Ashkar AA, Wan Y, Workenhe ST, Nelson BH, Bruno TC, Mossman KL. Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. Commun Biol 2021;4:859. [PMID: 34253827 DOI: 10.1038/s42003-021-02375-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 848 |
Damaskos C, Garmpis N, Garmpi A, Nikolettos K, Sarantis P, Georgakopoulou VE, Nonni A, Schizas D, Antoniou EA, Karamouzis MV, Nikolettos N, Kontzoglou K, Patsouras A, Voutyritsa E, Syllaios A, Koustas E, Trakas N, Dimitroulis D. Investigational Drug Treatments for Triple-Negative Breast Cancer. J Pers Med 2021;11:652. [PMID: 34357119 DOI: 10.3390/jpm11070652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 849 |
Copeland J, Oyedeji A, Powell N, Cherian CJ, Tokumaru Y, Murthy V, Takabe K, Young J. Breast Cancer in Jamaica: Stage, Grade and Molecular Subtype Distributions Across Age Blocks, the Implications for Screening and Treatment. World J Oncol 2021;12:93-103. [PMID: 34349853 DOI: 10.14740/wjon1389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 850 |
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. Oncoimmunology 2021;10:1950411. [PMID: 34290909 DOI: 10.1080/2162402X.2021.1950411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 851 |
Wolfson B, Padget MR, Schlom J, Hodge JW. Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. J Immunother Cancer 2021;9:e002258. [PMID: 34244306 DOI: 10.1136/jitc-2020-002258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 852 |
Li T, Tao Z, Zhu Y, Liu X, Wang L, Du Y, Cao J, Wang B, Zhang J, Hu X. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. Cell Death Dis 2021;12:684. [PMID: 34238922 DOI: 10.1038/s41419-021-03963-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 853 |
Ross DS, Pareja F. Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations. Surg Pathol Clin 2021;14:455-71. [PMID: 34373096 DOI: 10.1016/j.path.2021.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 854 |
Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 2021;12:714483. [PMID: 34305619 DOI: 10.3389/fphar.2021.714483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 855 |
Rzhevskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A, Thiery JP, Maslennikova A, Zvyagin AV, Ebrahimi Warkiani M. Emerging role of circulating tumor cells in immunotherapy. Theranostics 2021;11:8057-75. [PMID: 34335980 DOI: 10.7150/thno.59677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 856 |
Petrelli F, Morelli AM, Luciani A, Ghidini A, Solinas C. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Targ Oncol. [DOI: 10.1007/s11523-021-00824-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 857 |
Zheng H, Siddharth S, Parida S, Wu X, Sharma D. Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation. Cancers (Basel) 2021;13:3357. [PMID: 34283088 DOI: 10.3390/cancers13133357] [Cited by in Crossref: 12] |
